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Summary 
 
Papillary thyroid cancer (PTC) is the most common type of endocrine cancer. Partial or 
complete removal of the thyroid lobe, followed by radioactive iodine treatment (131I) 
(RAI) is the standard treatment strategy for the treatment of thyroid cancer. But the 
management of tumors that cannot undergo resection, mostly due to distant metastasis 
and/or development of resistance to RAI is challenging. Identifying and understanding 
the molecular pathogenesis underlying thyroid cancer is important for the development 
of better diagnosis and treatment. The main aim of the project is the identification and 
validation of novel molecular alterations in PTC patient samples by employing  
genomic and proteomic approaches. 
 
From a set of patients whose PTC did not harbour any BRAF or RAS mutations (the 
most common mutations in PTC), a 35 years old male patient’s normal, primary tumor 
and metastatic tissues were selected for both genomic and proteomic analysis. We 
identified a novel RET gene fusion in this patient and the oncogenic ability of this novel 
gene fusion was tested in transformation assays. Stable expression of the novel RET 
fusion gene activated several oncogenic signalling pathways and transformed 
immortalized human thyroid cells. The novel RET fusion exhibited high kinase activity 
and formed dimers and oligomers partially in a PB1 domain dependent manner. 
Quantitative proteomic analysis of normal vs tumour vs metastasis of the same patient 
revealed the upregulation of proteins involved in the ubiquitination machinery including 
HECT carrying E3 ligase HUWE1 and Deubiquitinating enzymes (DUBs) like USP9X 
and UBP7 in the tumour and metastatic lesions. Inhibition of RET, HUWE1 and DUBs 
by small molecule inhibitors significantly reduced RET-mediated oncogenesis. Apart 
from unveiling a novel oncogenic RET fusion in PTCs, our data opens a novel avenue 
of targeting ubiquitin signalling machinery in human PTCs. 
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 Zusammenfassung 	
Das papilläre Schilddrüsenkarzinom (= papillary thyroid carcinoma, PTC) ist die 
häufigste endokrine Krebserkrankung. Zur Behandlung wird den betroffenen Patienten 
zunächst teilweise oder vollständig die Schilddrüse entfernt und im Anschluss erhalten 
sie eine Radiojodtherapie (RAI). Eine Behandlung von Tumoren, die z. B. auf Grund 
von Metastasierung nicht mehr operativ entfernt werden können oder Resistenzen gegen 
die RAI Therapie entwickelt haben, ist jedoch eine Herausforderung. Das Erkennen und 
Verstehen der molekularen Pathogenese, die dem Schilddrüsenkrebs zu Grunde liegt, ist 
wichtig für die Entwicklung besserer Behandlungsmöglichkeiten sowie diagnostischer 
Strategien. Durch genomische und proteomische Analysen von primärem PTC Material 
war ein Hauptziel dieser Arbeit die Identifizierung und nachfolgende Validierung 
neuartiger molekularer Veränderungen bei dieser Krebserkrankung. 
 
Aus einer Gruppe von Patienten, deren Schilddrüsentumore keine BRAF- oder RAS-
Mutationen aufwies (die häufigsten Mutationen bei PTC), wurden normales sowie 
primäres Tumorgewebe  und Gewebe von Metastasen eines 35-jährigen männlichen 
Patienten genauer analysiert. In weiterführenden Genom- und Proteomanalysen  
konnten wir eine neue RET-Genfusion bei diesem Patient identifizierten. Die onkogene 
Funktion wurde durch in vitro Transformationsassays getestet: Die stabile Expression 
des neuen RET-Fusionsgens aktivierte mehrere onkogene Signalwege und 
transformierte immortalisierte, humane Schilddrüsenzellen. Die neue RET-Fusion 
zeigte eine hohe Kinaseaktivität und bildete, teilweise in Abhängigkeit von der PB1-
Domäne, Dimere und Oligomere. Die quantitative proteomische Analyse von normalem 
vs. Tumorgewebe vs. Gewebe isolierter Metastasen desselben Patienten ergab, dass 
Proteine, die an der Ubiquitinierungsmaschinerie beteiligt sind, einschließlich der 
HECT Domäne tragenden E3-Ligase HUWE1 und DUBs wie USP9X und UBP7 im 
Tumor und Metastasen hochreguliert sind. Die Hemmung von RET, HUWE1 und 
Deubiquitinasen (DUBs) durch niedermolekulare Inhibitoren reduzierte die RET-
vermittelte Onkogenese signifikant. In dieser Arbeit konnten wir eine neuartige 
onkogene RET-Fusion in primärem Tumormaterial eines PTC-Patienten nachweisen. 
Darüberhinaus weisen unsere Daten daraufhin, dass die Inhibierung der 
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Ubiquitinmaschinerie eine Möglichkeit bietet, neue therapeutische Ansätze für die 
Behandlung von Schilddrüsenkarzinomen zu entwickeln. 
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1 Introduction 
 
1.1 The Thyroid 
 
The thyroid (Latin: glandula thyreoidea) is an endocrine gland that synthesises, stores 
and secretes vital hormones that are involved in the proper development of brain in 
infants, regulation of metabolism and growth rate of the body throughout the lifespan. 
During development, the thyroid gland is the first endocrine gland to develop and is 
located in the back of the tongue, which then migrates to the front of the neck before 
birth. It has a butterfly shaped structure – the right and the left lobe, which lies around 
the trachea and are connected by a narrow strip of tissue called the isthmus (Figure 1.1). 
The thyroid comprises of - i) the follicular cells that form thyroid follicles, which 
enclose colloids containing lumen and ii) the parafollicular C cells. The thyroid gland 
produces three hormones - Triiodothyronine (T3) and Tetraiodothyronine (thyroxine or 
T4), which are produced by the follicular cells - collectively called the thyroid 
hormones, and calcitonin which is secreted by the C cells [2, 3]. The levels of thyroid 
hormones in the plasma are maintained within a narrow normal range by the thyroid 
stimulating hormone (TSH) secreted by the pituitary gland which is in turn regulated by 
the thyroptin releasing hormone (TRH) secreted by the hypothalamus [2] (Figure 1.2). 
Iodine is essential for the synthesis of thyroid hormones. The sodium/iodide symporter 
(NIS) protein present on the basolateral plasma membrane of the epithelial follicular 
cells of the thyroid mediates the uptake of iodide from the plasma in a Na+-K+-ATPase 
dependent manner [4]. The iodide is concentrated and oxidised at the follicular cell-
colloidal interface to form iodine, which then iodinates the tyrosine residues of a protein 
called thyroglobulin to form mono- or di-iodinated tyrosine residues. These iodinated 
tyrosine residues couple to form the thyroglobulin bound T3 (one mono- and one di-) 
and T4 (2 di-) hormones and are stored in the lumen. A normal thyroid gland stores 
enough hormones that the body requires for a month. Before being released into the 
plasma, the thyroglobulin bound T3 and T4 hormones are taken up by the follicular 
cells and are subjected to protease activity, hence releasing the T3 and T4 hormones 
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from the thyroglobulin before its secretion into the bloodstream. The secreted T3 and 
T4 hormones negatively regulate the secretion of TRH, hence when there are enough 
thyroid hormones in the body, the thyroid hormones inhibits the secretion of TRH from 
the hypothalamus [4].  Besides the thyroid hormones, the thyroid gland also produces 
the hormone called calcitonin. The parafollicular C cells of the thyroid secrete 
calcitonin when the serum calcium level increases, protecting against hypercalcemia 
[3].  
       
Figure 1.1: The structure of thyroid (from[5]).        Figure 1.2:  Thyroid hormone regulation (from [6]). 
          
1.2 Thyroid Disorders 
 
1.2.1 Benign alterations of the thyroid 
 
Thyroid associated diseases are amongst the most common endocrine disorders and can 
be broadly classified as thyroid dysfunction disorders – hypothyroidism (insufficient 
levels of thyroid hormone) and hyperthyroidism (excessive amounts of thyroid 
hormones), as well as structural diseases – goitre, nodules and cancer [7]. Various 
studies reveal that thyroid disorders exhibit a clear preponderance in females, though 
the exact reasons underlying this is unclear [8, 9].  
 
Hypothyroidismhas an adverse effect on human spermatogenesis and
negatively affects sperm count andmotility (Rajender et al., 2011) aswell
as morphology (Corrales Hernandez et al., 1990). Hyperthyroidism is
associated with abnormalities in sperm motility (Krassas et al., 2008)
and DNA damage (Meeker et al., 2008).
TPO-Ab
The presence of thyroid autoantibodies was higher in subfertile men
compared with a control group (Baker et al., 1985).
Altogether, hypothyroidism, hyperthyroidism and presence of
TPO-Ab are associated with an adverse effect on sperm parameters.
No studies are available showing a causal effect of thyroid hormone
andTPO-Abon spermparameters.No intervention studies areavailable
on treating thyroid disorders and the effect on sperm parameters. The
clinical significance remains therefore unclear, especially since some of
the reported abnormalities in sperm parameters do not affect fertility.
Fertilization and embryogenesis
Thyroid hormone disorders
We identified only one study that reports on the effect of thyroid status
on fertilization. This study showed that fertilization rateswere significant-
ly lower in cows treated with propylthiouracil and who were hypothy-
roid, compared with control euthyroid cows (Bernal et al., 1999).
In humans, the number of embryos of higher quality was significantly
higher in women with subclinical hypothyroidism who were treated
with T4 supplementation compared with those who were not. In add-
ition, women that were treated with T4 had a higher live birth rate per
initiated cycle, with no difference in the live birth rate in TPO-Ab positive
patients (Kim et al., 2011a).
The thyroid hormone transporters and receptors, as well as deiodi-
nases, are expressed in the human pre-implantation embryo (Supple-
mentary data, Fig. S1).
TPO-Ab
Evidence for the influence of TPO-Ab on embryo quality is limited. One
study showed a decreased percentage of 3–4 cell stage mouse embryos
cultured in serum with TPO-Ab compared with mouse embryos cultured
in normal mouse serum (74 versus 90%, P, 0.05) but the number of
expanded blastocysts (66 versus 73%) and hatching blastocysts (36 versus
37%) did not significantly differ between the two groups (Lee et al., 2009).
In a study of 14 women with TPO-Ab (also in follicular fluid), oocyte
fertilization, gradeAembryosandpregnancy rateswere lowercompared
with 17 women without TPO-Ab and this effect was independent of
thyroid hormone status (Monteleone et al., 2011). Another study
found no statistical differences in the number of grade 1 and grade 2
embryos comparing women with unexplained subfertility and positive
thyroid autoantibodies (TPO-Ab and/or Tg-Ab) with unexplained sub-
fertility without thyroid autoantibodies (Kilic and Tasdemir, 2008). This
discrepancymight be due to the fact that this study also includedwomen
positive for Tg-Ab.
In conclusion, both hypothyroidism and the presence of TPO-Ab
seem to negatively affect fertilization rates and embryo quality, but to
date, only associations have been reported and studies exploring the
pathophysiology are lacking.
Endometrium
Thyroid hormone disorders
There is ample evidence thatDIO2andDIO3are present in human endo-
metrium throughout themenstrual cycle (Kohrle, 1999; Aghajanova et al.,
2009, 2011). The expression in the mid-secretory phase is lower and the
Figure 1 Thyroid hormone physiology. Circulating thyroid hormone
concentrations are regulated via a negative feedback system at the level
of the hypothalamus and the pituitary. The production of thyroid
hormone by the thyroid is regulated by thyroid-stimulating hormone
(TSH) produced by the anterior pituitary, which itself is regulated by
thyrotropin-releasing hormone (TRH) produced by the hypothalamus.
Thyroid hormone circulates as the inactive prohormone thyroxine (T4)
and as the active hormone triiodothyronine (T3). Thyroid hormone can
only enter target cells by virtue of specific transporters (MCT8, MCT10
and Oatp1c1). In target cells, thyroid hormone can be activated (T4 to
T3) or inactivated (T4 to rT3 or T3 to T2) depending on the local activity
of specific deiodinases (D1,D2 andD3). Subsequently, active T3 can bind
to the nuclear thyroid hormone receptors (TR-alpha and TR-beta) and
induce transcription.
382 Vissenberg et al.
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Iodine deficiency is a major cause of hypothyroidism. There is a vast disparity in the 
global epidemiology of hypothyroidism - geographically, areas in the mountain regions, 
and economically, the diet regime of poorer countries may not contain enough iodine. 
In iodine-replete regions, Hashimoto thyroiditis – a chronic auto immune response 
where there is a progressive destruction of the thyroid is a leading cause of 
hypothyroidism. Symptoms of hypothyroidism include fatigue, weight gain and cold 
intolerance. Thyroid hormone replacement is the treatment of choice for 
hypothyroidism. Hyperthyroidism is less common than hypothyroidism and can be 
caused by auto immune responses where the auto reactive TSH receptor antibodies 
abnormally stimulate the TSH receptor resulting in increased thyroid activity (Graves 
disease). Symptoms of hyperthyroidism include weight loss, anxiety, breathlessness and 
palpitation [7]. Treatment for hyperthyroidism includes anti-thyroid drugs, radioactive 
iodine treatment and surgery. Determining thyroid dysfunction is performed by testing 
serum TSH levels.  
 
Goitre is a condition where there is an asymmetrical enlargement of the thyroid as a 
consequence of impaired thyroid hormone synthesis and may cause hyperplasia and 
hypertrophy of thyroid cells. Dietary iodine deficiency is the leading cause of goitre. 
Goitre may develop as a solitary thyroid nodule or as multiple nodules on both sides of 
the thyroid resulting in an overall enlargement of the thyroid gland. Goitre is a benign 
neoplasia and, thus, is not cancerous [7]. 
 
1.2.2 Thyroid cancer 
 
Thyroid cancer is the most common type of endocrine cancer and there has been a 
world wide increase in thyroid cancer in the past decades [10]. It is the most rapidly 
increasing cancer in the US, with an estimated annual increase in incidence by 3.6% per 
year from 1974 to 2013, as well as a significant increase in the thyroid cancer related 
mortality [11, 12]. A study by Rahib et al. predicted that, by 2030, thyroid cancer would 
be the fourth leading cancer to be diagnosed following breast, prostate and lung cancer 
[13]. However, there are varied notions regarding the increase in thyroid cancer. A 2014 
study by Davies et al. suggested that the increased incidence of thyroid cancer is an 
epidemic of diagnosis rather than an epidemic of disease because of advancement and 
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increased use of diagnostic techniques resulting in increased diagnosis of indolent 
localised tumor and/or small cancers [14]. But a more recent study by Lim et al. 
concluded that the increase is true, demonstrated by a significant increase in the 
incidence and mortality associated with larger and advanced-stage thyroid cancer 
patients [12]. The estimated new cases of thyroid cancer in the US for the year 2018 is 
53,990 which would account for 3.1% of all the cancer cases reported in 2018 and 
caused 2060 deaths [15]. The relative 5-year survival of thyroid cancer ranges from 98-
99% for localised cancer to only about 55.5% in cases with distant metastasis.  
Thyroid cancer is the fifth common cancer in women [16]. Many studies, including the 
data from National Cancer Institute’s Surveillance, Epidemiology and End Results 
Program (SEER 9) shows not only that the incidence of thyroid cancer is higher in 
women (occurs about 3 times more in women when compared to men), but also that the 
relative increase in the incidence rate of thyroid cancer has been larger in women than 
in men (about 4 times greater in women) [14]. The study also showed that this 
difference in the rate of incidence between the genders did not reflect in the mortality, 
as there seemed to be not much difference in mortality rate between men and women. 
The possible reason for this could be that the incidence of aggressive cancer is more 
prevalent or equal in men when compared to women and/or that men are usually older 
at diagnosis, though the exact reasons for higher incidence in women remain largely 
unclear. Thyroid cancer seems to be more prevalent in young adults, though all age 
groups can be affected. Exposure to ionizing radiation, especially in childhood, is the 
only known cause of thyroid cancer [17]. Two large geographical cohorts that 
demonstrate ionizing radiation induced thyroid cancer are the Japanese atomic-bomb 
survivors and the victims of the 1986 Chernobyl nuclear fall out [18, 19]. Various 
studies including the study by Imaizumi et al. show that young individuals when 
exposed to atomic bomb radiations were at higher risk of thyroid cancer and that there 
was a dose-dependent increase in prevalence [18]. In 1992, a report suggested that there 
was a marked increase in frequency of thyroid cancer in children from 1990 onwards in 
Belarus and associates this rise with the Chernobyl tragedy [19]. Patients exposed to 
radioactive iodine 131I and are given external radiotherapy are also susceptible to thyroid 
cancer [17]. Gender, age, size of tumor, presence of lymph node and distant metastasis 
are factors that are often considered in the risk assessment of thyroid cancer, though not 
all of these factors have reached a consensus. Other risk factors that may contribute to 
the increase in incidence of thyroid cancer include familial history, exposure to fertility 
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drugs [20], overweight in post menopausal women [21], menstrual and reproductive 
factors [22], at least in certain ethnic populations. 
 
1.3 Management of thyroid cancer  
 
Abnormal growth of the thyroid cells that forms a lump within the thyroid gland are 
referred to as thyroid nodules. Defining the nature of a thyroid nodule, accurate 
stratification of the lesions and deciding on the optimal treatment strategy are the 
challenges in the management of thyroid cancer. Thyroid nodules are a common clinical 
finding and are detected in 5% of the population by physical examination of the neck. 
Ultrasound examinations reveal a much higher occurrence of thyroid nodules (between 
20-70%) [23]. Though most of the cases presented with thyroid nodules are non-
malignant in nature, studies indicate that patients with multiple thyroid nodules are at a 
higher risk to develop thyroid cancer. A study by Smith JJ et al. [24] implied that nearly 
1 in 5 patients presented with multiple thyroid nodules had thyroid cancer. It is very 
important to diagnose if the nodules are only benign or actually malignant in order to 
ensure that the patient is not overtreated or undertreated. Surgical removal of the 
thyroid, which is the standard treatment for thyroid cancer, can result in undesired 
consequences including hormone imbalance, hypoparathyroidism, laryngeal nerve 
injury or infections. Hence, it is important to limit unnecessary thyroidectomy of non-
malignant lesions. If the nodules are diagnosed to be benign, they would be subjected to 
serial ultra sound examinations in order to further monitor the nodules, sparing the cost 
and complications of surgery. Techniques and advancements in methods for the 
management of thyroid cancer are discussed below. 
 
1.3.1 Ultra sonography and TSH levels 
 
Thyroid nodules are usually detected by thyroid or neck sonography and less frequently 
by palpation. Ultrasound can reveal certain features of the nodules like 
hypoechogenecity, microcalcifications and extrathyroidal extensions that can be 
indicative of its malignancy status. It is also very useful in the determination of the size 
and monitoring the growth of thyroid nodules. But it is often not completely reliable to 
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distinguish benign from malignant lesions. Many studies have tried to investigate any 
correlation between the size of thyroid nodules and risk of malignancies, and the 
findings were not very conclusive. While some studies recommended surgical treatment 
for larger nodules following their evaluation that larger size was associated with higher 
risk of malignancy, other studies ruled out the correlation of nodule size with the risk of 
malignancy [25, 26]. A study by Kamran et al. concluded that though 15% of nodules 
>2 cm in size were cancerous as opposed to only 10.5% cancerous cases in nodules with 
sizes 1.0-1.9 cm, they saw that above 2 cm diameter, increasing thyroid nodule size 
(nodule diameter 2.0-2.9 cm, 3.0-3.9 cm and >4 cm) had a nonlinear impact on the risk 
of cancer respective percentage of cancerous cases 14%, 16% and 15% [26]. Studies 
were also conducted to investigate TSH levels as predictors of malignancy. Most of the 
patients with thyroid cancer are euthyroid and do not present with abnormalities in their 
TSH levels. Haymart et al. for the first time in a retrospective study showed an 
increased risk of malignancy with higher TSH levels [27]. While patients with TSH 
levels less than 0.06 mIU/litre had 11% likelihood of malignancy, patients with TSH 
levels greater than or equal to 5 mIU/litre had a 46% likelihood of malignancy. Even 
when the patients are presented within the accepted normal TSH ranges (0.4–4.99 
mIU/liter), there was a significantly higher likelihood of thyroid cancer when the TSH 
level was above the population mean [27]. 
 
1.3.2 Fine needle aspiration biopsy (FNAB) 
 
Introduction of FNAB in clinical practice has played an important role in improving the 
diagnostic prediction, reducing the number of diagnostic and unnecessary therapeutic 
surgeries associated with thyroid nodules. Owing to reduced inadequate sampling, ultra 
sound guided fine needle aspiration had higher sensitivity, specificity, accuracy and 
predictive values than palpation guided FNA [28]. FNA is quick, accurate, cost-
effective, causes less morbidity in the patients and can be used in sampling smaller 
thyroid nodules. The recent years saw a 50% reduction in the number of 
thyroidectomies and improved predictions of malignant cases (from 14% to 30-50% 
surgical cases) [29]. Despite how FNA has improved diagnosis of thyroid nodules, there 
are few problems that are of major concern in the FNA mediated diagnostics. 
Cytological evaluation followed by FNA categorises about 25% cases as indeterminate 
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after FNAB, hence requiring a diagnostic surgery or more FNAB samples for 
appropriate diagnosis. False negative FNA cytology as high as 8%, resulting in delayed 
treatment can have a major negative impact on the prognosis and outcome of the 
patients [30]. Studies suggest that false negative FNAs are higher in nodules larger than 
3-4 cm and this could be attributed to eccentric malignant foci present in the nodules, 
but could not be sampled, hence not exactly representing the true cytology of the 
nodules [30, 31]. Also, a study by Mazzaferri et al. noted that FNA of thyroid nodules 
smaller than 5 mm yielded very high rates of non-diagnostic FNA [32]. Even in larger 
thyroid nodules FNA may yield indeterminate diagnostics. Additional to the 
ambiguities associated with FNA, cytological evaluation also comes with its 
complexities like overlap of cytological patterns between neoplastic and non-neoplastic 
lesions and between different neoplasms and existence of multiple malignancies in the 
same gland. Despite improvement in diagnostic methods and several studies 
investigating risk factors and better predictors of malignancy, precise classification of 
the cancer and determination of appropriate management protocols has been a challenge 
in the field of thyroid cancer. Tremendous efforts have been put into compiling 
available information and methods used for evaluation and interpretation of thyroid 
nodules, with the aim of developing evidence-based guidelines for accurate diagnosis, 
stratification and management of thyroid cancer. ‘The NCI Thyroid FNA State of the 
Science Conference’ organized by the National Cancer Institute in Bethesda in 2007 
was one such initiative that brought together many pathologists, endocrinologists, 
surgeons and radiologists and came up with a 6-tiered classification system (The 
Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) with malignancy 
risk associated with each category, hence hoping to have a uniform FNA reporting and 
management system. The TBSRTC was revised in 2017 where the malignancy risks 
associated with each category and recommendations for management of each category 
have been updated based on patient data post 2010 [33].  While most of the categories 
are very well defined by the Bethesda classification, it still has the drawback of having 
indeterminate FNA categories comprising of non-diagnostic or unsatisfactory diagnosis, 
atypia or follicular lesion of unknown significance and suspicious follicular neoplasms.  
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1.3.3 Surgical management 
 
Surgery is the standard treatment for thyroid cancer, though the extent of thyroidectomy 
is a matter of debate in the field. Reasons that support total thyroidectomy include 
higher chances of adequate removal of the disease, prevention of recurrence, and 
avoidance of further surgery in cases of progression to malignancy. Though treatment 
guidelines recommend that only thyroid lobectomy would be enough for the 
management of indeterminate thyroid nodules, small (<1 cm), unifocal low-risk thyroid 
cancers, such cancers are also extensively managed with total thyroidectomy [34]. This 
is a matter of concern as it can have severe consequences due to complications in 
surgery and the patient is subjected to life long thyroid hormone therapy as well as 
higher treatment and treatment related expenses. Though surgical skill and experience 
play an important role the extent of success and good outcome of the surgery, studies 
also suggest that the type of surgery also has an influence on morbidity [34]. In a study 
that aimed at reviewing the impact of thyroid lobectomy versus total thyroidectomy 
with tumors ranging 1-4 cm in size on tumor recurrence and survival, it was implied 
that lobectomy and total thyroidectomy yield comparable oncologic outcomes [35]. 
Hence, it is very important to avoid any unnecessary surgical intervention, especially in 
the management of benign and small tumors. 
1.3.4 Radioiodine treatment (RAI) 
 
Owing to the ability of thyroid cells to uptake iodine, when radioactive iodine (131I) is 
administered in liquid or capsule form, it is taken up only by the thyroid cells of the 
body, which are consequently ablated. Thyroidectomy is usually followed by RAI for 
the removal of residual thyroid tissue post surgery as well as for the treatment of 
metastasized thyroid cancer. Appropriate levels of TSH stimulation and absence of 
iodine contamination are key prerequisites for successful RAI uptake and effective 
treatment. About two-thirds of patients with metastatic cancer demonstrate significant 
RAI uptake, but despite successful RAI uptake the treatment might become ineffective. 
There could be several reasons for this including lower radiation dose in tumor tissue 
and shorter effective half-life of 131I as well as heterogeneity in 131I uptake within a 
given metastasis [36]. Tumors responding to 131I treatment display decrease in tumor 
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volume on anatomical imaging. Better responses are achieved in younger patients and 
patients with small pulmonary metastasis, while patients with bone metastasis tend to 
have poorer prognosis, likely owing to larger size of the lesions. Older patients and 
patients with advanced stages of thyroid cancer are refractory to 131I treatment [36] [37]. 
Loss of ability of the tumors to uptake iodine is also a major reason for 131I 
refractiveness. One approach that has been investigated in the treatment of 131I 
refractory patients is the restoration of the ability of tumor cells to uptake iodine. A 
study by Ho et al. showed that treatment with MEK1/2 inhibitor selumetinib 4 weeks 
prior to 131I therapy reversed the RAI refractiveness of tumour in patients with advanced 
thyroid cancer [38]. Similarly, another group showed that Dabrafenib (a BRAF 
inhibitor) administration to patients with unresectable or metastatic iodine-refractory 
PTC harbouring BRAFV600E mutation could stimulate RAI uptake in 60% of the 
patients in the study [39].  
 
Patients refractive to 131I are also considered for chemotherapy. Various new agents 
including doxorubicin, gemcitabine, oxaliplatin and combinatorial therapies are being 
investigated for the treatment of RAI refractory thyroid cancer. Further, with the 
increasing understanding of the molecular mechanisms underlying thyroid cancer, 
various molecular targeted therapies are also being extensively investigated for the 
treatment of RAI refractory thyroid cancer, which are discussed in the later sections. 
 
1.4 Types of thyroid cancer 
 
Thyroid cancer has been categorised into various types and subtypes, primarily based 
on histocytology, cell of origin and stage. Histologically, there are 4 main types of 
thyroid cancer – differentiated, anaplastic, poorly differentiated and medullary thyroid 
cancer (figure 1.3) [40]. 
 
Introduction	
	 26	
 
  
Figure 1.3: Main types of thyroid cancer. The broad classification, cellular origin and prevalence of the 
thyroid cancer are shown above. 
 
1.4.1 Differentiated thyroid cancer (DTC) 
 
DTC includes both papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC), 
which are very well differentiated cancers. Both originate from the follicular cells of the 
thyroid. Increase in the occurrence of thyroid cancer has been almost exclusively 
attributed to the increase in PTC [10]. Histopathology of PTC includes well 
recognisable papillar projections of the cells, calcified cellular clumps probably 
originating from the necrosed papillas and large, clear nuclei often referred to as 
‘Orphan Annie eyed’ nuclei, whereas FTC exhibits abnormal extracapsular and 
intravascular spread of thyroid follicles. PTC accounts for 80-85% of thyroid cancer 
[40]. Morphological variants of PTC include conventional PTC (CPTC), follicular-
variant of PTC (FVPTC) and tall-cell PTC. FTC accounts for only about 10-15% of 
total thyroid cancers, though they have high propensity for metastasis and poor 
prognosis. Hürthle cell carcinoma, though was earlier considered an oxyphilic variant of 
FTC, it is now widely being considered as a distinct clinicopathological entity and 
accounts for 3% of all thyroid carcinomas [40]. Presence of oncocytes - large polygonal 
cells with hyperchromatic nuclei and an eosinophilic granular cytoplasm as a result of 
abundant mitochondria, is a characteristic feature of Hürthle cell carcinoma [41]. 
Metastasis of DTC usually occurs in the lymph nodes, lungs and bone. The standard 
treatment for differentiated thyroid cancer is partial or complete thyroidectomy. In cases 
presented with aggressive disease or metastasis, surgery is followed by TSH 
suppression and radioactive iodine (RAI) ablation. Patients can be or develop 131I 
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refractiveness, in such cases they are subjected to levothyroxine treatment or focal 
treatment of metastasis is performed (surgery), if possible.  
 
1.4.2 Anaplastic thyroid cancer (ATC) 
 
ATC is an undifferentiated cancer that arises from the thyroid follicular cells. 
Aggressiveness and poor prognosis of thyroid cancer is inversely related to the degree 
of differentiation of the constituting cells, thus making ATC a very lethal type of 
thyroid cancer. They usually possess heavy mutational burden. An analytical validation 
study of hybridisation capture-based assay targeting all coding regions of 341 tumor 
associated genes by Cheng et al. detected a median mutation burden of 6 per tumor in 
ATC, which is much higher than the median mutation burden detected in PTC (1 per 
tumor), a relatively indolent type of thyroid cancer [42]. Many of the genetic alterations 
in ATC are also seen in the less aggressive DTC, thus indicating that ATC may derive 
de novo from DTC. This is also supported by histological studies that show that DTC 
exists in about 30-50% of ATC [43]. Though it is an uncommon (2-3%) form of thyroid 
cancer, it has been categorised as a stage IV disease by the American Joint Committee 
on Cancer Staging as it is a rapidly growing, highly aggressive cancer with mortality 
rate as high as almost 100% and has a median survival of only 5 months [44, 45]. Partly 
owing to the rarity of the disease, there is no defined treatment protocol for ATC. 
Treatment is usually multimodal and surgery is performed whenever possible – like 
when the cancer is only intra and/or extrathyroidal and has not invaded the 
aerodigestive tract. Less than 10% of patients presented with ATC have the tumor 
confined to the thyroid, while most patients also show local or distant metastasis [46]. 
So, surgery is followed by radiotherapy or chemotherapy and such multimodal 
treatment approaches seem to improve the overall survival of ATC patients [43]. 
Chemotherapeutics like docetaxel, paclitaxel and cisplatin have been used post 
surgically or in combination with radiation therapy in order to improve the overall 
survival of ATC patients. Owing to the improvement in understanding the biology and 
molecular basis of ATC, various drugs are being considered for targeted therapeutics. In 
May 2018, the FDA has approved a combinatorial chemotherapeutic treatment with 
dabrafenib (BRAF inhibitor) and trametinib (MEK1/2 inhibitor) for cases of local and 
distant metastasised ATC, which are diagnosed with a BRAFV600E mutation [47]. 
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1.4.3 Poorly differentiated thyroid cancer (PDTC) 
 
PDTC was considered as a variant of DTC until the World Health Organisation (WHO) 
classified it as a distinct pathological entity in 2004. The WHO define PDTC as 
follicular neoplasms that show limited evidence of structural follicular cell 
differentiation and occupy both morphologically and behaviorally an intermediate 
position between differentiated (follicular and papillary carcinomas) and 
undifferentiated (anaplastic) carcinomas. PDTC is not a commonly occurring type of 
thyroid cancer, studies imply its occurrence in 2-3% of thyroid cancer patients in North 
America [48]. Since it is a rare disease, there is not a lot of data available about the 
growth pattern, histological subtypes or prognostic markers of PDTC. In an attempt to 
report the treatment outcomes of 91 patients with a median follow up of 50 months, 
who were treated for PDTC with or without adjuvant therapy, it was observed that with 
appropriate surgical and adjuvant therapy, excellent locoregional control could be 
achieved and disease specific deaths mostly occurred due to distant metastases [49]. 
 
1.4.4 Medullary thyroid cancer (MTC) 
 
MTC is a relatively rare form of thyroid cancer (2-5% of all thyroid cancers), which 
arises from the parafollicular C cells of the thyroid. Elevated calcitonin levels are a 
characteristic feature of this tumor [50]. Nests of round or ovoid cells with fibrovascular 
stroma are the histopathological signatures of MTC. Majority cases (75-80%) of MTC 
are sporadic in occurrence, while others are associated with familial inheritance due to 
multiple endocrine neoplasia (MEN2A and MEN2B) or familial medullary thyroid 
cancer (FMTC). As the C cells reside on the upper poles of the thyroid gland, MTC 
patients often have nodules on the upper portions of the thyroid. While sporadic MTC is 
usually seen only in one of the two thyroid lobes, MEN associated MTC tend to occur 
bilaterally and are multicentric [50]. Indeed patients presented with distant metastasis 
have poorer prognosis (about 20% 10-years survival) when compared to the 95.6% 10-
years survival rate in patients with non-metastatic MTC [51]. Distant metastasis in 
MTC usually occurs in liver, lung and bone. Surgery is the primary line of treatment for 
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MTC, while it is non-responsive to conventional chemotherapy. Unlike cancers arising 
from the follicular cells, owing to its parafollicular origin, cells of the MTC cannot take 
up 131I and hence, the residual cells cannot be managed using RAI treatment. External 
beam radio therapy also has shown to be beneficial in the treatment of MTC including 
cases with unresectable metastasis [52]. A study by Berber et al. demonstrated that 
laparoscopic radiofrequency thermal ablation treatment in a group of patients with 
neuroendocrine liver metastasis prevented cancer progression in 41% of patients and 
65% patients showed a partial or significant reduction in tumor markers during follow-
up [53]. Assessment of serum calcitonin levels and also carcinoembryonic antigen post 
therapy monitors the prognosis of the patient, as absence both these markers in serum is 
an indication of disease free condition. MTC carries relatively lesser types of mutations 
and RET mutation is the predominant genetic alteration found. This has been exploited 
in the development of targeted therapy of MTC. In a randomised Phase III trial, 
vandetanib (multi kinase inhibitor against RET, VEGFR and EGFR) treatment in 
patients with locally advanced or metastatic hereditary MTC demonstrated a 
prolongation of progression free survival [54]. Another phase III study investigating the 
effect of cabozantinib (pantyrosine kinase inhibitor) in patients with progressive MTC 
showed that the drug benefitted the patients with improved response rates and 
progression free survival [55]. The US Food and Drug Administration (FDA) approved 
vandetanib and cabozantinib for the treatment of patients with progressive systemic 
disease [56-58].  
 
1.5 Genetic alterations in thyroid cancer 
1.5.1 Gene mutations  
 
Undisputedly, the advent of better diagnostic tools, particularly FNAB evaluation has 
improved the management of thyroid cancer. Yet, precise stratification and 
consequently the right therapeutic intervention and prediction of prognosis are major 
issues in the management of thyroid cancer. Clearly, understanding the molecular 
events underlying its pathogenesis can be a powerful tool in the refinement of 
stratification, staging and risk evaluation of thyroid cancers. So far, with the advances in 
molecular biology and genetic screening techniques, the field has managed to 
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remarkably expand the knowledge and understanding about the disease. Some major 
discoveries at the level of molecular mechanisms and pathogenesis of thyroid cancer are 
discussed below. 
                                                                                                                                                                                                                                                 
 
Figure 1.4: Main subtypes of thyroid cancer and associated genetic alterations (from [59]) 
 
1.5.1.1 BRAF mutation 
 
RAF kinases (ARAF, BRAF and CRAF) are serine-threonine kinases and play a central 
role in the mitogen-activated protein kinase (MAPK) pathway which comprises of the 
RAS-RAF-MEK1/2-ERK1/2 signal transduction network. This pathway plays an 
important role in the regulation of a variety of cellular processes including cell 
proliferation, differentiation, apoptosis and oncogenic transformation. Binding of GTP-
bound RAS, along with other regulatory events including phosphorylation, 
dephosphorylation and dimerisation results in the membrane recruitment and activation 
of RAF proteins, which in turn phosphorylate MEK1/2 at residues S217 and S221 
leading to the subsequent phosphorylation and activation of ERK1/2, which then 
alterations thathavebeendescribed for thyroid cancer and themost
recent efforts to ﬁnd other activated oncogenes, approximately 5%
to 10% of PTCs, 50% to 60% of MTCs, and 10% of ATCs are still
negative for all known genetic abnormalities (38, 39).
Mutations identiﬁed may have diagnostic and prognostic
implications, and provide an opportunity to develop therapies
that are targeted at these potential molecular drivers. BRAFmuta-
tions are present in 30% to 67% of PTCs and are associated with
locoregional metastases, extrathyroidal extension, and higher
AJCC stage at presentation (refs. 40–43; Fig. 2). Both BRAF and
TERT promoter mutations, which in one study were present in
13% of 242 PTCs, were associated with the clinicopathologic
features of high-risk thyroid cancer (44). These and other genetic
mutations and rearrangements, such as those affecting RAS, RET/
PTC, and PAX8/PPAR¤ , are now used as molecular markers and
included in a multigene mutational panel investigated in FNA or
surgically resected specimens. Using this gene panel to analyze
thyroid nodules with indeterminate cytology (Bethesda system)
showed 91% sensitivity and 92% speciﬁcity for cancer detection,
and a 97%negative predictive value and a 77%positive predictive
value (15, 45). Another approach to molecular diagnosis of
intermediate thyroid nodules is the gene expression classiﬁer
using extracted RNA and analysis of 167 transcripts (46). The
gene expression classiﬁer has a sensitivity of 92% and 52%
speciﬁcity, negative predictive values of 95%, and negative pre-
dictive value of 47%, respectively, for detecting benign nodules
(46). Additional studies validating themutation panels are ongo-
ing (47, 48); long-term outcome data from a strategy of using
molecular markers in indeterminate FNA specimens to stratify
surgical approach are currently lacking (15).
Once thyroid cancer is highly suspected or diagnosed, a deci-
sion must be made regarding the extent of surgery. Risk factors
must be taken into consideration, like clinical risk factors asso-
ciated with aggressive tumor behavior, the patient's age and sex,
the initial tumor size and location, the presence of lymph node
and/or distant metastases, cytologic and mutational data, and
patient preferences. A positive test for BRAF mutations means a
close to 100% probability of malignancy (49, 50)—this is likely
helpful to guide the extent of thyroidectomy.
Surgical Therapy for DTC
The treatment for thyroid cancer is predominantly surgical, and
total thyroidectomy with preservation of the recurrent laryngeal
nerve and parathyroid glands is generally considered standard.
This achieves disease clearance and minimizes the risk of thyroid
bed recurrence. A second aim of primary surgery is preparing the
patient for adjuvant radioactive iodine (RAI) therapy by removing
all thyroid tissue. This allows optimal follow-up using thyroglob-
ulin (TG) as a tumor marker and addresses concerns about
multifocal disease within the gland. PTC commonly metastasizes
to the central neck, followed by the lateral neck. If this is
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translocate to the nucleus and phosphorylates transcription factors, thereby regulating 
the expression of various genes [60]. Owing to its constitutive phosphorylation at S445 
and the presence of negatively charged amino acid in the N-region, BRAF seems to be 
more primed for activation in comparison with ARAF and CRAF [61]. Among the RAF 
kinases, BRAF exhibits the highest basal kinase activity and has the strongest activity as 
well as binding affinity towards MEK [62]. Mutations in BRAF are among the most 
common molecular events in human cancer including melanoma, colorectal cancer and 
non-small cell lung (NSCLC) cancer. About 30 single site missense mutations 
associated with BRAF in human cancers have been identified, mostly within the 
glycine-rich ATP-phosphate-binding P-loop or the activation segment within or 
adjacent to the DFG motif, both of which are located in the protein kinase domain 
proximal to the C-terminus, and majority of these mutations leads to increased BRAF 
kinase activity [63]. 90% of BRAF mutations are attributed to the point mutation caused 
by the substitution of Valine for Glutamic acid at residue 600 in the activation segment 
of BRAF (BRAFV600E). BRAFV600E has elevated kinase activity and has the ability 
to stimulate ERK1/2 activity independent of RAS activation [64]. A study by Paul 
T.C.Wan et al. showed that substitution of the medium sized, hydrophobic valine side 
chain with a larger, charged residue like glutamic acid would confer an active 
conformation to BRAF by destabilizing the interactions that maintains the DFG motif in 
an inactive state [63].  
 
BRAFV600E is the most frequent genetic alteration seen in PTC, occurring in about 36-
83% cases [65]. It is also prevalent in up to 25% of ATC cases, but does not seem to 
occur in neither FTC nor MTC [40]. A rarer form of BRAF mutation is the 
BRAFK601E resulting also in the activation of the MAPK pathway, which was 
detected in about only 5% of the follicular variant of PTC [66]. A comprehensive meta-
analysis examining the association of BRAFV600E with clinicopathological outcomes 
demonstrated that patients carrying this mutation are closely related to high-risk 
clinicopathological factors like extrathyroidal invasion and advanced TNM (tumor, 
node, metastasis) stage across different study populations [67]. A retrospective 
multicentre study investigating the relationship between BRAFV600E mutation and 
recurrence of PTC demonstrated that in patients with the mutation, recurrence rates 
were significantly higher than in patients without the mutation, even in patients 
diagnosed with low risk stage I and II disease [68]. However, these observations seem 
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to be contradictory. In a study by Trovissco et al. it was observed that BRAFV600E 
mutation was exclusively detected in PTC with a papillary or mixed follicular/papillary 
architecture, although did not correlate with tumor aggressiveness, hence implying a 
predictable phenotype associated with BRAFV600E genotype [66]. The study also 
indicated that PTC harbouring BRAFV600E mutation did not correlate with higher 
aggressiveness in terms of vascular invasion, extra-thyroid extension and nodal 
metastasis and were less often multicentric than PTC without BRAFV600E mutation. In 
another extensive study, Henke L.E et al. analysed the relationship between BRAF 
mutation status and recurrence-free survival (RFS) and disease specific survival (DSS) 
[69]. While the multivariate analysis correlated the presence of BRAFV600E mutation 
with capsular invasion, cervical node involvement and classic papillary histology, it did 
not find any significant correlation with recurrence-free survival and disease specific 
survival. Similar findings were reported in a study which compared the 
clinicopathological features of PTC patients with and without BRAF mutation which 
concluded that there was no significant association between BRAF mutation and 
features suggestive of disease aggressiveness like tumor multicentricity, 
lymphovascular invasion, extranodal extension, central neck involvement, advanced 
stage, and distant metastasis [70]. All these studies suggest that BRAF is minimally 
prognostic in PTC.  
 
Despite the uncertainties regarding BRAFV600E as a significant prognostic predictor, 
efforts were put into exploiting BRAFV600E as a candidate for targeted therapy in 
ATC, as differentiated thyroid cancer with BRAFV600E mutation with late-event 
mutations is thought to lead to progressive dedifferentiation to ATC. McFadden et al. 
demonstrated that though treatment of ATC-bearing BRAFV600E with only BRAF 
inhibitor (PLX4720) did not lead to tumor regression, the combination of (PLX4720) 
and MEK inhibitor (PD0325901) suppressed the MAPK signalling in mouse and human 
ATC cell lines and improved the survival of the mouse models [71]. Subsequently, a 
Phase II trail in ATC patients with BRAFV600E mutation showed that combination 
therapy targeting both BRAF (dabrafenib) and MEK1/2 (trametinib) demonstrated a 
high overall response rate, prolonged duration of survival and survival with manageable 
toxicity [72]. Currently, the FDA has approved combination therapy with dabrafenib 
and trametinib for the treatment of patients positive for BRAFV600E with unresectable 
ATC [47]. A phase I study wherein patients with BRAFV600E positive metastatic PTC 
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were treated with the oncogenic BRAF kinase inhibitor Vemurafenib showed that the 
treatment resulted in partial response and prolonged stabilisation of locoregional and 
distant disease, thus suggesting potential clinical benefits of targeted therapy with 
Vemurafenib in BRAFV600E PTC patients [73]. This was further demonstrated by 
antitumor activity of Vemurafenib in a phase II trial including patients with recurrent or 
metastatic BRAFV600E positive PTC refractory to 131I treatment [74]. 
 
1.5.1.2 Rat sarcoma (RAS) mutations 
 
Ras genes are proto-oncogenes originally identified in the genome of rodents. By 
introducing them into human cells in vitro, cells were transformed [75]. In normal cells, 
RAS is ubiquitously present and RAS signals via various downstream effector pathways 
including RAF-MEK-ERK and PI3K-Akt pathways. These pathways are important in 
the regulation of various cellular processes including growth, differentiation, apoptosis 
and membrane trafficking. RAS is a guanine nucleotide binding protein – RAS in the 
GTP bound state is active, while GDP bound RAS is inactive. Upon growth factor 
stimulation, the RAS guanine nucleotide exchange factors (RASGEFS) activates 
RASGDP to RASGTP by the release of GDP and transient formation of RASGTP, 
subsequently activating the downstream signalling pathways. RAS GTPase activating 
proteins (RASGAPs) hydrolyses the RAS bound GTP to return RAS to its inactive 
state. When RAS is mutated, RAS lacks any intrinsic or RASGAP mediated hydrolysis 
activity, thus RAS is stabilized in its active GTP bound state [76]. About 30% of all 
human cancer including lung, colon and pancreatic cancer which are listed as 3 of the 
top 4 cancer killers, carry activating RAS mutations [77]. RAS genes encode four 
mammalian protein isoforms – KRAS 4A, KRAS 4B, HRAS and NRAS. KRAS is the 
most frequently mutated isoform (86%), followed by NRAS (11%) and HRAS (3%) 
[78]. Up to 99% of mutations occur at the residues G12 and G13 located in exon 1 or 
Q61 located in exon 2 [78]. Although RAS signalling has been extensively studied and 
various approaches including targeting mutant RAS, GTP-competitive inhibition of 
RAS or inhibition of RAS isoprenylation mediated membrane association of RAS, 
which is a key step in the activation of RAS, RAS proteins still remain as undruggable 
targets. Up to date there are no inhibitors of RAS approved for use in clinic. 
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 Mutations in all three RAS genes have been reported in various types of thyroid cancer 
though studies suggest that mutation in NRAS (67-88%) is the most prevalent RAS 
mutation in thyroid cancer [79]. RAS mutations occur more in FTC (40-50%) when 
compared to PTC (10-20%) most of which are FVPTC, as well as in PDTC and ATC. 
They are also present in about 20-40% of non malignant follicular adenomas [40]. Its 
prevalence in FTC makes it utilizable as a diagnostic marker, but since RAS mutations 
are present in both benign and malignant thyroid tumors, its role as a prognostic 
predictor is controversial [79]. When the occurrence of RAS mutations across the full 
differentiation spectrum of thyroid cancer was examined, its presence was detected in 
all stages of differentiation from early anapalsia to late anaplastic stages [80]. Existence 
of RAS mutations in the more evolved PDTC and ATC along with other mutations 
might be indicative of the possibility of earlier acquired RAS mutations predisposing 
the differentiated cancer to further molecular alterations resulting in the 
dedifferentiation and aggressiveness of cancer [79]. There are few studies that relates 
RAS mutation with distant metastasis, recurrence and death, hence associated the 
mutation with poor prognosis/outcome [79]. A study in which the regions of RAS 
codons 12,13 and 61 were sequenced indicated that NRASQ61 mutation was prevalent 
in follicular adenoma and FTC [81]. This was also suggested in other studies, while 
Hurthle cell carcinomas lacked this mutation and exhibited mutation of HRAS and 
KRAS conferring a histotypic association [82].  
 
1.5.1.3 TERT Activation and mutations 
 
Telomeres are special chromatin structures, comprising of repetitive chromosomal 
regions that play an important role in the maintenance of the structural integrity and 
stability of the chromosomes. In humans, the telomeres contain tandem repeats of 
TTAGGG sequence and as a consequence of the inability of DNA polymerase to 
completely replicate the linear chromosomes at the end, these repeats are lost 
progressively during the course of continuous cell division, resulting in the shortening 
of telomeres and leading to chromosomal instability and loss of cell viability [83]. The 
mammalian telomeres consist of various components including telomerase, various 
telomere binding proteins, chromatin regulators and DNA repair proteins [84]. The 
most extensively studied and a very important component of the telomere complex is 
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telomerase. This enzyme is involved in the maintenance of telomere length by adding 
tandem repeat sequences to the 3’end of the telomeres. The telomerase is comprised of 
the reverse transcriptase catalytic subunit (TERT), which adds tandem repeat sequences 
to the 3’ end of the telomeres and the RNA subunit that serves as the template for DNA 
addition by TERT. Expression and activity of telomerase is tightly regulated, it is highly 
expressed in cells that have high proliferative potential and is, thus, considered as a 
hallmark of cancer [85]. A study by Kim et al. demonstrated that in cells cultured from 
different human tissues, 98 of the 100 immortal cell types were positive for telomerase 
activity while, all the mortal cell types were negative for telomerase. Hence, a link 
between telomerase activity and cell immortality is implied [86]. Further, a comparison 
of telomerase activity between human primary tumor material and normal somatic 
tissues revealed the presence of telomerase in 89% of biopsies representing 12 different 
types of tumor, while it was absent in all the normal and benign tissues tested [86]. 
Various other studies have also investigated and strengthened the idea of the link 
between telomerase activity and cell proliferation, immortalization and tumor growth 
[87]. TERT is expressed in up to 90% of all human cancers and has been shown to have 
a dominant role in the reactivation of telomerase leading to the malignant 
transformation of cells [88]. Many studies also demonstrate the role of other 
mechanisms than just telomere elongation that accounts for the role of reactivated 
telomerase in cancer. Telomerase has been shown to directly regulate NF-κB-dependent 
gene expression [89], modulate EGFR regulated growth promotion [90] and stabilise 
MYC levels thereby regulating MYC driven oncogenesis [91]. 
 
Apart from the ‘solid cell nests’ of the thyroid, which are thought to be a pool of stem 
cells in the adult thyroid that are positive for telomerase activity, the rest of the cells in 
the thyroid are negative for telomerase activity [92]. While up to 80-90% of various 
human cancer types exhibit telomerase activation, an analysis of results from many 
studies that examined telomerase activity suggested that only about 66% of thyroid 
cancer had telomerase activation [93]. This study also showed that telomerase activation 
was more associated with ATC, the more advanced form of thyroid cancer (up to 78%). 
Activation was also present in both PTC and FTC but with a lesser frequency. Apart 
from the increased telomerase activity, mutations in the promoter region of TERT have 
also emerged as a carcinogenic event in thyroid cancer. Mutations at residues 228 
(C228T) and 250 (C250T) of TERT, of which the C228T is far more common but occur 
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mutually exclusively with C250T, are known to be associated with thyroid cancer 
arising from the follicular cells - PTC, FTC, PDTC and ATC, though is more prevalent 
in the more aggressive PTDC and ATC, while no mutations were found in the 
parafollicular C cells derived MTC [94]. Mechanistically, both mutations contain a 11 
base pair nucleotide which serves as a consensus binding site for E-twenty-six (ETS) 
transcription factors resulting in the augmentation of TERT mediated transcriptional 
activity [95]. TERT mutations coexist with BRAF as well as RAS mutation carrying 
thyroid cancers [96]. Studies associate TERT promoter mutations with aggressive 
clinicopathological parameters like distant metastasis, advanced disease stage, cancer 
recurrence and patient mortality [96]. 
 
 
1.5.1.4 TP53 mutations 
 
Mutations in the tumor suppressor gene TP53 leading to either dominant negative 
expression of the mutated P53 or complete absence of the protein have been associated 
with various human cancers including colon, lung, brain and breast cancer. TP53 
inactivation was thought to be mostly absent in well-differentiated types of thyroid 
cancer, while it was associated with ATC (seen in up to 59%), hence has been 
considered as a hallmark of ATC [97]. Though a more recent study that employed next 
generation sequencing (NGS) to analyse DNA from 228 thyroid neoplastic and non-
neoplastic samples revealed the presence of TP53 mutations concurrent with 
BRAFV600E bearing PTC in 2 of the 19 samples in which mutations were identified 
[98]. While one of these cases presented with lung metastasis, the other presented with 
local reccurrence. This study also could detect TP53 mutation in about 20% of Hürthle 
cell carcinoma, hence implying the mutation as an indicator of tumors with a tendency 
for dedifferentiation. The detection was attributed to the high allelic frequency of these 
mutations, rather than the sensitivity of the NGS approach. 
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1.5.1.5 PI3K, AKT and PTEN alterations 
 
The phosphoinositide 3-kinase (PI3K)/Akt signalling pathways can be activated by both 
receptor tyrosine kinases (RTKs) and G-protein-coupled receptors and is important in 
the regulation of various cellular processes including cell growth, proliferation and 
survival. The p110 catalytic subunit of PI3K can be activated by the binding of RAS to 
its RAS binding site or by the activation of RTKs like epidermal growth factor receptor 
(EGFR), vascular epithelial growth factor receptor (VEGFR), platelet-derived growth 
factor receptor (PDGFR) in response to growth factor stimulation. In turn this results in 
the membrane localisation and activation of AKT, which triggers the mammalian target 
of rapamycin (mTOR signalling) leading to cellular consequences including increased 
cell survival, cell migration and inhibition of apoptosis [99]. Activating mutations in 
PIK3CA, the gene encoding for the α-type p110 catalytic subunit of the PI3K heteromer 
(PIK3CA) is prevalent in many human cancers including ovarian, breast and colorectal 
cancers [100]. In a study that investigated PIK3CA mutations in DTC and ATC, non-
synonymous mutations were identified in 23% of ATC, 8% of FTC and 2% of PTC and 
activation of AKT was seen in most of the ATC with PIK3CA mutations [101]. Also, in 
PIK3CA mutation positive cases where ATC coexisted with differentiated cancer, the 
mutations were restricted to the ATC component within the kinase domain. Hence, 
these observations imply an oncogenic role of PIK3CA rather in ATC than in well-
differentiated thyroid carcinoma. Another major genetic alteration involving the 
PIK3CA gene is copy number gain, which is seen in FTC (24%) and more prominently 
in ATC (42%) [102, 103]. PTEN is a phosphatase protein that antagonizes the 
PI3K/AKT pathway and acts as a major tumor suppressor protein and is inactivated in 
many cancers by gene mutations or epigenetic gene silencing. A study by Halachmi N 
et al. demonstrated that 27% of follicular carcinomas and 7% of follicular adenomas 
exhibited loss of PTEN heterozygosity implying the inactivation of PTEN in follicular 
thyroid cancer [104]. A more recent study demonstrated PTEN inactivation in up to 
24.5% of PTC samples, especially the follicular variant of PTC [105]. However, in the 
presented immunohistochemical studies no association between loss of protein 
expression and gene deletion were found. Thus, other mechanisms like promoter 
methylation-mediated gene silencing might lead to the inactivation of PTEN. 
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Figure 1.5: Major oncogenic alterations in the MAPK and PI3K-AKT-MTOR pathways occurring in 
thyroid cancer (from [106]). (Gain of function mutations indicated by *) 
 
 
1.5.2 Gene Fusions 
 
Chromosomal translocations between genes belonging to the same or different 
chromosomes can give rise to different patterns of chimeric transcripts. The expression 
of these chimeric transcripts may result in fusion proteins having altered functions and 
thus may have pathological consequences. Figure 1.6 shows a schematic representation 
of the various patterns of chromosomal rearrangements.  
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Molecular diagnostics
Cytology
FNAB and cytological assessment have been a corner-
stone of diagnostic thyroid nodule management since the 
1980s and this basic preoperative assessment has sub-
stantially reduced the number of patients sent for 
diagnostic surgery for nodules that ultimately prove to be 
benign. A meta-review of 11 large studies from the USA, 
published between 2002 and 2010, showed that a median 
of 72% (range 62–85%) of FNAB undertaken were benign, 
5% (1–8%) were malignant, 17% (10–26%) were 
indeterminate, and 6% (1–11%) were non-diag nostic.14 A 
median of 34% (range 14–48%) of patients with 
indeterminate cytology who underwent surgery had a 
malignancy. This occurrence is too high to recommend 
watchful waiting. The United States National Cancer 
Institute (NCI) sponsored a State of the Science Con-
ference in 2007, in Bethesda, MD, to review diagnostic 
terminology and morphological criteria for cytological 
diagnosis of thyroid lesions. The investigators proposed a 
Bethesda classifi cation scheme that divided indeter-
minate FNAB results into three subcategories: atypia 
of undetermined signifi cance or follicular lesion of 
undetermined signifi cance, with malignancy in 5–10% of 
cases; follicular neoplasm or suspicious for follicular 
neoplasm, with malignancy in 20–30% of cases; and 
suspicious for malignancy, with malignancy in 50–75% of 
cases.15 Large FNAB studies applying the NCI Bethesda 
classifi cation scheme have confi rmed the malignancy 
rates for follicular neoplasm or suspicious for follicular 
neoplasm and suspicious for malignancy cited at the NCI 
Conference, but occurence of malignancy for patients 
undergoing diagnostic surgery for atypia of undetermined 
signifi cance or follicular lesion of un determined signifi -
cance was much more variable (7–48%), suggesting that 
watchful waiting might not be the best approach.16–20 
Ideally, FNAB and cytological interpretation should be 
done by specialists with much experience of the pro-
cedures to reduce the variability noted in the atypia of 
undetermined signifi cance or follicular lesion of undeter-
mined signifi cance category, but because of the many 
patients with thyroid nodules undergoing assessment, 
this recommendation might not be practical.
Most patients with an FNAB specimen suspicious for 
malignancy should undergo surgery and the question is 
what type of diagnostic or therapeutic surgery should be 
done. Diagnostic surgery, a lobectomy, or total thyroid-
ectomy is used to establish whether a thyroid nodule is 
benign or malignant, whereas therapeutic thyroid 
surgery is done to decrease the risk of cancer recurrence 
and mortality. Patients with atypia of undetermined 
signifi cance or follicular lesion of undetermined signifi -
cance or follicular neoplasm or suspicious for follicular 
neoplasm FNAB cytology have a lower risk of malignancy 
than do those with nodules suspicious for malignancy, 
but, as discussed for the indeterminate cytology overall, 
this risk might be too high for watchful waiting in most 
patients. The question for these patients is whether 
other preoperative diagnostic instruments are available 
to help confi dently avoid diagnostic surgery in those 
who do not need it.
Molecular markers
Ident fi cation of uitable olecular markers t  guide 
surgery or watchful waiting for patients with indeter-
minate FNAB of thyroid nodules has been the so-called 
holy grail of thyroid nodule research for more than 
20 years. Many potential markers and combinations of 
markers have been studied in thyroid tissues and FNAB 
specimens.21–23 Here, we focus on large studies assess-
ing these molecular markers in FNAB specimens with 
indeter minate cytology, which is where the need for such 
Figure 1: MAPK and PI3K-AKT-MTOR pathways—genetic alterations and therapeutic targets in thyroid cancer
Right side sh ws the MAPK pathway; left side hows e PI3K- KT-MTOR pathway. The two classic signalling 
pathways are coupled to the receptor thyrosine kinase (RTK) at the cell membrane which transduces extracellular 
growth signals into intracellular signalling downstream of the two pathways. RAS can couple the signalling from 
RTK to both pathways. PTEN terminates the PI3K signalling. Genetic RTK amplifi cations are common. Common 
activating mutations in the MAPK pathway include RET-PTC rearrangement, RAS mutation, and BRAF mutation. 
Common genetic alterations in the PI3K pathway include RAS mutation, PTEN mutation or deletion, PIK3CA 
mutation or amplifi cation, and AKT1 mutation. The two pathways, driven by these genetic alterations, have a 
fundamental role in thyroid tumorigenesis. Amplifi cations of RTK genes are also common. *Denotes therapeutic 
targets in the two pathways that are currently being actively tested clinically. 
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            Figure 1.6: Schematic representation of the various patterns of chromosomal rearrangements 
(from [107]).  
 
Kinase fusions, particularly tyrosine kinase (TK) fusions seem to occur at higher rates 
in thyroid cancers. The major oncogenic fusions that are known to occur in thyroid 
cancer are discussed below. 
 
 
1.5.2.1 RET fusions 
 
In 1985, Takahashi M et al. identified a novel-transforming gene present in NIH3T3 
cells that were transfected with human lymphoma DNA [108]. The transforming gene 
consisted of two segments of DNA that were unlinked in normal human and primary 
growth and proliferation. TFE3 is involved in chromo-
somal translocations that result in various gene fusions
(such as PRCC-TFE3, RCC17-TFE3, PSF-TFE3, NON-
O(p54nrb)-TFE3 and ASPL-TFE3) in papillary renal cell
carcinomas. PLAG1 is an oncogenic tra scription factor
associated with the neoplastic transformation of pleo-
morphic adenomas of the salivary gland and lipoblastomas
through upregulation of IGF2, CRLF1, CRABP2, CRIP2,
and PIGF. NFIB binds viral and cellular promoters activat-
ing transcription and replication. POU5F1 and PAX8 are
homeobox-containing transcription factors, a family of
genes that play a role in cell fate and differentiation pro-
grams, and whose role in cancer is well recognized, particu-
larly PAX8 in thyroid cancer [22].
Other functional classes
Metabolic enzymes
CD44-SLC1A2/EAAT2 gene fusions are detected in 1–
2 % of gastric cancers involving the glutamate transporter
SLC1A2 [85], and cause intracell lar accumulation of glu-
tamate, a growth-promoting amino acid associated with
oncogenic functions [97, 98]. Thus, this gene fusion
may be establishing a pro-oncogenic metabolic milieu,
akin to the increased levels of sarcosine reported in
prostate cancer [99].
Wnt/β-catenin signaling pathway
RNA sequencing of 68 “microsatellite stable” subtype
colorectal cancer samples revealed two recurrent fusions
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Fig. 2 Diversity in the architecture of gene fusions. Schematic representation of different patterns of chromosomal rearrangements inferred from
chimeric transcripts. Exons of genes involved in fusions are shown in blue and orange, and their transcriptional orientation is denoted by arrows.
The likely mechanisms of chimera generation are indicated. Chr chromosome
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lymphoma DNAs but were co-transcribed in transformed NIH3T3 cells. This 
transforming gene was activated by rearrangement of normal human DNAs during the 
transfection process and was called REarranged during Transfection (RET). Following 
its initial discovery in transforming NIH3T3 cells, the RET transforming gene was 
characterised as a recombination between the RET proto-oncogene, encoding a putative 
kinase receptor, and the rfp gene, encoding for a putative zinc finger protein [109, 110]. 
The RET protein is a single-pass transmembrane, tyrosine kinase protein which has 
three splice isoforms – RET9, RET43 and RET51, of which RET9 and RET51 are the 
most abundant isoforms [111]. RET is expressed in the precursor cells of the neuronal 
crest and urogenital tract and is known to play an important role in the development of 
several subpopulations of cells derived from the neuronal crest, including enteric, 
sensory and sympathetic neurons, kidney and spermatogenesis [112, 113]. RET 
signalling involves its activation triggered by the binding of ligands belonging to the 
GDNF family to the glycosylphophatidylinositol-anchored GDNF-family receptors to 
form a ligand-receptor complex which then interacts with RET leading to the 
subsequent autophosphorylation and activation of RET [113]. RET signalling regulates 
various pathways involved in cell survival, differentiation, proliferation and migration. 
Different signalling pathways are triggered by phosphorylation of the different sites of 
RET kinases – up to 18 different phosphorylation sites have been identified in RET 43 
and 51, while RET 9 has 16 phosphorylation sites of which at least 12 are 
autophosphorylation sites [114]. The RET signal transduction is involved in the 
activation of various proteins and associated pathways including Src, Protein Kinase C 
enzymes, PI3K/AKT pathway, MAPK pathway and JNK pathway [113]. 
 
The clinical significance of RET rearrangements or fusions was first demonstrated in 
PTC and now we know that these fusions are a common event in PTC, and occur in up 
to 40% of PTC patients [113]. These chromosomal aberrations occur as a consequence 
of DNA damage occurring after exposure to external radiation. It was reported that 60% 
cases of post Chernobyl PTCs were positive for RET fusions and it was also prevalent 
in patients who underwent external irradiation for the treatment of benign or malignant 
disease [115, 116]. Gene fusions involving RET are such that the kinase domain 
containing C terminus of the RET gene, which in most cases is not normally expressed 
in the thyroid follicular cells, is fused with the promoter containing N terminus of an 
unrelated gene which is ubiquitously expressed in these cells. A study by Nikiforova et 
Introduction	
	 41	
al. implied that spatial contiguity of the genes involved in the fusion during interphase 
may be the structural basis for radiation induced gene fusions [117]. 11 in 12 
autophosphorylation sites are preserved in the fusion protein. The phosphorylation of 3 
sites - Y905, Y1015 and Y1062, which is important for promoting cell survival and 
clonal propagation, recruitment of various signal transduction proteins are required for 
the oncogenic signalling of RET fusions [113, 114]. In almost all cases the breakpoint 
in the ret gene involved in the fusions occurred at sites distributed across intron 11 of 
the gene, which resulted in the loss of transmembrane domain as well as the deletion of 
negative regulatory domains of the protein, hence promoting the cytoplasmic 
localisation, constitutive and ligand-independent activation of the fusion protein [118, 
119]. Further, almost all the fusion partners of RET protein are predicted to possess a 
coiled-coiled domain which are protein-protein interaction domains able to mediate 
dimerisation of proteins. As dimerisation is an important event in the oncogenic 
activation of RET fusions, these domains play an important role in RET fusion- 
mediated oncogenesis. Figure 1.7 summarises the crucial events involved in the 
activation of RET fusion proteins [119]. As a consequence of RET fusions, various 
oncogenic signalling pathways are hyperactivated including ERK1/2 signalling [120], 
PI3K/AKT signalling [121], NFkB signalling [122] as well as activation of signal 
transducer and activator of transcription (STAT1) [121, 123]. RET/PTCs are known to 
exist mutually exclusively with activating RAS and BRAF mutations [124].  
So far, 12 different RET fusion partner genes have been identified and some of them 
have different breakpoints hence giving rise to 17 different RET fusion oncogenes. 
Figure 1.8 (bottom panel) schematically illustrates many of the RET fusion genes 
reported so far. RET fusions account for up to 13-25% of PTCs and for up to 13% of 
PDTCs [125]. Of these RET/PTC1 and RET/PTC3 are the most commonly occurring 
RET fusions accounting for up to 60-70% and 20-30%, respectively [113]. CCDC6 and 
NcoA4 are the respective fusion partners of RET/PTC1 and RET/PTC3, and both these 
partners are located on the same chromosome as RET (chromosome 10). It has also 
been reported that other fusion partners are present in different chromosomes, hence 
implying paracentric inversion and chromosomal translocation as the mechanism of 
DNA rearrangement underlying RET fusions [119]. 
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                       Figure 1.7: Important events in the activation of RET fusions (from [126]). 
 
Some groups successfully established transgenic mouse models expressing RET/PTCS: 
In these models animals develop slowly progressive thyroid carcinomas, which 
exhibited nuclear cytogenic features, developed thyroid hyperplasia and local invasion 
similar to human PTC [127-129]. A study by Santoro et al. showed that injection of 
RET/PTC into a differentiated rat thyroid epithelial cell line resulted in the complete 
loss of their thyroid differentiation markers as well as their ability to trap iodine, 
although RET/PTC expression was not enough to transform these cells in vitro (soft 
agar colonies) or induce tumors in nude mice. But with the introduction of additional 
KRAS mutations, these cells could achieve a malignant phenotype, hence implying the 
possible involvement of other genetic alterations in RET/PTC harboring tumors [130]. 
The prognostic relevance of these fusions are still not very clear though some studies 
could associate particular fusions with certain types of thyroid cancer. The RET/PTC3 
fusion was found to be highly enriched in children who were victims of the Chernobyl 
tragedy and patients suffering from a more aggressive solid variant of PTC [131]. 
RET/PTC has also been associated with Hürthle cell carcinoma. Apart from PTCs, 
recent studies reported the detection of RET fusions including RET/PTC1, RET/PTC3 
in NSCLC, colon adenocarcinoma as well as breast cancer [132-134].  
 
Targeted next generation sequencing studies that aimed at studying the genomic 
landscape of RET aberrations in human cancers implied that RET aberrations occurred 
Menicali et al. Thyroid cell transformation by RET/PTC
rare types of RET/PTC are inter-chromosomal translocations
(Castellone and Santoro, 2008).
Several mechanisms sustain the conversion of RET in a dom-
inant oncogene for thyroid follicular cells after formation of
RET/PTCs (Figure 4). In first instance, the ubiquitously expressed
promoter of the fusion partner warrants ectopic RET expression
in the cells harboring the rearrangement. Moreover, the partner
genes are predicted to provide one or more coiled-coil domains
that are essential for dimerization and ligand-independent activa-
tion of the truncated RET protein (Bongarzone et al., 1993; Tong
et al., 1997; Monaco et al., 2001). Furthermore, RET/PTCs lack
FIGURE 3 | Schematic drawing of RET/PTC variants. At least 13
RET/PTC variants have been reported to date, that differ according to the 5′
partner gene involved in the rearrangement.
the intracellular juxtamembrane domain which forms an integral
part of the autoinhibited RET dimer interface (Knowles et al.,
2006). As a consequence the TK domain is favored to adopt the
active conformation. Finally, the delocalization of the rearranged
protein to the cytosol is also expected to contribute to activa-
tion of the oncogene (Castellone and Santoro, 2008). In first
instance, the altered subcellular localization uncouples RET/PTCs
from receptor-mediated endocytosis and lysosomal degradation,
leading to increased protein stability (Richardson et al., 2009).
Moreover, it could prevent RET/PTC from interacting with nega-
tive regulators located at plasma membrane level, i.e., the tyrosine
phosphatase ProteinTyrosine Phosphates Receptor type-J (PTPRJ;
Iervolino et al., 2006).
The possible functional interactions between RET/PTC and
EGFR in PCCL3 cells was examined after the observation that the
epidermal growth factor receptor (EGFR) kinase inhibitor PKI166
decreased RET/PTC kinase auto-phosphorylation and activation
of downstream effectors in thyroid cells (Croyle et al., 2008). This
study showed that RET/PTC induces EGFR gene expression and
kinase activation in part through MAPK signaling and forms a
complex with EGFR in a kinase-independent manner. In turn
EGFR stimulates RET phosphorylation (Croyle et al., 2008).
It is well known that PTC in general, but those harboring
RET/PTC rearrangements in particular, present relatively indo-
lent phenotypes compared with RET -related medullary thyroid
carcinomas (MTC; Elisei et al., 2008). Considering that RET/PTCs
possess similar if not greater oncogenic potential thanmembrane-
bound RET when expressed at similar levels (Richardson et al.,
2009), the explanation of this phenotype difference has to be
searched in divergences of the oncogene expression levels or of the
FIGURE 4 | Mechanism of RET/PTC activation. (1) The ubiquitously
expressed promoter of the fusion partner warrants ectopic RET expression in
the cells harboring the rearrangement. (2) The partner genes provide one or
more coiled-coil domains that are essential for dimerization and
ligand-independent activation of the truncated RET protein. (3) The lack of the
inhibitory intracellular juxtamembrane domain favors RET/PTC to adopt the
active conformation. (4) The delocalization of the rearranged protein to the
cytosol abolishes receptor-mediated endocytosis and lysosomal degradation,
leading to increased protein stability, and interaction with negative regulators
located at plasma membrane level. (5) RET fusion genes appear to code
negative modulators of transformation. Thus, their structural alteration might
contribute to the oncogenic potential of the RET/PTC rearrangements.
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in up to 1.8% of the 4,871 cancers analysed and mutations in RET were the most 
common aberrations accounting for up to 38.6% RET aberrations [135]. Activating 
somatic mutations of RET has also been reported in thyroid cancer and they are found 
in about 40-50% of sporadic MTCs, though they are not known to occur in follicular 
cell derived DTC [136]. M918T mutation is the most commonly occurring RET 
mutation in MTC [137]. Other RET mutations associated with MTC include mutations 
in codon 634, 883, 630 and 611 [136]. Germ line mutations of RET are hallmarks of 
Multiple Endocrine Neoplasia (MEN2) that include MEN2A, MEN2B and familial 
MTC [136]. A study by Shumei Kato et al. wherein 4,871 patients were screened for 
RET aberrations in various cancers reported that RET mutations were also detected in 
16.7% of ATC as well as paraganglioma and urothelial carcinoma [135]. As far as 
targeted therapy of RET altered cancers are concerned, only multikinase inhibitors 
(MKIs), which nonselectively inhibit RET are used in the clinics. Vandetanib is a MKI 
capable of blocking the tyrosine kinase activity of vascular endothelial growth factor 
receptor 2 (VEGFR2), epidermal growth factor receptor (EGFR) as well as RET 
kinases. A double-blind phase III trial involving 331 patients with advanced MTC 
demonstrated therapeutic efficiency of this drug and currently vandetanib is an FDA 
approved drug for MTC [54]. Cabozantinib (XL184), yet another inhibitor that inhibits 
multiple tyrosine kinases in a phase III clinical trial demonstrated an improvement in 
the progression free survival of MTC patients across all subgroups including by age, 
prior tyrosine kinase inhibitor (TKI) treatment and RET mutations associated with both 
hereditary and sporadic MTCs [55]. FDA approved cabozantinib for the treatment of 
MTC in 2012. As both these drugs and many other MKIs are non-specific inhibitors, 
they are quite obviously associated with off target side effects, and not very successful 
in the potent reduction of RET pathway. 
Hence, there are a lot of efforts being made in search of inhibitors, which are more 
specific to RET. A recent study by Subbiah et al. tested the ability of LOXO-292, a 
highly selective ATP-competitive small molecule RET inhibitor in the inhibition of 
diverse RET fusions, activating mutations and acquired resistance mutations [138]. 
They demonstrated that LOXO-292 was effective as a RET specific inhibitor in cell 
lines harboring RET alterations and patient-derived xenografts. Further, they could 
show that LOXO-293 treatment in a patient with metastatic M918T MTC, who also 
possessed an acquired RET V804M gatekeeper resistance mutation, following treatment 
with six MKI regimens showed a tumor response demonstrated by rapid reductions in 
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tumor calcitonin, cell-free DNA, resolution of painful hepatomegaly and tumor-related 
diarrhea. 
 
 
 
 
 Figure 1.8: Top panel: Schematic drawing of RET protein (JM-juxtramembrane domain, TM – 
transmembrane domain, TK-tyrosine kinase domain). Bottom panel: Schematic drawing of RET fusions 
(arrows indicate breakpoints).(from[119]). 
 
 
heterogeneity is another factor that can affect the
evaluation of RET/PTC prevalence. In addition to PTC
samples with ‘clonal’ RET/PTC rearrangements (those
affecting the majority of tumor cells), there are samples
with ‘non-clonal’ rearrangements (those affecting a
small portion of tumor cells) (12, 13). Whereas RET/
PTC is likely to be important for tumor formation in
samples with clonal rearrangements, RET/PTC could
not be a ‘driver’ mutation in PTC samples with non-
clonal rearrangements (13). This distinction has
important implications for the stratification of patients
who could potentially benefit from novel therapeutic
approaches based on the use of RET kinase inhibitors
(see below). It is still controversial the presence of RET/
PTC rearrangements in non-neoplastic cells in Hashi-
moto’s thyroiditis. It is possible that a heterogeneous
presence of the rearrangement may account, at least in
part, for such a controversy (8, 9, 13). Tumor
heterogeneity and multiclonality is also indicated by
the presence of multiple RET/PTC variants in individ-
ual PTC samples (14).
RET/PTC rearrangements have so far been identified
only in thyroid lesions, and in particular in PTC (8–10).
Most studies concur that RET/PTC rearrangements are
rare or absent in benign follicular adenomas, and absent
in follicular and medullary carcinomas (8–10). Various
PTC histological variants have been identified, namely
classic, follicular, diffuse-sclerosing, columnar-cell,
Hurthle-cell, cribriform, solid and tall-cell variants (4).
Classic (w45%) and follicular (w18%) variants are the
most prevalent (4). RET/PTCs are more frequent in
tumors that have a classic architecture (15) and in
microcarcinomas (!1 cm) (16). They are rare in the
follicular variant of PTC (15). RET/PTCs have been
reported in the cribriform variant, which is typically
associated with familial adenomatous polyposis (17), in
the Hurthle-cell variant (18, 19), and in hyalinizing
trabecular adenoma, a rare tumor that can be
Figure 1 Schematic drawing of the RET
protein with the four extracellular cadherin-like
domains, the cysteine-rich box adjacent to the
plasma membrane, the juxtamembrane
domain and the split tyrosine kinase domain
(TK). In PTCs, RET is rearranged with diverse
genes, encoding protein dimerization motifs
(highlighted) that mediate ligand-independent
RET dimerization. The arrowheads indicate
RET breakpoints.
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Yet another study demonstrated the potency of BLU-667 as a RET inhibitor which 
could selectively inhibit thyroid xenografts driven by RET mutant and fusion proteins, 
without inhibiting VEGFR-2. Its potential as a treatment option for RET altered MTC 
was demonstrated by durable clinical responses in patients without notable off target 
toxicity [139]. 
 
1.5.2.2 NTRK fusions 
 
Neurotrophic tyrosine receptor kinase (NTRK) proteins are encoded by the 
genes NTRK1, NTRK2 and NTRK3, and they function as high affinity receptors for 
nerve growth factors (NGFs). Upon activation by NGF, they can promote various 
signalling events including activation of RAS, MAPK and PI3K signalling resulting in 
the regulation of proliferation, differentiation and apoptosis. All the NTRK isoforms 
have been reported to form oncogenic fusions in various cancers including PTC, 
NSCLC, glioblastoma and sarcoma, although they have only a very low frequency [134, 
140]. NGS analysis revealed the existence of both NTRK1 and NTRK2 fusions in 
thyroid cancer [134]. NTRKI fusions include genomic rearrangement with TPM3, TPR 
and TFG. Frequency of somatic NTRK1 rearrangements is reported to be much lesser 
than RET fusions in PTC and an association of these mutations with radiation is not yet 
documented [134]. Larotrectinib is a TRK inhibitor that has been very recently 
approved by FDA for solid tumors with NTRK gene fusions [141]. 
 
 
1.5.2.3 Other fusions in thyroid cancer 
 
Other less common gene fusions reported in thyroid cancer include PAX8/PPARG 
which are seen in FTC and FVPTC [131].With the tremendous advancement in NGS 
techniques, it is now possible to conduct large screening for genetic alterations in cancer 
and this has obviously lead to a growing list of fusion proteins that are being reported. 
In a search of the landscape of recurrent kinase fusions in solid tumors, fusions 
involving CRAF, BRAF, MET, and ALK were identified in thyroid cancer [134]. 
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1.6 Ubiquitination associated proteins in cancer 
 
Ubiquitination is a multi-step, reversible post-translational modification that involves 
the covalent conjugation of mono-ubiquitin or poly-ubiquitin chains to target proteins. 
Although initially ubiquitination was thought to be a mechanism that marks misfolded 
and desuete proteins for proteasomal degradation, we now know that ubiquitination 
plays an important role in the mediation of several cellular processes like gene 
transcription, subcellular localisation, DNA repair, endocytosis, antigen processing and 
apoptosis [142]. Ubiquitination involves the attachment of ubiquitin on lysine residues 
of target proteins in an ATP-dependent manner, through a sequential three-step 
mechanism that involves three classes of enzymes namely, the E1 activating enzyme, 
E2 conjugating enzyme and the E3 ligases (Figure 1.9). The initial step in the 
ubiquitination pathway involves the ATP-dependent activation of the C terminus of 
ubiquitin and its conjugation to the active site of the E1 enzyme via a thiol-ester bond, 
following which ubiquitin is transferred to the active site of the E2 enzyme by trans-
thiolation. In the third step, which is catalyzed by the E3 ligase, ubiquitin is transferred 
from the E2 enzyme to the amino group of the lysine in the target enzyme. Further, the 
deubiquitinases (DUBs) cleaves ubiquitin from the substrate proteins which is important 
for maintaining ubiquitin homeostasis as well as regulating ubiquitin mediated cellular 
processes [143]. Based on the structural composition of their E2 binding domain and 
mechanism of action, E3 ligases are classified into three categories namely the 
homologous to E6-AP carboxyl terminus (HECT) domain containing, the really 
interesting new gene (RING) finger domain containing and the U box E3 ligases. There 
are different types of ubiquitination that in turn lead to a wide range cellular processes 
[144]. Target proteins can be monoubiquitinated, that is, ubiquitinated by a single 
ubiquitin molecule at a single lysine residue of the substrate or multi-ubiquitinated, 
where many single ubiquitin molecules are conjugated at different lysine residues of the 
substrate (Figure 1.9). Since ubiquitin itself contains 7 lysine residues (Lys 6, Lys 11, 
Lys 27, Lys 29, Lys 33, Lys 48 and Lys 63), consecutive conjugation of ubiquitin 
molecules to these residues results in formation of ubiquitin chains of varying/various 
lengths leading to polyubiquitination. Further, polyubiquitination can be homotypic 
where sequential ubiquitination occurs at the same lysine residue of all the ubiquitin 
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molecules in the polyubiquitin chain or mixed linkage chains where different lysines of 
ubiquitin are used for sequential conjugation [145]. 
 
 
 
 
 
 
Figure 1.9: The Ubiquitination pathway. The figure illustrates the major steps involved in ubiquitination 
of proteins, the different types of ubiquitination and the known consequences of ubiquitination (from [1]). 
 
Given their role in the regulation of cellular processes like gene transcription, cell-cycle 
and apoptosis which are very relevant mechanisms in the context of tumorigenesis, 
quiet expectedly, the ubiquitination pathway is deregulated in various human cancers 
[1]. A remarkable achievement in cancer therapy that came out from understanding the 
ubiquitin mediated proteasomal degradation of proteins is the use of bortezomib to 
target the proteasome itself in the treatment of multiple myeloma and mantle cell 
lymphoma [146]. Bortezomib mediated inhibition of the proteasome complex has been 
shown to induce various pro-apoptotic pathways, inhibit the NF-kB pathway, which in 
turn down regulates of various growth and survival factors [146, 147]. With respect to  
the players in the ubiquitination pathway, of particular importance are the E3 ligases 
and DUBs, as they impart target specificity to the ubiquitination mechanism. E3 ligases 
can be exploited therapeutically by either inhibiting the E3 ligases that target tumor-
suppressor proteins for degradation or by promoting the activity of E3 ligases that 
targets oncoproteins for degradation, the latter being a more challenging approach.  
Deregulation of several E3 ligases and DUBs has been reported in various cancers, 
which has created platforms for novel therapeutic interventions (table 1.1, table 1.2).  
Ubiquitination mediated regulation of the tumor supressor p53 has been studied to a 
good extent: the RING type E3 ligase MDM2 is involved in the polyubiquitination and 
degradation of the tumor suppressor p53 [148]. Reports indicate the overexpression of 
MDM2 in cancers including non-small cell lung cancer, osteosarcoma and 
pursue development of proteasome inhibitors to treat other
kinds of cancer as well (Chen et al, 2011). In this review, we will
provide the basic description of the ubiquitin machinery,
summarize the role of ubiquitin in molecular medicine
approaches in the field of immune disorders and cancer as
well as the current therapeutic strategies targeting these
pathologies.
Principles of ubiquitin signalling
The attachment of ubiquitin to target-proteins, i.e. the
ubiquitylation process, usually occurs on lysin residues and
proceeds via a three-step procedure involving three different
types of enzymes. In the first step, an E1-activating enzyme
forms a thioester bond with ubiquitin in an ATP-dependent
manner. In the second step, ubiquitin is transferred to an E2
enzyme by trans-thiolation (Schulman & Harper, 2009). Finally,
the E3 ubiquitin ligases catalyze the transfer of ubiquitin from
the E2 to the e-amino group of a lysine residue in a target-specific
manner (Fig 1). The human genome encodes two E1 enzymes,
37 E2 enzymes and more than 600 E3 ligases. The three classes
of E3 ligases (RING, HECT, U-box) are responsible for the
recognition of substrates (Grabbe et al, 2011). RING-type
ubiquitin E3 ligases contain the RING domain, a zinc-binding
protein–protein interaction motif, while HECT E3 ligases
harbour a m tif with a catalytic Cys residue, which becomes
part of a thioester intermediate when ubiquitin is transferred to
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Figure 1. Principles of ubiquitin signalling. Ubiquitylation is mediated by the sequential activity of a set of enzymes including activating (E1), conjugating (E2)
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glioblastoma, and associate high MDM2 expression to poor prognosis, increased 
likelihood of distant metastasis and dampened responses to therapeutic intervention 
[149-152]. Studies attribute MDM2 mediated oncogenicity to its role in p53 
degradation. Activation of p53 by the inhibition of MDM2, which can in turn induce 
apoptosis and growth arrest, is a possible therapeutic strategy that can be employed for 
cancer treatment [153]. Small molecule inhibitors that either target the E3 ligase activity 
of MDM2 (HLI98) or disrupt the interaction of MDM2 with p53 have demonstrated 
promising anti-tumor activity in cancer cells [1, 154]. Further, in terms of role of DUBs 
in p53 regulation, it has been shown that downregulation of Herpes virus-associated 
ubiquitin-specific protease (HAUSP)/USP7, a DUB protein that directly stabilises p53, 
is associated with the reduced expression of p53 in NSCLC [155]. A study by Li et al. 
showed that although partial reduction of HAUSP indeed reduced p53 levels, a nearly 
complete ablation of HAUSP resulted in p53 stabilisation. This might be explained by 
the fact that HAUSP also stabilises MDM2 in a p53-dependent manner, hence playing a 
dynamic role in the regulation of functional p53 levels [156]. USP10 is another DUB 
protein that has been demonstrated to be stabilised upon DNA damage, which in turn 
regulates the nuclear translocation and activation of p53 [157]. Casitas B-lineage 
lymphoma (CBL), inhibitors of apoptosis (IAPs) and the stem cell factor (SCF) 
complex, a multi-subunit ubiquitin ligase complex are other well studied E3 ligases that 
have implications in cancer [158]. Many drugs that target these machineries are already 
in different phases of clinical trials [1].  
Other studies reveal the role of DUBs in cancer. For example USP28 shows 
high expression in colon and breast carcinoma and has been demonstrated to 
deubiquitinate and stabilise the proto-oncogene c-MYC [159]. Therefore, inhibition of 
USP28 might be a potential approach in tumors where downregulation of MYC 
expression is a potential therapeutic strategy. Inactivation of A20, a negative regulator 
of NF-KB, has been implicated in the pathogenesis of B-cell lymphomas [160]. The list 
of E3 ligases and DUBs that may play a role in cancer has been increasing and with 
further understanding of their mechanism of fine-tuning the cellular processes, they 
hold potential as targets for therapeutic intervention (table 1.1).  
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Table 1.2: Ubiquitin machinery targeting anti cancer drugs in clinical trials (adapted from [1]); Source: 
www.clinicaltrials.gov. 
 
Drugs	 Properties	 Source	 Stage	of	clinical	development	Bortezomib	 20S	proteasome	inhibitor	 Millennium	Pharmaceuticals	 Approved	for	multiple	myeloma,	mantle	cell	lymphoma	MLN9708	 Oral	proteasome	inhibitor	 Millennium	Pharmaceuticals	 Phase	I	Carfilzomib/PR-171	 Proteasome	inhibitor	derived	from	epoxomycin	 Onyx	Pharmaceuticals	 Phase	I/II	NPI-0052	 Irreversible	20S	proteasome	inhibitor	 Nereus	Pharmaceuticals	 Phase	I	ONYX	0912	 Oral	proteasome	inhibitor	 Onyx	Pharmaceuticals	 Phase	I	RO5503781,	RO5045337	 Small	molecule	MDM2	antagonist	 Hoffmann-La	Roche	 Phase	I	MLN4924	 NEDD8	inhibitor	 Millenium	Pharmaceuticals	 Phase	I	JNJ-26854165	 MDM2	inhibitor	 Johnson	&	Johnson	Pharmaceutical	Research	&	Development,	LLC	 Phase	I	AT-406	 IAP	inhibitor	 Ascenta	Therapeutics	 Phase	I	LCL-161	 IAP	antagonist	 Novartis	Pharmaceuticals	 Phase	I		
of plasminogen activator inhibitor-1 (Lim et al, 2007). These
findings indicate that CYLD can differentially regulate signalling
pathways during the innate immune response to bacterial
infections, depending at least in part on the pathogen. In
addition, CYLD has been shown to act as a negative regulator of
the anti-viral response by removing polyubiquitin chains from
the RNA helicase retinoic acid inducible gene I (RIG-1)
(Friedman et al, 2008; Zhang et al, 2008). RIG-1 activates the
IRF3 signalling pathway to induce interferon type I gene
expression in response to viral infections.
A20 (TNFAIP3) acts as a negative feedback regulator of NF-
kB signalling in response to numerous inflammatory stimuli,
including TNFa, IL-1b and pathogens. A20 possesses both E3
ligase and DUB activities and attenuates TNFa signalling by
removing Lys63-linked chains from RIP1 and promotes Lys48-
linked chains for proteosomal degradation (Wertz et al, 2004).
A20-deficient mice show profound activation of the immune
system leading to multiorgan inflammation autoimmunity,
characterized by spontaneous production of inflammatory
cytokines such as TNFa, IL-1b and IL-6 (Matmati et al,
2011). Further, loss of A20 in keratinocytes leads to hyperker-
atosis, which is a common feature in psoriasis. A20 is associated
with various immune-pathologies in humans such as rheuma-
toid arthritis, systemic lupus erythematousus (SLE), type I
diabetes, Crohn’s disease and psoriasis (Vereecke et al, 2009).
Interestingly, efficiency of A20 in myeloid cells has recently
been shown to promote erosive polyarthritis that resembles
rheumatoid arthritis in a mouse model, pointing to a crucial and
cell-specific function of A20 in the pathogenesis of rheumatoid
arthritis (Matmati et al, 2011). Furthermore, A20 has been
characterized as a susceptibility gene for several autoimmune
disorders (Fig 2) (Vereecke et al, 2009). The roles of CYLD and
A20 in cancer are discussed below.
Though increased NF-kB activity is associated with inflam-
mation-associated disorders, recent studies revealed that
inhibition of NF-kB in non-immune cells such as epithelia
leads to spontaneous inflammation in a TNFa-dependent
manner (Pasparakis, 2009). However, in chronic inflammatory
diseases it has been shown to be quiet useful to reduce the
effects of the pro-inflammatory cytokines, especially TNFa.
Anti-TNFa therapeutics (e.g. infliximab) have successfully been
employed in treating several autoimmune disorders including
rheumatoid arthritis, Crohn’s diseases, ulcerative colitis and
SLE. A better understanding of the mechanisms and the tissue-
specific roles is clearly warranted to pursue therapeutics that
target NF-kB for the treatment of inflammatory disorders.
Ubiquitin system in cancer
Numerous evidence indicate that the deregulation of ubiquitin
pathways can directly and indirectly contribute to the devel-
opment and progression of human cancers (Hoeller & Dikic,
2009) (Table 1). One of the most studied aspects is linked to
defective quality control that is essential for the removal of
damaged organelle, misfolded or aggregated proteins. For
example, the deregulation of proteasomal degradation can lead
to the accumulation of mutated or oncogene-encoded proteins.
Perturbing the fine balance between the tumour suppressors
and proto-oncogenes would already predispose normal cells
towards oncogenic transformation. Similarly, accumulation of
damaged mitochondria due to deficient autophagy, for example
Review
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Table 1. E3 ligases and DUBs associated with cancers
Enzymes Targets Cancer association
E3 ligases
MDM2 (HDM2) p53 Over-expressed in multiple cancers including soft tissue sarcoma and lung cancer
(Anderson et al, 1999; Lind et al, 2006; Menin et al, 2006)
CBL RTKs, e.g. FLT3, c-Kit c-Cbl point mutation (Cbl-R420Q) was detected in AML and myoproliferative disorders
(Grand et al, 2009)
FBW7 Myc, Jun, cyclin E, KLF5, Notch1
and TGIF1, Mcl-1
Deleted or mutated in various cancers including T-ALL (Inuzuka et al, 2011;
Wertz et al, 2011)
FBX011 Bcl-6 Deleted or inactivated in diffuse large B-cell lymphoma (Duan et al, 2011)
IAPs Various substrates Over-expressed in various cancers. C-IAP2 is associated with MALT-lymphoma
(Dierlamm et al, 1999; Fulda & Vucic, 2011)
Deubiquitinases
CYLD Various substrates including
RIP1 and Bcl3
Mutated in familial cylindromatosis, inactivated in skin cancers, hepatocellular and
cervical carcinoma (Bignell et al, 2000; Massoumi et al, 2006; Strobel et al, 2002)
USP7 MDM2, PTEN, FOXO4 and others Downregulation reported in non-small cell lung cancer (Masuya et al, 2006)
A20 RIP1, RIP2, TRAF2, TRAF6, UBCH5,
NEMO and others
Frequent inactivation in B-cell lymphomas (Kato et al, 2009)
Usp9x Mcl-1, b-catenin and others Over-expressed in follicular lymphomas and diffuse large B-cell lymphomas,
multiple myeloma (Schwickart et al, 2010)
Usp10 P53 Downregulated in renal cell carcinomas (Yuan et al, 2010)
DUB3 Cdc25A Overexpression in breast cancers (Pereg et al, 2010)
Others
PTEN Promoted ubiquitylation of EGFR
through formation of EGFR–CBL
complex
Inactivated in various cancers (Trotman et al, 2007)
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Table	1.1:	E3	ligases	and	DUBs	associated	with	cancer	(from	[1]	
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1.7 Aims of the project 
 	
 The occurrence of thyroid cancer and associated mortality has been increasing 
over the past decades. PTC is the most common type of endocrine malignancy and 
accounts for about 80-85% cases of thyroid cancer [40]. The development of diagnostic 
tools like sonography and molecular analysis of the tumor has tremendously contributed 
to the treatment and prognosis of PTC. Surgery followed by RAI usually leads to good 
prognosis of PTC. But disease recurrences leading to distant metastasis, tumors that 
cannot be surgically removed and/or become resistant to RAI treatment are still major 
challenges in the treatment of PTC patients. Another important factor in the 
management of thyroid cancer is the appropriate risk stratification of the thyroid 
lesions. Precise risk stratification of the thyroid lesions is important, not only for the 
optimisation of treatment strategies which can in turn reduce disease recurrence, but 
also to prevent over treatment of the patients which is very important in preventing 
unnecessary adverse affects. A better understanding of the molecular basis of PTC is 
important in improving both diagnostic and treatment strategies for PTC. 
 The major aim of the project is the identification and validation of novel targets 
and molecular mechanisms that underlies the pathogenesis of PTC by employing next 
generation genomics and proteomics approaches. In order to achieve this, we chose a 
patient sample that does not harbour any of the known PTC oncogenic alterations 
(BRAFV600E and NRAS). The workflow of the study is outlined below: 
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2 Materials and Methods 
2.1 Patient tissue acquisition and omics analysis 
2.1.1 Patient sample acquisition 
 
Informed consent was obtained from the patients prior to surgery according to the 
recommendations of the institution’s Ethics Committee. Tumor and normal tissue were 
harvested intraoperatively from a 35 years old male patient, and the patient is referred as 
the patient #1 in this study. The right thyroid lobe comprised mostly of tumor, while the 
left thyroid lobe consisted predominantly of normal tissue. Ultrasound examination 
revealed that the patient had multiple lateral lymph node metastases. The staging was: 
pT4b (5.3cm tumor), pN1b (17 metastases in 29 lymph nodes), M1 (pulmonary 
metastases), multifocal bilateral tumor, some with follicular pattern and also in the left 
lobe, capsular invasion but no invasion of adjacent structures. Routine Sanger 
sequencing was performed on the BRAF V600E, BRAF wild type and K, H, NRAS. 
Normal, tumor and metastasis (from lymph node) tissue were taken for further analysis. 
 
2.1.2 Isolation of proteins, DNA and RNA from patient tissue 
 
The tumor tissue was incubated in collagenase-D solution (1mg/ml) (11088866001, 
Roche) at 37˚C for 2 h and then transferred to a 6 well plate. The tissue was cut into 
smaller pieces with a scalpel and crushed using the thumb press of a syringe plunger. 
The tissue suspension was filtered by passing it through a 70 µm cell strainer (Easy 
Strainer 70 µm, 542070, VWR,), centrifuged at 1500 rpm for 5 min and subsequently 
washed with cold PBS. The cell pellet was re-suspended in lysing buffer (250 mM 
NaCl, 50 mM Tris-HCl pH 7.5, 10% Glycerine, 1% Triton X-100, 0.2 mM Na3VO4 
and protease inhibitor cocktail (Calbiochem, cat.no.539131)) and kept on ice for 10 
min. The cell suspension was sonicated (3 times 10 sec ,with 10 sec cooling intervals on 
ice between consecutive pulses, 50% amplitude), centrifuged at 13,000 rpm, 4˚C for 10 
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min and then the supernatant was subsequently used for mass spectrometric analysis. 
DNA and RNA was isolated using AllPrep DNA/RNA Mini Kit (80204, Qiagen) 
following manufacturer’s protocol. 
 
2.1.3 Sequencing 
 
RNA-seq libraries were prepared using TruSeq RNA Sample Preparation v2 kit 
(Illumina).  Exome capture was performed using the Agilent SureSelect Human All 
Exome kit (50 Mb).  RNA-seq and Exome capture libraries were sequenced on HiSeq 
(Illumina) to generate 2 x 150 bp and 2 x 75 bp paired-end data respectively.  
 
2.1.4 Exome data analysis  
 
BWA software [161] set to default parameters was used to map sequencing short 
reads to UCSC human genome (GRCh37) using. Local realignment, duplicate 
removal and raw variant calling were performed as described previously [162] [161]. 
Strelka was used for somatic variant calling on tumor and its matched normal BAM 
file [163]. Known germline variants represented in the Exome Aggregation 
Consortium (ExAC) were filtered out [164]. 
 
2.1.5 RNA-seq data analysis  
 
GSNAP was used to align RNA-seq reads to the human genome version NCBI 
GRCh37 [165]. Differential gene expression analysis performed using DESeq2 [166]. 
Fusions were identified using a computational pipeline called GSTRUCT-fusions 
[167]. 
2.1.6 Immunohistochemistry 
H&E (Haemotoxylin and Eosin) staining of the patient tissue was performed on 
formalin fixed paraffin embedded sections using standard laboratory procedures. 
Antibodies were purchased from Dako (Thyroglobulin - M0781, calcitonin - A0576) 
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and immunohistochemistry was performed on paraffin sections by using the DAKO-
EnVision FLEX-kit (Dako, Glostrup, Denmark). Staining was performed on an 
immunostainer (Autostainer +; Dako, Glostrup, Denkmark) according to the 
manufacturer ́s instructions.  
2.1.7 In-solution digestion  
 
Four volumes of ice cold acetone was added to the protein lysates (prepared as 
mentioned in previous section (Isolation of proteins, DNA and RNA from patient 
tissue), vortexed and precipitated at -20°C overnight. Samples were centrifuged at 
16,000 x g for 20 min at 4°C and the supernatant was discarded. Proteins were re-
dissolved in 50 µl 6 M urea and 100 mM ammonium bicarbonate, pH 7.8. For reduction 
and alkylation of cysteines, 2.5 µl of 200 mM DTT in 100 mM Tris-HCl, pH 8 was 
added and the samples were incubated at 37°C for 1 h followed by addition of 7.5 µl 
200 mM iodoacetamide for 1 h at room temperature in the dark. The alkylation reaction 
was quenched by adding 10 µl 200 mM DTT at 37°C for 1 h. Subsequently, the proteins 
were digested with 10 µg trypsin GOLD (Promega) for 16 h at 37°C. The digestion was 
stopped by adding 5 µl 50 % formic acid and the generated peptides were purified using 
OMIX C18, 10 µl (Agilent, Santa Clara), and dried using a Speed Vac concentrator 
(Concentrator Plus, Eppendorf). 
 
2.1.8 Liquid chromatography-mass spectrometry (LC-MS) 
 
The tryptic peptides were dissolved in 10 µl 0.1% formic acid/2% acetonitrile and 5 µl 
analyzed using an Ultimate 3000 RSLCnano-UHPLC system connected to a Q Exactive 
mass spectrometer (Thermo Fisher Scientific) equipped with a nano-electrospray ion 
source. For liquid chromatography separation, an Acclaim PepMap 100 column (C18, 2 
µm beads, 100 Å, 75 µm inner diameter, 50 cm length) (Dionex, Sunnyvale CA, USA) 
was used. A flow rate of 300 nL/min was employed with a solvent gradient of 4-35% B 
in 180 min. Solvent A was 0.1% formic acid and solvent B was 0.1% formic acid/90% 
acetonitrile. The mass spectrometer was operated in the data-dependent mode to 
automatically switch between MS and MS/MS acquisition. Survey full scan MS spectra 
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(from m/z 400 to 2,000) were acquired with the resolution R = 70,000 at m/z 200, after 
accumulation to a target of 1e6. The maximum allowed ion accumulation times were 60 
ms. The method used allowed sequential isolation of up to the ten most intense ions, 
depending on signal intensity (intensity threshold 1.7e4), for fragmentation using 
higher-energy collisional induced dissociation (HCD) at a target value of 1e5 charges, 
NCE 28, and a resolution R = 17,500. Target ions already selected for MS/MS were 
dynamically excluded for 30 sec. The isolation window was m/z = 2 without offset. For 
accurate mass measurements, the lock mass option was enabled in MS mode.  
For label-free quantification analysis, raw data were imported into PEAKS v8.5 
(Bioinfomatics Solutions Inc, Toronto, CA). Processed raw data were searched in 
PEAKS against the UniProt SwissProt database (Human, 20,279 proteins) assuming the 
digestion enzyme trypsin, at maximum two missed cleavage sites, parent ion tolerance 
of 10 ppm, fragment ion mass tolerance of 0.02 Da, carbamidomethylation of cysteines 
as fixed modification, and oxidation of methionines, deamidation of asparagine and 
glutamine residues as variable modifications. Label-free quantification was performed 
in the PEAKS software using a maximum mass difference of 15 ppm and a maximum 
retention time difference of 1.5 min for clustering and a 0.1% FDR threshold for peak 
annotation. 
 
2.2 Molecular biology methods 
2.2.1 Plasmids and constructs 
pENTR221 TFG-RET, pENTR221 TFG-RETK14ER21ER22E and pENTR221 TFG-
RETΔ97-124 were synthesized from Invitrogen and were cloned into expression 
plasmids pPHAGE C-TAP (FLAG and HA tagged), a kind gift from Prof. Dr. Christian 
Behrends, and Gateway™ pcDNA™-DEST40 Vector (His and V5 tagged) (12274015, 
ThermoFischer Scientific). 
2.2.2 Quantitative RT-PCR 
 
Total RNA was extracted using TRIzolTM reagent (15596018, Thermofisher scientific) 
according to manufacturer’s protocol. Equal amounts of total RNA were used to 
Materials	and	Methods	
	 55	
synthetize the corresponding cDNA using RevertAid reverse transcriptase cDNA 
Synthesis Kit (EP0441, Thermofisher scientific). To quantify gene expression levels, 
SYBR-Green (A25780, Thermofisher scientific) based qRT-PCR was performed using 
the StepOnePlus™ Real-Time PCR System (4376600). The normalized expression 
level of Huwe1, Usp7 and Usp9 was determined and three replicates were used for each 
determination.  
 
2.2.3 Primer sequences: 
 
Huwe1: Ref: NM_031407 
for –TTGGACCGCTTCGATGGAATA, rev-TGAAGTTCAACACAGCCAAGAG 
Usp9x: Ref: NM_001039590.2 
for – GTGTCAGTTCGTCTTGCTCAGC, rev – GCTGTAACGACCCACATCCTGA 
Usp7: Ref: NM_001286457.1 
for – ACTTTGAGCCACAGCCCGGTAATA 
rev - GCCTTGAACACACCAGCTTGGAAA 
18s: Ref: NT_167214.1 
 for-AGAAACGGCTACCACATCCA, rev-CACCAGACTTGCCCTCCA 
Rps13: Ref: NM_001017 
for-CGAAAGCATCTTGAGAGGAACA, rev-TCGAGCCAAACGGTGAATC 
 
2.3 Biochemical methods 
 
2.3.1 SDS–PAGE and Western blot 
 For SDS–PAGE, cell lysates with equal amounts of total proteins were prepared in 
SDS-sample buffer (0.125 M Tris-HCl, pH 6.8, 4% SDS, 10% glycerol, 10 mM DTT 
and bromophenol blue) followed by boiling at 95˚C for 10 minutes. 20 µl of cell lysates 
from each sample were then loaded onto 4–15% mini-PROTEAN®TGX™ Precast 
protein gels (4561084, Biorad) or lab made polyacrylamide gels (comprising of 2 layers 
– resolving layer (7.5% or 12% gel, pH 8.8) and the stacking layer – (5% gel, pH 6.8). 
The proteins were then transferred to nitrocellulose blotting membranes (10600001, GE 
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Healthcare) by Western blotting. For immunoblot analysis, membranes were blocked 
with 5 % low-fat milk in phosphate-buffered saline for 30 min at room temperature and 
then incubated in primary antibodies (in 3% BSA, A7906, Sigma) overnight at 4°C. 
Subsequently, the membranes were washed in PBST, 3 times, 5 min per wash and 
incubated with horseradish peroxidase-coupled secondary antibodies for one hour at 
room temperature, followed by washes as previously stated. The antigen–antibody 
complexes were detected by enhanced chemiluminescence (Immobilon Western 
Chemiluminescent HRP Substrate, WBKLS0500, Millipore) using Biorad ChemiDoc™ 
Touch Imaging System (Biorad,). Quantification of Western blots was performed by 
densitometry using the quantification software provided by Biorad.  
2.3.2 Antibodies 
 
Anti-Phospho-Tyrosine (P-Tyr-1000) MultiMab™ (8954S,CST), anti- Myelin Basic 
Protein (MBP) (1344,CST), anti-V5 antibody (Invitrogen R960-25), anti-FLAG® M2-
Peroxidase (A8592, Sigma), anti-phospho-RET (Y905) (3221S,CST), anti-RET 
(C31B4)(3223S, CST), anti-phospho-STAT3 (Ser727)(9134P,CST), anti-STAT3 
(9129P, CST), anti-phospho-Akt (Thr308) (9275, CST), anti-Akt (C67E7) (4691, CST), 
anti-phospho MEK1/2 (9154, CST), anti-MEK1 antibody (2352,CST), anti-phospho-
p44/42 MAPK (Thr202/Tyr204) (ERK1/2) (9101L, CST), anti- p44/42 MAPKinase 
(ERK1/2) (9102, CST), anti-M2-PK (S-1, Schebo Biotech), anti-histone H3 (4499S, 
CST) and Na-K ATPase (MA3-928, Thermo Scientific). 
 
2.3.3 In vitro kinase assay 
 
Two million HeLa cells were seeded in 10 cm cell culture plates and V5-tagged 
plasmids were transfected using PEI (as described in Cell culture and transient 
transfection) on the following day. Two days  post transfection, cells were lysed in lysis 
buffer (250 mM NaCl, 50 mM Tris-HCl pH 7.5, 10% Glycerine, 1% Triton X-100 with 
protease inhibitor cocktail) and V5-tagged proteins were immunoprecipitated using V5 
antibody immobilised to agarose-coupled protein A/G beads (Roche, cat. nos. 11-134-
515-001 and 11-243-233-001) overnight. Protein bound beads were washed with the 
lysis buffer and used for in vitro kinase assay. Kinase assay was performed using 
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dephosphorylated myelin basic protein (MBP) (13-110, Merck) as substrate in 25 mM 
Tris (pH 7.5), 5 mM β-glycerophosphate, 2 mM DTT, 0.1 mM Na3VO4, 10 mM 
MgCl2 and 5mM ATP (Enzo, BML-EW9805-0100), 40µl final volume. The kinase 
assay mixture was incubated with the immunoprecipitated V5 tagged proteins for 30 
min at 30˚C. The kinase reaction was terminated by adding 20 µl SDS-sample buffer 
(0.125 M Tris-HCl, pH 6.8, 4% SDS, 10% glycerol, 10 mM DTT and bromophenol 
blue) followed by boiling at 95˚C for 10 min. The samples were loaded onto 12% SDS-
PAGE gel and subjected to immunoblotting analysis. 
 
2.3.4 Protein Dimerisation experiments 
 
RET Wild type, TFG-RET and TFG-RET mutant constructs in pPHAGE C-TAP 
(FLAG, HA tagged) and pcDNA3 Dest 40 (V5, His tagged) were co-transfected as 
indicated in the results in HeLa cells using PEI (see Cell culture and transient 
transfection). 48 h post transfection, cells were lysed in lysis buffer (250 mM NaCl, 50 
mM Tris-HCl pH 7.5, 10% Glycerine, 1% Triton X-100 with protease inhibitor 
cocktail) and flag-tagged protein was immunoprecipitated using FLAG beads (ANTI-
FLAG® M2 Affinity Gel, A2220-5ML, Sigma). The co-precipitation of V5-tagged 
proteins was tested by immunoblots. 
Nthy-ori 3-1 cells stably expressing pPHAGE C-TAP RET wild type and pPHAGE C-
TAP TFG-RET were seeded in 6 well cell culture plates. Upon becoming 70% 
confluent, cells were treated with DMSO (A3672.0250 Applichem) or Dithio-
bismaleimidoethane (DTME) (0.2 mM, 1h), (22335,Thermo Scientific) or DTME 
followed by Dithiothreitol (DTT) (100 mM, 15 min). After thorough washes with PBS, 
cells were lysed in sample buffer (cells treated with only DTME were lysed in non-DTT 
containing sample buffer) and subjected to immunoblot analysis. 
 
2.3.5 Gel filtration 
 
HeLa cells were transiently transfected with TFG-RET, TFG-RET K14E.R22E.R23E 
and TFG-RET Δ97-124 in pcDNA3 Dest 40 (V5, His tagged). Cells (about 15 million 
cells per condition) were lysed 48 h post transfection in 500 µl lysis buffer (50 mM Tris 
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pH7.5, 150 mM NaCl, 10% Glycerol, protease inhibitor cocktail (539131, Calbiochem)) 
by sonication (50% Amplitude, five seconds, four cycles). Cell lysates were subjected 
to ultracentrifugation (30,000 x g for 1 h at 4 ˚C) and the supernatant (cytosolic 
fraction) was separated by size exclusion chromatography using an ÄKTA-Pure25 
system equipped with two Superose-6 HR-10/30 columns (GE Healthcare, Freiburg, 
Germany) connected in series. The columns were pre-equilibrated with running buffer 
(50 mM Tris pH7.5, 150 mM NaCl buffer, filtered 0.22 µm). 500 µl of cytosolic 
fraction were injected and separated at a flow rate of 0.5 ml/min. Fractions of 500 µl 
were collected and subjected to immunoblot analysis. Molecular weight reference 
proteins (Gel Filtration Markers Kit (mwgf1000, Sigma-Aldrich) were separated under 
identical conditions and a calibration curve was obtained by plotting molecular weight 
(log scale) against elution volume.  
 
2.3.6 Cellular fractionation assay 
 
Nthy-ori 3-1 cells stably expressing pPHAGE C-TAP RET wild type and pPHAGE C-
TAP TFG-RET were cultured in 10 cm dishes. 48 h post seeding, the growth media was 
removed from the culture dish and the cells were washed with cold PBS. Cells were 
subsequently lysed using buffers from ProteoExtract® Subcellular Proteome Extraction 
Kit (539790, Merck) according to manufacturer’s protocol. Lysates collected were 
subjected to immunoblot analysis. 
 
2.3.7 Cycloheximide-chase assay 
 
NThy-ori-3-1 cells were transiently transfected using PEI (as described earlier) with 
different plasmids in 10 cm dishes. 24 h post transfection, cells were reseeded in 12-
well plates. After 24 h, cycloheximide (100 µg/mL) was added to the cells and samples 
were collected in SDS-sample buffer at indicated time points and boiled at 95°C for 10 
min. Cell lysates were subjected to immunoblot analysis. 
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2.3.8 Endogenous Ubiquitination experiments 
 
Nthy-ori 3-1 cells stably expressing pPHAGE C-TAP TFG-RET (in 10 cm cell culture 
dishes, about 70% confluent) were treated with DMSO or with 20 µM BI-8622 or BI-
8626 (synthesized by Syngene International limited) inhibitors for 2 h followed by 
treatment with 10 µM MG132 for 5 h at 37˚C. Following treatment, cells were lysed in 
lysis buffer and 250 µg protein was used to isolate ubiquitinated protein using 
UBIQAPTURE-Q® kit (BML-UW8995-0001, Enzo) according to manufacturer’s 
protocol. Ubiquitination of proteins was determined by immunoblot analysis. 
 
2.4 Cell biology methods 
 
2.4.1 Cell culture  
 
Nthy-ori 3-1 cells (90011609, Sigma) were cultured in RPMI-1640 medium 
supplemented with 10% heat inactivated FBS at 37°C in 5% carbon dioxide. HeLa 
(DSMZ) and 293T cells (a kind gift from Dr. Andreas Ernst) were cultured in DMEM 
supplemented with 10% heat inactivated FBS at 37°C in 5% carbon dioxide.  
 
2.4.2 Transient transfections 
 
Two million cells were seeded in 10 cm cell culture plates and the cells were transiently 
transfected on the following day. 5 µg plasmid and 27 µl of 10 mM polyethylenimine 
was mixed in 500 µl of PBS and incubated for 15 min at room temperature. After 
incubation, the transfection mixture was added drop-wise to cells cultured in 10 cm 
plates. Experiments were carried out 48 h post transfection.  
 
2.4.3 Lentivirus production and stable cell line generation 
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For the production of lentiviruses, we adapted the protocol from Jiang W et al. [168]. 
293T cells cultured in 10 cm culture dishes (4 dishes for each transfection) were 
transfected with pPHAGE C-TAP (empty vector) or 
pPHAGE_CMV_C_FLAG_HA_IRES_Puro (as well as the TFG-RET mutants) 
together with the pLenti package (HDM-VSV-G; HDM-tatlb; HDM-Hgprn2 (gag-pol); 
RC-CMV- Rev1b). Two days later, the virus-containing medium was collected and 
subsequently pre-cleaned by centrifugation for 5 minutes at 3000 g and a 0.45 µm 
filtration. The filtrate was overlaid on a sucrose buffer (50mM Tris HCl, pH 7.4, 
100mM NaCl, 0.5mM ethylenediaminetetraacetic) at a 4:1 v/v ratio and centrifuged at 
10,000 g for 4 h at 4°C. After centrifugation, the supernatant was carefully discarded 
and the pellet was re-suspended in 800 µl PBS for overnight recovery in 4°C. 
For the generation of stable cell lines, 100 µl of the suspension was subsequently added 
to Nthy-ori 3-1 cells in presence of 8 µg/ml of polybrene. After 24 h, cells were 
subjected to puromycin selection by addition of puromycin to the cell culture media (2.5 
µg/ml puromycin).  
 
2.5 Phenotypic studies 
 
2.5.1 MTT assay 
 
MTT assay assay was performed by employing the Cell Proliferation Kit I, 
(11465007001, Roche). Nthy-ori 3-1 cells stably expressing pPHAGE C-TAP empty 
vector and pPHAGE C-TAP TFG-RET were seeded in 96-well cell culture plate in 100 
µl of complete growth medium. (10,000 cells/well, triplicates per condition). 10 µl of 
MTT solution was added 2 h, 48 h and 72 h post seeding and incubated in CO2 
incubator for 2-4 h. After incubation, 100 µl of solubilisation buffer was added to each 
well and incubated overnight in CO2 incubator. Absorbance of the solubilized MTT was 
measured by absorbance plate reader (O.D.570). Absorbance readings of 48 and 72 h 
time points were normalised to the respective absorbance measured at 2 h. 
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2.5.2 Soft agar colony formation assay 
 
1.5 % agarose solution was mixed with 2X growth medium (with 20% FCS, 2X 
inhibitor) to get a final mixture with 0.75% agarose in 1X growth medium (bottom agar 
medium). 1.5ml of this bottom agar medium was added per well in a 6-well plate and 
incubated at room temperature for at least 10 min to solidify agarose. Nthy-ori 3-1 cells 
stably expressing pPHAGE C-TAP empty vector and pPHAGE C-TAP TFG-RET were 
diluted in 2X growth medium (with 20 % FCS, 2X inhibitors) and mixed with 0.9 % 
agarose solution to a final concentration of 0.45% agarose. 1.5 ml of this cell 
suspension was added to the bottom agarose layer (20,000 cells/condition). The cells 
seeded in soft agar were cultured for 2 to 4 weeks with addition of 100 µl of complete 
medium (with inhibitor) twice weekly. The colonies were stained with 0.02% crystal 
violet solution by gentle agitation at room temperature for about 30 minutes followed 
by washes with water. The images were taken with a ChemiDoc Touch (Bio-Rad) 
imaging System and the number of colonies was counted by image J software. 
 
 
2.5.3 Imaging studies 
 
NThy-ori-3-1 cells stably expressing flag tagged pPHAGE C-TAP TFG-RET or 
pPHAGE C-TAP RET were seeded onto glass coverslips (15 mm). The cells were 
transiently transfected with EGFP-C1 Lck-GFP (61099, addgene) using PEI (as 
described in Cell culture and transient transfection). 48 h later, the cells were fixed 
using 4 % PFA for 10 min after media removal and 2 PBS washes. The cells were 
permeabilised using 0.1% Triton X100 (3 min, room temperature). After 2 subsequent 
washes with PBS, the cells were blocked with 1% BSA for 30 mins at room 
temperature. The cells were then stained for TFG-RET/RET using anti-FLAG® M2-
Peroxidase (A8592, Sigma, 1:500 dilution in 1 % BSA) for 1 h at room temperature. 
The cells were then washed with PBS and stained with anti –mouse Cy3 antibody 
(1:100 dilution in 1% BSA) along with Hoechst (2.5 µg/ml in 1% BSA) for 30 min (in 
dark, room temperature). The cells were washed with PBS and mounted on glass slides 
with Mowiol (+DABCO). Cells were imaged using a Leica SP8 confocal microscope 
(63X, oil immersion objective, Cy3 excitation at 552nm, GFP excitation 488nm).
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3 Results 
3.1 Identification of novel molecular alterations in PTC 
3.1.1 Patient sample acquisition and immunohistochemical analysis 
 
 
Figure 3.1: PTC with follicular growth - immunohistochemical analysis. (A) H&E staining of 
paraffin fixed primary tumor and metastatic tissue revealed distinct nuclear features characteristic of PTC 
(scale bar, 50 µm). (B) Primary and metastasis tissue were stained for thyroglobulin and calcitonin (scale 
bar, 50 µm). 
 
With an aim to identify novel molecular events driving PTCs, we selected a small 
cohort of patients that have undergone partial thyroidectomy for genomics and 
proteomics analysis. A 35-year-old male patient (referred to as patient#1 in this study) 
was presented with a thyroid tumor, whose right thyroid lobe comprised mostly of 
tumor, while the left thyroid lobe predominantly was normal tissue. Ultrasound 
evaluation revealed the presence of multiple lateral lymph node metastases. The staging 
of the tumor was: pT4b (5.3 cm tumor), pN1b (17 metastases in 29 lymph nodes 
analyzed), M1 (pulmonary metastases), multifocal bilateral tumor, some with follicular 
pattern and also in the left lobe, capsular invasion but no invasion of adjacent structures. 
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Normal (thyroid), tumor (thyroid) and metastatic (lymph node) tissue were collected 
from the patient intra-operatively after obtaining informed consent from the patient 
prior to surgery. Routine Sanger sequencing for BRAF V600E, K-RAS, H-RAS and N-
RAS (exon 2, 3 and 4) was carried out, which revealed the absence of any common 
BRAF and RAS mutations in the tumor. This observation was further confirmed by 
next-generation RNA sequencing of the patient sample (discussed later). Formalin fixed 
paraffin embedded sections of primary tumor and metastatic tissue was subjected to 
immunohistochemical analysis (Figure 3.1). Haemotoxylin and Eosin (H & E) staining 
revealed the distinct nuclear morphology of the cells indicative of PTC and it also 
showed the follicular nature of the tumor tissue. Both primary and metastatic tissue 
stained positive for thyroglobulin, implying the follicular cell origin of the tumor, as c-
cells derived from the tumor would not be positive for thyroglobulin. The metastatic 
tissue was negative for calcitonin staining, a marker for c-cells, although few cells in the 
primary tumor were calcitonin positive. This may be indicative of c-cell hyperplasia. 
Also, the tumor tissue revealed calcitonin calcification, which is also typical of PTC. 
Together, these immunohistological observations suggest that the tumor is a PTC with 
follicular growth. 
 
3.1.2 Identification of a novel RET fusion 
 
Our next aim was the identification of genomic alterations in the patient-derived tissue. 
For this, we employed both exome sequencing and RNA-sequencing of normal, tumour 
and metastasis samples. We performed exome data analysis of normal vs tumor and 
tumor vs metastasis that revealed the occurrence of a total of 14 protein-altering 
mutations none of which were well-characterised oncogenic mutations (Figure 3.2A, 
3.2B). 6 of these mutations were shared between the tumor and metastasis samples 
(Table 3.1). Further, we examined the RNA sequencing data to look for other genomic 
alterations. RNA sequencing did not identify any BRAF or RAS mutations, hence 
confirming the previous results obtained by Sanger sequencing.  
RNA-sequencing based fusion analysis revealed the presence of a novel inter-
chromosomal fusion between exon 4 of TFG located on chromosome 3 and exon 11 of 
RET located on chromosome 10 (Figure 3.2C). We also looked into the genes that 
exhibit significant differential expression in the tumor samples. Our analysis showed the 
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differential expression of 244 expressed genes, of which RET kinase was significantly 
overexpressed in the tumor sample, compared to the normal (Figure 3.2D). By 
comparing the Reads Per Kilobase Million (RPKM) values of RET, we found that it 
was significantly up regulated in metastatic (14.7) and tumor samples (10.2) as 
compared to adjacent normal tissue (0.3) (Figure 3.2E). 
 
              Table 3.1: List of mutations identified in tumor and metastasis tissue. 
 
 
A       B 
 
 
 
 
 
 
 
Table	S1	
Gene_Name	 #	Samples	 Samples	 Polyphen2_pred	 (COSMIC_ID)	
Unique	concatenate	with	
count(HGVS_p)	
Mean	
(PhyloP100way_	
vertebrate)	
Kinase	
type	 GPCR	Family	
ADRA1D	 2	 M,	T	 D	 p.Arg282Cys(2)	 2.866	 Adrenoceptors	
MAP2K2	 1	 M	 B	 p.Gln391His(1)	 4.539	
Protein	
Kinase	
ACCSL	 1	 T	 D	 p.Pro382Ser(1)	 6.356	
ALCAM	 2	 M,	T	 B,B,	D,D	
p.Arg304Lys(2),	
p.Arg304Ser(2),	
p.Ser324Pro(2)	 1.566333333	
ATP10A	 1	 T	 B	 p.Met1280Thr(1)	 8.977	
MUC3A	 1	 T	 ?	 p.Thr2064Asn(1)	
MYC	 1	 T	 B	 p.Ser21Asn(1)	 1.778	
OR2L8	 1	 T	 B	 COSM226497	 p.Leu132Pro(1)	 -4.646	
OR5R1	 2	 M,	T	 D	 p.Leu101Gln(2)	 2.593	
PLEKHA5	 2	 M,	T	 ?	 p.Gln412fs(2)	
PPP1CC	 1	 T	 B,	D	
p.Ile244Leu(1),	
p.Phe227Ser(1)	 8.537	
RP1L1	 1	 T	 B	 COSM3762979	 p.Glu1343Lys(1)	 2.372	
TG	 2	 M,	T	 ?	 p.Thr1432_Ser1433del(2)	
ZFP42	 2	 M,	T	 D	 p.Lys231Asn(2)	 -0.012	
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Figure 3.2: Exome analysis. (A) Exome analysis of patient#1 tissue. (B) Number of protein altering 
mutations detected in exome analysis of the patient. (C) Schematic representation of TFG-RET fusion 
protein. The N-terminal of TFG and C-terminal of RET forms a 626 amino acid containing fusion 
product. (D) Heat map of the exome analysis of patient tissue. (E) RPKM values for RET expression 
obtained from RNA-seq analysis of normal, tumor and metastasis patient tissue.  
TFG-RET	–	in-frame	transloca5on	
1	 4	 8	 1	 11	 20	
1	 4	 11	 20	
5’	 5’	3’	 3’	
TFG(+)	
Chromosome	3	 Chromosome	10	
RET(+)	
3’	5’	TFGRET	
CCAGGACCTTCCACCAATATTCCTGAAAATG|ATCCACTGTGCGACGAGCTGTGCCGCACGGTGATCGCAGCCGCTG	
TFGRET	–	in-frame	transloca=on	
Protein	domains	
PB1	START	 STOP	
1
138	
400	T
FG
	
RE
T	 TyrKc	START	 STOP	
1
626	
1114	1009	724	
PB1	START	 STOP	
1
138	
626	
TF
G
-R
ET
	
236	 521	
TyrKc	
TFG- ET	
SAM24288937 SAM24288938 SAM24288939
TFF3
TPO
MATN2
ALDH1A1
COL9A3
SLC26A4
RAP1GAP
CDH16
CRABP1
OGDHL
COL23A1
CSGALNACT1
SLC26A7
PLEKHH1
TMEM171
PKHD1L1
PLA2R1
GRIN2C
SORD
APOE
PCSK2
ECM1
SERPINA1
GDF15
PCSK1N
APOC1
PDLIM4
TNFRSF12A
C8orf4
SLIT1
SLC22A31
PHLDA2
FAM20A
RXRG
MYO1G
KRT17
CHI3L1
CXCL14
SFTPB
CHIT1
LYZ
NFE2L3
PDZK1IP1
SERPINE1
ALOX5
G0S2
KCNN4
NAPSA
TNC
PRR15
PLAUR
RGS8
FER1L6
VSTM2A
KIAA1239
KCNA2
GLP2R
BMP5
CARTPT
MYOT
IHH
CUX2
AGTR1
ZNF804B
TCEAL5
CNTN5
LRP1B
SCARA5
FOXJ1
IGFBPL1
IP6K3
DDX25
TMEM139
C12orf39
TMEM253
CTTNBP2
EPHB1
MROH2A
SLITRK5
FAM180B
LINGO2
C1orf64
TFF2
ALDH1L1
FLRT1
ZMAT4
SEMA3D
GPM6A
RELN
TCEAL2
DPT
GATM
ABI3BP
RYR2
AOX1
CWH43
SLC5A5
SLC5A8
DPP6
MYOC
BEX1
ATP2C2
WDR72
GDF10
TDRD9
WSCD2
OCA2
KIT
CLCNKB
MMRN1
PRR15L
FAXDC2
MPPED2
LYVE1
ROR2
KIAA1456
SCUBE3
FHDC1
PKNOX2
CHRDL1
BTBD11
RETN
CD70
OIT3
SAA1
CSF2
CXCL17
GRIA3
AZU1
NMU
MYBPH
GPR37
SYT12
GRHL3
TRPC5
CYSLTR2
ABCC11
CDH15
ANKRD22
ZNF560
PRSS2
CPNE4
CBLN1
TMPRSS4
SLC27A6
MUC21
PPP1R1B
FOSL1
MARCO
CLDN16
FCN3
MMP9
TREM2
F5
TUBB3
PAX9
RET
NGEF
SCEL
SKOR2
PRMT8
PHEX
LAMP5
ACAN
LIPH
RASGRF1
MISP
HS6ST2
PLEKHN1
APOC4−APOC2
AOC1
CDC45
CCL13
STK32A
PRSS1
CCL17
MMP7
IL4I1
IVL
SLC12A5
UBE2C
HMGA2
FCN1
RUNX1
SMIM22
TREM1
CATSPER1
TRIM36
KRT14
SLC22A18AS
ADCY8
PTCHD4
MFSD2A
STRA6
KLHDC7B
NKAIN4
SFN
KRT15
ALOX15B
KLHDC8A Diagnosis
Normal
Tumor
−1
−0.5
0
0.5
1
RET	
Normal	 Tumor	
SAM24288937 SAM24288938 SAM24288939
TFF3
TPO
MATN2
ALDH1A1
COL9A3
SLC26A4
RAP1GAP
CDH16
CRABP1
OGDHL
COL23A1
CSGALNACT1
SLC26A7
PLEKHH1
TMEM171
PKHD1L1
PLA2R1
GRIN2C
SORD
APOE
PCSK2
ECM1
SERPINA1
GDF15
PCSK1N
APOC1
PDLIM4
TNFRSF12A
C8orf4
SLIT1
SLC22A31
PHLDA2
FAM20A
RXRG
MYO1G
KRT17
CHI3L1
CXCL14
SFTPB
CHIT1
LYZ
NFE2L3
PDZK1IP1
SERPINE1
ALOX5
G0S2
KCNN4
NAPSA
TNC
PRR15
PLAUR
RGS8
FER1L6
VSTM2A
KIAA1239
KCNA2
GLP2R
BMP5
CARTPT
MYOT
IHH
CUX2
AGTR1
ZNF804B
TCEAL5
CNTN5
LRP1B
SCARA5
FOXJ1
IGFBPL1
IP6K3
DDX25
TMEM139
C12orf39
TMEM253
CTTNBP2
EPHB1
MROH2A
SLITRK5
FAM180B
LINGO2
C1orf64
TFF2
ALDH1L1
FLRT1
ZMAT4
SEMA3D
GPM6A
RELN
TCEAL2
DPT
GATM
ABI3BP
RYR2
AOX1
CWH43
SLC5A5
SLC5A8
DPP6
MYOC
BEX1
ATP2C2
WDR72
GDF10
TDRD9
WSCD2
OCA2
KIT
CLCNKB
MMRN1
PRR15L
FAXDC2
MPPED2
LYVE1
ROR2
KIAA1456
SCUBE3
FHDC1
PKNOX2
CHRDL1
BTBD11
RETN
CD70
OIT3
SAA1
CSF2
CXCL17
GRIA3
AZU1
NMU
MYBPH
GPR37
SYT12
GRHL3
TRPC5
CYSLTR2
ABCC11
CDH15
ANKRD22
ZNF560
PRSS2
CPNE4
CBLN1
TMPRSS4
SLC27A6
MUC21
PPP1R1B
FOSL1
MARCO
CLDN16
FCN3
MMP9
TREM2
F5
TUBB3
PAX9
RET
NGEF
SCEL
SKOR2
PRMT8
PHEX
LAMP5
ACAN
LIPH
RASGRF1
MISP
HS6ST2
PLEKHN1
APOC4−APOC2
AOC1
CDC45
CCL13
STK32A
PRSS1
CCL17
MMP7
IL4I1
IVL
SLC12A5
UBE2C
HMGA2
FCN1
RUNX1
SMIM22
TREM1
CATSPER1
TRIM36
KRT14
SLC22A18AS
ADCY8
PTCHD4
MFSD2A
STRA6
KLHDC7B
NKAIN4
SFN
KRT15
ALOX15B
KLHDC8A Diagnosis
Normal
Tumor
−1
−0.5
0
0.5
1
SAM24288937 SAM24288938 SAM24288939
TFF3
TPO
MATN2
ALDH1A1
COL9A3
SLC26A4
RAP1GAP
CDH16
CRABP1
OGDHL
COL23A1
CSGALNACT1
SLC26A7
PLEKHH1
TMEM171
PKHD1L1
PLA2R1
GRIN2C
SORD
APOE
PCSK2
ECM1
SERPINA1
GDF15
PCSK1N
APOC1
PDLIM4
TNFRSF12A
C8orf4
SLIT1
SLC22A31
PHLDA2
FAM20A
RXRG
MYO1G
KRT17
CHI3L1
CXCL14
SFTPB
CHIT1
LYZ
NFE2L3
PDZK1IP1
SERPINE1
ALOX5
G0S2
KCNN4
NAPSA
TNC
PRR15
PLAUR
RGS8
FER1L6
VSTM2A
KIAA1239
KCNA2
GLP2R
BMP5
CARTPT
MYOT
IHH
CUX2
AGTR1
ZNF804B
TCEAL5
CNTN5
LRP1B
SCARA5
FOXJ1
IGFBPL1
IP6K3
DDX25
TMEM139
C12orf39
TMEM253
CTTNBP2
EPHB1
MROH2A
SLITRK5
FAM180B
LINGO2
C1orf64
TFF2
ALDH1L1
FLRT1
ZMAT4
SEMA3D
GPM6A
RELN
TCEAL2
DPT
GATM
ABI3BP
RYR2
AOX1
CWH43
SLC5A5
SLC5A8
DPP6
MYOC
BEX1
ATP2C2
WDR72
GDF10
TDRD9
WSCD2
OCA2
KIT
CLCNKB
MMRN1
PRR15L
FAXDC2
MPPED2
LYVE1
ROR2
KIAA1456
SCUBE3
FHDC1
PKNOX2
CHRDL1
BTBD11
RETN
CD70
OIT3
SAA1
CSF2
CXCL17
GRIA3
AZU1
NMU
MYBPH
GPR37
SYT12
GRHL3
TRPC5
CYSLTR2
ABCC11
CDH15
ANKRD22
ZNF560
PRSS2
CPNE4
CBLN1
TMPRSS4
SLC27A6
MUC21
PPP1R1B
FOSL1
MARCO
CLDN16
FCN3
MMP9
TREM2
F5
TUBB3
PAX9
RET
NGEF
SCEL
SKOR2
PRMT8
PHEX
LAMP5
ACAN
LIPH
RASGRF1
MISP
HS6ST2
PLEKHN1
APOC4−APOC2
AOC1
CDC45
CCL13
STK32A
PRSS1
CCL17
MMP7
IL4I1
IVL
SLC12A5
UBE2C
HMGA2
FCN1
RUNX1
SMIM22
TREM1
CATSPER1
TRIM36
KRT14
SLC22A18AS
ADCY8
PTCHD4
MFSD2A
STRA6
KLHDC7B
NKAIN4
SFN
KRT15
ALOX15B
KLHDC8A Diagnosis
Normal
Tumor
−1
−0.5
0
0.5
1 Nor al	
Tu r	
Di gnosis	
RPKM	=	0.3	in	normal	
Metastasis	 Tumor	 Normal	
0
2
4
6
8
10	
12	
14	
RE
T	
RP
KM
	
Results	
	 66	
3.2 Functional and molecular characterisation of TFG-RET 
3.2.1 TFG-RET expression upregulates oncogenic cell signalling and proliferation 
 
A       B 
 
C 
 
 Figure 3.3: TFG-RET expression upregulates oncogenic cell signalling and proliferation. (A) 
Western blots for indicated proteins (phos, phosphorylated) from cell lysates obtained from  N-Thy-Ori 3-
1 cells stably transfected or 293T (B) cells transiently transfected with FLAG tagged TFG-RET fusion 
protein or with empty vector control (pHAGE C-TAP). (C) To analyze cellular proliferation, N-Thy-Ori 
3-1 cells stably transfected with FLAG tagged TFG-RET (Nthy TFG-RET) or with empty vector control 
(Nthy ctrl) cells (expression shown on the right) were seeded in 96 well plates and subjected to an MTT 
assay. TFG-RET expression lead to an increase in cell proliferation after 72 hours (n = 3, error bars = 
standard error, p = 0.0003; paired t-test, two tailed distribution).  
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In order to functionally characterize the novel fusion protein, we first established stable 
expression of TFG-RET in the immortalised thyroid cell line, NThy-ori-3-1 (NThy 
TFG-RET cells), as well as NThy-ori-3-1 cells stably expressing the empty vector 
(NThy ctrl) as described in the methods. Immunoblot analysis showed that TFG-RET 
expression lead to the upregulation of various cancer-associated events like 
phosphorylation of Akt (T308), STAT3 (S727) and ERK1/2 (T202/Y204) (Figure 
3.3A). Importantly, TFG-RET also exhibited phosphorylation of RET (Y905). The 
tyrosine residue 905 is an autophosphorylation site of RET which has been shown to be 
important for the transforming activity of RET [114, 169]. Further, immunoblot analysis 
also showed that transient expression of TFG-RET in 293T cells induced 
phosphorylation of RET (Y905) as well as up regulation of some cancer related 
phosphorylation events (Figure 3.3B). Next, we checked the effect of TFG-RET 
expression on cell proliferation. An MTT-based cell proliferation assay implied that 
NThy TFG-RET exhibited significantly higher cell proliferation (72 hours post cell 
seeding) as compared to empty vector carrying NThy-ori-3-1 cells (NThy ctrl) (Figure 
3.3C). 
 
3.2.2 TFG-RET localises in the cytoplasm 
 
As RET fusion proteins exhibit cytoplasmic localisation following the 
loss of transmembrane domain of RET in its fusion product, we conducted subcellular 
localisation studies to check if this holds true for TFG-RET as well. The cytosolic, 
plasma membrane and nuclear fractions were collected using cell fractionation as 
described in materials and methods. We used specific cytosolic, plasma membrane and 
nuclear markers (M2-PK, Na-K ATPase and Histone, respectively) to confirm the 
proper fractionation of cell lysates by immunoblot analysis. The immunoblot analysis 
showed that unlike wild type RET (WT-RET) protein, which was present largely in the 
plasma membrane fraction, TFG-RET was present in the cytosolic fraction as well. 
Both RET and TFG-RET were detected in the nuclear fraction (Figure 3.4A). Further, 
we performed confocal imaging studies, which also revealed similar observations 
(Figure 3.4B) 
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Figure 3.4: TFG-RET localizes in the cytoplasm. (A) Cellular fractions obtained from Nthy TFG-RET 
and Nthy RET WT cells were subjected to immunoblot analysis for TFG-RET (FLAG), RET WT 
(FLAG) and indicated markers for each of the cellular fractions. TFG-RET was detected in the cytosolic 
fraction. (B) Representative images of Nthy TFG-RET cells or Nthy RET WT grown on glass. While 
TFG-RET (FLAG tag, red) exhibited cytosolic distribution, RET (FLAG tag, red) expression was not 
seen in the cytoplasm. GFP-LCK (green) marks the plasma membrane (also, pericentrosome) Hoechst 
(nucleus). 
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3.2.3 TFG-RET can induce oncogenic transformation of Nthy-ori-3-1 cells  
 
  
Figure 3.5: TFG-RET expression transforms Nthy-ori-3-1cells - Soft agar colony formation assay. 
Nthy TFG-RET cells and Nthy ctrl cells were cultured in soft agar. After 2 weeks, the colonies were 
stained with crystal violet. TFG-RET could transform Nthy-ori-3-1 cells. (Paired t test, two tailed, n=3, 
P<0.05. 
 
We next investigated the transforming ability of TFG-RET by performing soft agar 
colony formation assays using NThy-ctrl and NThy-TFG-RET cells. Cells were seeded 
in soft agar media and were analysed for colony formation 14 days post seeding. We 
observed that stable expression of TFG-RET in the immortalised thyroid cell line 
induced colony formation, while NThy ctrl cells only formed very few colonies (Figure 
3.5).  Thus, expression of the TFG-RET fusion protein in the tested immortalized 
thyroid cancer cell line lead to anchorage independent growth (a classical marker of 
transformation) of these cells, indicating the ability of TFG-RET to induce oncogenic 
transformation. 
 
Together, these data (section 1.2.1-1.2.3) show that expression of TFG-RET leads to the 
increased phosphorylation, hence activation of many cancer associated proteins. TFG-
RET expression also resulted in the increased cell proliferation and transformation of 
NThy Ori-3 cells. 
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3.2.4 TFG-RET exhibits kinase activity 
 
Figure 3.6: TFG-RET exhibits kinase activity (in vitro kinase assay). HeLa cells were transiently 
transfected with V5 tagged WT RET, TFG-RET, TFG-RET.K270M (kinase dead TFG-RET) along with 
empty vector (EV). Two days post transfection, cells were lysed and subjected to immunoprecipitation 
using anti-V5 antibody. After subsequent washes, the immunoprecipitated proteins were used for in vitro 
kinase assay, using MBP protein as substrate. TFG-RET phosphorylates MBP thus exhibiting kinase 
activity like RET kinase and this kinase activity was abrogated in the TFG-RET kinase dead mutant 
(phos, phosphorylated).  
 
In order to investigate if the fusion protein exhibited enhanced kinase activity, which 
would in turn imply its probable role as a kinase in the phosphorylation and activation 
of other proteins, we conducted an in vitro kinase assay. Wild type RET and a kinase 
dead mutant of TFG-RET (TFG-RETK270M) were used as positive and negative 
controls, respectively. V5 tagged WT-RET, TFG-RET and TFG-RETK270M along 
with empty vector control were transiently expressed in HeLa cells and subsequently 
immunoprecipitated using V5 antibody and used for an in vitro kinase assay. The assay 
was performed using myelin-binding protein (MBP) as substrate, either in the presence 
or absence of Mg-ATP. The immunoblot observations using anti-phospho tyrosine 
antibody showed that in the presence of Mg-ATP, MBP was indeed phosphorylated by 
TFG-RET, while TFG-RETK270M lacked the ability to do so (Figure 3.6).  
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3.2.5 TFG-RET can form dimers 
 
Figure 3.7: TFG-RET can form dimers – co-precipitation experiments. HeLa cells were co-
transfected with FLAG-tagged and V5-tagged WT RET and TFG-RET as indicated. The cells were 
subjected to FLAG immunoprecipitation 48 hours post transfection. Lysates were analyzed by western 
blotting. WT RET co-immunoprecipitated with WT RET (V5) and also with TFG-RET (V5) (left panel), 
similarly, TFG-RET also co-immunoprecipitated with both RET WT (V5) and TFG-RET (V5), indicating 
that TFG-RET can form dimers with themselves, as well as with RET WT. Cells transfected with the 
empty vector (EV) were included as controls. 
 
Since dimerisation is an important event in the activation of protein kinases, we next 
investigated the ability of TFG-RET to form dimers with themselves (homodimers) as 
well as with RET WT (heterodimers). For this, HeLa cells were transiently transfected 
with RET WT and TFG-RET with FLAG or V5 tags, viz., FLAG-RET WT + V5-RET 
WT, FLAG-RET WT + V5-TFG-RET, FLAG-TFG-RET + V5-RET WT, FLAG-TFG-
RET + V5-TFG-RET. FLAG-tagged RET WT and TFG-RET were immunoprecipitated 
and were checked for co-precipitating V5-tagged proteins (Figure 3.7A). As expected, 
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we saw that V5-RET WT co-precipitated with FLAG-RET WT. We also detected the 
co-precipitation of V5-TFG-RET with FLAG-RET WT.  Similarly, we also observed 
that both V5-RET and V5-TFG-RET co-precipitated with FLAG-RET WT and FLAG-
TFG-RET. Together, these data suggest that TFG-RET has the ability to interact with 
TFG-RET, as well as RET-WT to form homo-dimers and heterodimers. 
 
3.2.6 TFG-RET can form oligomeric complexes in vivo 
 
Figure 3.8: TFG-RET can form heteromers – DTME cross-linking studies. Nthy TFG-RET and Nthy-
RET WT cells were treated with i) DTME (0.2 mM, 1 hour) or ii) DTME followed by (DTT) (100 mM, 
15 minutes) along with DMSO control. After thorough washes with PBS, cells were lysed in sample 
buffer (cells treated with only DTME were lysed in non-DTT containing sample buffer) and subjected to 
immunoblot analysis. Upon chemical crosslinking with DTME, similar to WT RET, TFG-RET also 
formed high molecular weight heteromeric complexes (lane 2 (band not seen due to high molecular 
weight of the complex) and lane 5, respectively) and these complexes were disrupted upon reduction with 
DTT (lane 3 and 6). 
 
Although dimerisation is an important event in the activation of kinases, it is not the 
only requirement in the activation of these proteins. Formation of heteromeric 
complexes with other proteins is also important in the functional regulation of kinases. 
In order to investigate the ability of TFG-RET to form heteromeric complexes, we 
carried out crosslinking experiments using the maleimide cross-linker dithio-bis-
maleimidoethane (DTME). NThy TFG-RET cells were treated with DMSO, DTME or 
DTME followed by DTT (reducing agent). NThy RET WT cells were also included, as 
RET WT is known to form heteromeric complexes. Immunoblot analysis revealed that 
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DTME crosslinking resulted in the formation of high molecular weight complexes: The 
TFG-RET band around 75kDa was no longer visible, since it was cross-linked with 
interacting proteins, leading to the formation of a high molecular weight complex (the 
cross-linked TFG-RET was not detected due to the limitation in the detection of larger 
oligomers with the employed gels). Addition of DTT disrupted these complexes, as seen 
by the re-emergence of TFG-RET around 75kDa. As expected, complex formation upon 
cross-linking was also observed in RET WT (Figure 3.8). 
 
3.3 Characterisation of the role of functional domains of TFG in TFG-RET 
 
3.3.1 The PB1 domain and coiled-coil domain of TFG play a role in RET 
phosphorylation 
 
The N-terminus of TFG has two putative functional domains – the Phox and Bem 1p 
(PB1) domain (position 10-91) and a coiled-coil domain (CC domain) (position 97-124) 
(Figure 3.9A). We next focused our investigation on the characterisation of the role of 
these domains of the TFG in regulating the kinase activity of TFG-RET. A structural 
comparison of TFG and PB1 domain containing p62 protein is shown in Figure 3.9B. 
We generated point mutations in the PB1 domain by replacing the positively charged 
lysine in position 14, and arginine in positions 22 and 23 with the negatively charged 
glutamic acid, as indicated in Figure 3.9C. HeLa cells were transiently transfected with 
TFG-RET.K14E, TFG-RET.R22E, TFG-RET.R23E as well as a triple mutant TFG-
RET.K14E.R22E.R23E (in pcDNA3 Dest 40 (V5, His tagged)) and immunoblot 
analysis was performed to investigate the effect of these mutations in the 
phosphorylation of RET. The results indicated that expression of the triple mutant 
construct (TFG-RET.K14E.R22E.R23E) resulted in the decreased phosphorylation of 
RET (Y905), indicating that this may possibly have functional consequences (Figure 
3.9D). 
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Figure 3.9: Mutations in PB1 domain reduces RET phosphorylation. (A) Schematic representation of 
human TFG protein (from [170]). (B). Structural comparison of TFG PB1 with PB1 domains of p62, 
Dvl2 DIX. (C) Point mutations to create PB1 domain mutant TFG-RET. HeLa cells were transiently 
transfected with RET WT, TFG-RET, and indicated point mutations (in pcDNA DEST40 Vector (His and 
V5 tagged)). (D) 48 hours post transfection, cells were lysed and the cell lysates were subjected to 
immunoblot analysis, which suggested that the TFG-RET. K14E.R22E.R23E mutant showed lesser 
phosphorylation of RET (Y905).  
FIGURE 1. Structure of the tropomyosin-receptor kinase fused gene (TFG) and pathogenic mutations of TFG-related neurological
disorders. (A) Illustration of the transcript variants from TFG. The longer form of exon 6 is 12 bp longer than the shorter form of
exon 6. (B) Schematic illustration of human TFG protein containing the Phox and Bem 1p (PB1) domain, coiled-coil (CC)
domain, and proline and glutamate (P/Q)-rich domain. (C) Immunocytochemistry for Sec16 (red) in HeLa cells transfected with
TFG wild type (WT) or P/Q-rich domain (DPQ) tagged with green fluorescent protein (green). Nuclei are stained with 4,6-
diamidino-2-phenylindole (DAPI). Scale bar: 10lm.
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#    -asequence emboss_needle-I20180326-092850-0363-51745817-pg.asequence
#    -bsequence emboss_needle-I20180326-092850-0363-51745817-pg.bsequence
#    -datafile EBLOSUM62
#    -gapopen 10.0
#    -gapextend 0.5
#    -endopen 10.0
#    -endextend 0.5
#    -aformat3 pair
#    -sprotein1
#    -sprotein2
# Align_format: pair
# Report_file: stdout
########################################
#=======================================
#
# Aligned_sequences: 2
# 1: p62
# 2: TFGRET
# Matrix: EBLOSUM62
# Gap_penalty: 10.0
# Extend_penalty: 0.5
#
# Length: 726
# Identity:      95/726 (13.1%)
# Similarity:   151/726 (20.8%)
# Gaps:         386/726 (53.2%)
# Score: 38.0
# 
#
#=======================================
p62                1 -MASLTVKAYLLGKEDAAREIRRFSFCCSPEPEAEAEAAAGPGPCERLLS     49
                      ...|.:...|:.|.....:|||.       |....:..     .:.|:.
TFGRET             1 MNGQLDLSGKLIIKAQLGEDIRRI-------PIHNEDIT-----YDELVL     38
p62               50 RVAALF--PALRPGGFQAHYRDEDGDLVAFSSDEELTMA-----------     86
                     .:..:|  ..|........|:||||||:......:|:.|           
TFGRET            39 MMQRVFRGKLLSNDEVTIKYKDEDGDLITIFDSSDLSFAIQCSRILKLTL     88
p62               87 -------------MSYVKDDIFRIYIKEKKECRRDHRPPCAQEAP-RNMV    122
                                  :.|::.::  |.::.|.....|...|..:..| .|:.
TFGRET            89 FVNGQPRPLESSQVKYLRREL--IELRNKVNRLLDSLEPPGEPGPSTNIP    136
p62              123 HPNVICDGCNGPVVGTRYKCSVCPDYDLCSVCEGKGLHRGHTKLAFPSPF    172
                     ..:.:||.....|:......|......|.:.|    :|..| |.|...|.
TFGRET           137 ENDPLCDELCRTVIAAAVLFSFIVSVLLSAFC----IHCYH-KFAHKPPI    181
p62              173 GHLSEGFSHSRWLRKVKHGHFGWPGWEMGPPGNWSPRPPRAGEARPGPTA    222
                     ......|.                            ||     |:..|.:
TFGRET           182 SSAEMTFR----------------------------RP-----AQAFPVS    198
p62              223 ESASG---PS----------------EDPSVNFL-------KNVGESVAA    246
                     .|:||   ||                |||...|.       |.:||    
TFGRET           199 YSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGE----    244
p62              247 ALSPLGIEVDIDVEHGGKRSRLTPVS----PESSSTEE-----------K    281
                       ...|..|.....|...|:..|.|:    .|::|..|           |
TFGRET          245 --GEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRD LSEFNVLK   292
############
# Program: needle
# Rundate: Mon 26 Mar 2018 09:30:04
# Commandline: needle
#    -auto
#    -stdout
#    -asequence emboss_needl -I20180326-092850- 63 5174 817-pg.asequence
#    -bsequence em oss_needl -I20180326-092850- 63 5174 817-pg.bsequence
#    -datafile EBLOSUM62
#    -gapopen 10.0
#    -gapextend 0.5
#    -endopen 10.0
#    -endextend 0.5
#    -aformat3 pair
#    -sprotein1
#    -sprotein2
# Align_format: pair
# Report_file: stdout
############
#============
#
# Aligned_sequences: 2
# 1: p62
# 2: TFGRET
# Matrix: EBLOSUM62
# Gap_penalty: 10.0
# Extend_penalty: 0.5
#
# Length: 726
# Identity:     95/726 (13.1%)
# Similarity:   151/726 (20.8%)
# Gaps:        386/726 (53.2%)
# Score: 38.0
# 
#
#============
p62            1 -MASLTVKAYLLGKEDAAREIRRFSFCCSPEPEAEAEAAAG G CERLLS     49
            ...|.:...|:.| . .:|| .       |... :..  : |
TFGRET            1 MNGQLDLSGKLIIKA GEDIRR -------P HNEDIT -YDELVL     38
p62            50 RVAALF--PALRPGGFQAHYRDEDGDLVAFSSDE LTMA-----------     86
            .:..:| ..|. . ...|:| ||||: ...: :.            
TFGRET            39 MMQRVFRGKLLSNDEVTIKY DEDG LI FDSSDLSFA QCSRILK TL     88
p62            87 ------------ MSYVKDDIFRIYIKEK ECRRDHRPPCAQ AP-RNMV    122
            :.|::.:: |. :.|. ...|. .| .: | .|:
TFGRET            89 FVNGQPRPLESSQ KYLR E --IELRNKVNR LDSLEPPGEPGPSTNIP    136
p62            123 HPNVICDGCNGPVVGTRYKCSVC DYDLCSV EGKGLHRGHTKLAFPSPF    172
            ..:.:||.....|:. ... | .. | : |    :| .| |.|...|.
TFGRET           137 ENDPLCDELCRTVIAAAVLFSFIVSVLLSAFC----IHCYH-KFAHKPPI    181
p62            173 GHLSEGFSHSRWLRKVKHGHFGWPGWEMGPPGNWS RPPRAGEARPG TA    222
            ......|.         || |:..|.:
TFGRET           182 SSAEMTFR------------ RP AQAFPVS    198
p62            223 ESASG---PS------- -- EDPSVNFL ---KNVGESVAA    246
            .|:|| ||        |||...|.    | : |
TFGRET           199 YSSSGARRPSLDSMENQVSVDAFKIL DPKWEFPR N VLG TLGE----    244
p62            247 ALSPLGIEVDIDVEHGGKRSRLTP S----PESSSTEE -------K    281
            ...|..|.....| .|:. | |:    .|:: .|        
TFGRET          245 --GEFGKVVKATAFHLK RAGYT VAVKMLKENASPSELRD LSEFNVLK    292
K14E R22E, R23E 
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Further, in order to investigate the role of the CC domain of TFG-RET, we created 
mutant TFG-RET, wherein the CC domain was deleted (TFG-RETΔ97-124) (Figure 
3.10 A). We then transiently transfected NThy ori-3-1 cells with TFG-RET and TFG-
RETΔ97-124 construct (in pcDNA3 Dest 40 (V5, His tagged)) and checked the status 
of RET (Y905) phosphorylation. Immunoblot analysis revealed that TFG-RETΔ97-124 
exhibited lesser phosphorylation when compared to TFG-RET, thus implying that 
deletion of the CC domain also may have functional consequences (Figure 3.10 B). 
A 
 
 
B 
 
 
Figure 3.10: Deletion of the CC domain of TFG reduces RET phosphorylation. The CC domain (L97 
to E124) of TFG-RET was deleted to create the TFG-RET Δ97-124 ((A)- deleted amino acids in red). 
Nthy-ori-3-1 cells were transiently transfected with TFG-RET and TFG-RET Δ97-124 in pcDNA 
DEST40 Vector (His and V5 tagged) along with empty vector control. 48 hours post transfection, cells 
were lysed and the cell lysates were subject to immunoblot analysis, which suggested that the TFG-RET 
Δ97-124 mutant showed lesser phosphorylation of RET (Y905) (B). 
 
 
 
 
1						MNGQLDLSGK	LIIKAQLGED	IRRIPIHNED	ITYDELVLMM	QRVFRGKLLS	NDEVTIKYKD	EDGDLITIFD	SSDLSFAIQC		
81			SRILKLTLFV	NGQPRPLESS	QVKYLRRELI	ELRNKVNRLL	DSLEPPGEPG	PSTNIPENDP	LCDELCRTVI	AAAVLFSFIV		
161	SVLLSAFCIH	CYHKFAHKPP	ISSAEMTFRR	PAQAFPVSYS	SSGARRPSLD	SMENQVSVDA	FKILEDPKWE	FPRKNLVLGK		
241	TLGEGEFGKV	VKATAFHLKG	RAGYTTVAVK	MLKENASPSE	LRDLLSEFNV	LKQVNHPHVI	KLYGACSQDG	PLLLIVEYAK		
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3.3.2 PB1 domain and CC domain are important for TFG-RET oligomerisation. 
 
A 
 
B        C 
 
Figure 3.11: Functional domains of TFG contribute to TFG-RET heteromerisation - Gel filtration 
studies. HeLa cells were transiently transfected with TFG-RET, TFG-RET K14E.R22E.R23E and TFG-
RET Δ97-124 in pcDNA3 Dest 40 (V5, His tagged). 48 hours post transfection, cells were lysed in 500 µl 
lysis buffer by sonication. Subsequently, the cell lysates were ultracentrifuged and the supernatant 
(cytosolic fraction) was separated by size exclusion chromatography. (C) Protein expression of TFG-RET 
K14E.R22E.R23E, TFG-RET Δ97-124 (in pcDNA DEST V5.His vector) in HeLa cells were verified by 
immunoblot analysis of the cell lysates. (A) Collected fractions (every second fraction) were subjected to 
western blotting and TFG-RET, TFG-RET K14E.R22E.R23E and TFG-RET Δ97-124 were detected 
using V5 tag. (A, B) Most of TFG-RET was detected in high molecular weight fractions, while TFG-RET 
K14E.R22E.R23E shifted towards the later, lower molecular weight fractions. TFG-RET Δ97-124 was 
distributed among higher and lower molecular weight fractions. 
  
Our next step was to investigate if the PB1 domain and CC domain of TFG played any 
role in the regulation of TFG-RET heteromeric complex formation. To check this, 
cytosolic fractions from cell lysates collected from HeLa cells transiently expressing 
TFG-RET, TFG-RET K14E.R22E.R23E and TFG-RET Δ97-124 (Figure 3.11C) were 
loaded on Superose6 gel filtration columns. Every second fraction collected after gel 
filtration was used for immunoblot analysis. As expected, most of TFG-RET was 
detected in the higher molecular weight fractions, indicating TFG-RET being present in 
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high molecular weight protein complexes, while in the case of TFG-RET 
K14E.R22E.R23E, most of the protein was detected in relatively lower molecular 
weight fractions. On the other hand, TFG-RET Δ97-124 was distributed among higher 
and lower molecular weight fractions, which looked like a combined pattern of TFG-
RET and TFG-RET K14E.R22.R23E. (Figure 3.11A, 11B). These data suggested that 
both PB1 domain and the CC domain have a role in the heteromeric complex formation 
of TFG-RET. 
 
3.3.3 PB1 domain is important for the stability of TFG-RET 
 
 
 
 
Figure 3.12: Functional domains of TFG influences TFG-RET stability (Cycloheximide chase 
assay). Nthy-ori-3-1cells were transiently transfected with TFG-RET, TFG-RET K14E.R22E.R23E and 
TFG-RET Δ97-124. 48 hours post transfection, cycloheximide (100ug/mL) was added to the cells and 
cell lysates were collected in SDS-sample buffer at indicated time points. The samples were subjected to 
immunoblot analysis. The results suggest that TFG-RET K14ER22.R23E exhibits lesser protein stability 
relative to TFG-RET, while, TFG-RET Δ97-124exhibits higher protein stability relative to TFG-RET. 
 
We next checked if either of these two putative functional domains of TFG played a 
role in maintaining the stability of TFG-RET. For this, transiently transfected NThy-ori-
3-1 cells with TFG-RET, TFG-RET K14ER22,23E and TFG-RET Δ97-124and 
performed a cycloheximide chase assay. Immunoblot analysis of the cell lysates showed 
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that the mutations on the PB1 domain resulted in a faster degradation of TFG-RET, 
while the deletion of CC domain resulted in a higher stability of TFG-RET (Figure 
3.12). This data implies that both the PB1 domain and CCdomain of TFG has a role in 
the regulation of stability of TFG-RET. 
 
3.3.4 Deletion of CC domain of TFG results in the reduction of TFG-RET induced 
transformation 
In order to investigate any possible role of the PB1 domain and CC domain in the 
transformation ability of TFG-RET, we conducted soft agar colony formation assay as 
described earlier. For this, we first established TFG-RET K14E.R22E.R23E and TFG-
RET Δ97-124 expressing stable NThy-ori-3-1 cell lines. The results indicated that the 
deletion of CC domain significantly reduced the colony formation ability of NThy-
TFG-RET cells (i.e, TFG-RET Δ97-124 cells). Though a similar observation was seen 
in the NThy-TFG-RET K14E.R22E.R23E cells, the result remain inconclusive due to 
the lower expression of TFG-RET K14E.R22E.R23E in these stable cell lines (Figure 
3.13). 
 
 Figure 3.13: Mutation in the PB1 domain of TFG affects the transformation ability of TFG-RET – 
soft agar colony formation assay. Nthy TFG-RET, Nthy TFG-RET Δ97-124 and Nthy TFG-RET 
K14E.R22E.R23E along with Nthy ctrl cells were cultured in soft agar for 2 weeks followed by staining 
with crystal violet. Nthy TFG-RET Δ97-124 cells exhibited reduced transformation ability compared to 
Nthy TFG-RET cells. TFG-RET K14E.R22E.R23E also might affect the transformation ability of TFG-
RET, but the results are inconclusive due to lower expression level of this mutant (Paired t test, two 
tailed, n = 3, P<0.05).  
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3.4 Mass spectrometric analysis of patient normal, tumor and metastatic tissue 
 
3.4.1 Differential expression of proteins in cancer tissue 
 
With the aim to investigate any differential expression of proteins between normal and 
cancer tissue, we conducted liquid chromatography-mass spectrometric (LC-MS) 
analysis of protein lysates prepared from normal, tumor and metastatic tissue of the 
same patient (three technical repeats of each sample). A total of 1,734 proteins were 
detected and the average signal intensities for every protein in each sample were 
determined and compared between the three samples. Label-free quantitative analysis of 
the mass spectrometry data implied differential expression of proteins among the three 
samples, with 184 proteins being expressed only in the tumor and metastatic samples 
(Figure 3.14A, C). The number of proteins with differential regulation between tumor 
and metastatic samples is shown in Figure 3.14 B. Table 2 and 3 enlists the proteins that 
were detected in the tumor and metastatic lesions only, respectively.  
 
A 
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Figure 3.14: Differential regulation of protein expression in tumor and metastatic tissue. (A, B) 
Venn diagrams representing the differential regulation of proteins in normal, tumor and metastasis tissue 
from the patient tissue. (C) Scatter plots showing differential expression of proteins between various sets 
of tissues. 
Table 2: List of proteins that were detected only in tumor lesions in the mass spectrometric analysis. 
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Table 3: List of proteins that were detected only in metastatic lesions in the mass spectrometric 
analysis. 
 
 
3.4.2 Ubiquitination pathway-related proteins are up regulated in patient cancer tissue 
 
As we are interested in the ubiquitination machinery, we then looked into the regulation 
of ubiquitination-associated proteins in the patient’s tissue. The mass spectrometric data 
suggested that the ubiquitination pathway associated proteins HUWE1, USP9X and 
UBP7 were upregulated in the tumor and metastatic tissue of the patient (Figure 3.15A). 
Our next step was to investigate if the upregulation of these ubiquitination pathway 
associated proteins could also be detected in NThy TFG-RET cells. We carried out RT-
PCR studies as well as immunoblot analysis to compare the expression of these 
ubiquitination-associated molecules both at the mRNA and protein level in NThy-TFG-
RET cells and NThy-ctrl cells. Immunoblot analysis implied an upregulation of 
HUWE1, USP9X and USP7 proteins in NThy TFG-RET cells compared to NThy ctrl 
cells (Figure 3.15 B). The RT-PCR data indicated higher levels of Huwe1, Usp9x and 
Usp7 at mRNA levels, although not significant in all cases (Figure 3.15 C).  
 
 
 
 
 
 
Table	4	
Protein	List	Tumor	only		 Accession	 Entry	 Description	1	 P01258	 CALC_HUMAN	 Calcitonin	OS=Homo	sapiens	GN=CALCA	PE=1	SV=2	2	 P22748	 CAH4_HUMAN	 Carbonic	anhydrase	4	OS=Homo	sapiens	GN=CA4	PE=1	SV=2	3	 P16671	 CD36_HUMAN	 Platelet	glycoprotein	4	OS=Homo	sapiens	GN=CD36	PE=1	SV=2	4	 P35908	 K22E_HUMAN	 Keratin		type	II	cytoskeletal	2	epidermal	OS=Homo	sapiens	GN=KRT2	PE=1	SV=2	5	 Q16647	 PTGIS_HUMAN	 Prostacyclin	synthase	OS=Homo	sapiens	GN=PTGIS	PE=1	SV=1	6	 P63267	 ACTH_HUMAN	 Actin		gamma-enteric	smooth	muscle	OS=Homo	sapiens	GN=ACTG2	PE=1	SV=1	7	 Q15326	 ZMY11_HUMAN	 Zinc	finger	MYND	domain-containing	protein	11	OS=Homo	sapiens	GN=ZMYND11	PE=1	SV=2	8	 P55058	 PLTP_HUMAN	 Phospholipid	transfer	protein	OS=Homo	sapiens	GN=PLTP	PE=1	SV=1	9	 P50440	 GATM_HUMAN	 Glycine	amidinotransferase		mitochondrial	OS=Homo	sapiens	GN=GATM	PE=1	SV=1	10	 Q8IWL1	 SFPA2_HUMAN	 Pulmonary	surfactant-associated	protein	A2	OS=Homo	sapiens	GN=SFTPA2	PE=1	SV=1	11	 O00422	 SAP18_HUMAN	 Histone	deacetylase	complex	subunit	SAP18	OS=Homo	sapiens	GN=SAP18	PE=1	SV=1	12	 Q86XX4	 FRAS1_HUMAN	 Extracellular	matrix	protein	FRAS1	OS=Homo	sapiens	GN=FRAS1	PE=1	SV=2	13	 P30566	 PUR8_HUMAN	 Adenylosuccinate	lyase	OS=Homo	sapiens	GN=ADSL	PE=1	SV=2	14	 P17661	 DESM_HUMAN	 Desmin	OS=Homo	sapiens	GN=DES	PE=1	SV=3	15	 Q06828	 FMOD_HUMAN	 Fibromodulin	OS=Homo	sapiens	GN=FMOD	PE=1	SV=2		
	
	Table	5	
Protein	List	–	Metastasis	Only		 Accession	 Entry	 Description	
1	 Q04446	 GLGB_HUMAN	 1	4-alpha-glucan-branching	enzyme	OS=Homo	sapiens	GN=GBE1	PE=1	SV=3	
2	 Q96C23	 GALM_HUMAN	 Aldose	1-epimerase	OS=Homo	sapiens	GN=GALM	PE=1	SV=1	
3	 Q96CN7	 ISOC1_HUMAN	 Isochorismatase	domain-containing	protein	1	OS=Homo	sapiens	GN=ISOC1	PE=1	SV=3	
4	 Q06124	 PTN11_HUMAN	 Tyrosine-protein	phosphatase	non-receptor	type	11	OS=Homo	sapiens	GN=PTPN11	PE=1	SV=2	
5	 P32456	 GBP2_HUMAN	 Guanylate-binding	protein	2	OS=Homo	sapiens	GN=GBP2	PE=1	SV=3	
6	 Q9NVE7	 PANK4_HUMAN	 Pantothenate	kinase	4	OS=Homo	sapiens	GN=PANK4	PE=1	SV=1	
7	 Q53RD9	 FBLN7_HUMAN	 Fibulin-7	OS=Homo	sapiens	GN=FBLN7	PE=2	SV=1	
8	 Q9UDY2	 ZO2_HUMAN	 Tight	junction	protein	ZO-2	OS=Homo	sapiens	GN=TJP2	PE=1	SV=2	
9	 P35237	 SPB6_HUMAN	 Serpin	B6	OS=Homo	sapiens	GN=SERPINB6	PE=1	SV=3	
10	 P07358	 CO8B_HUMAN	 Complement	component	C8	beta	chain	OS=Homo	sapiens	GN=C8B	PE=1	SV=3	
11	 Q6RW13	 ATRAP_HUMAN	 Type-1	angiotensin	II	receptor-associated	protein	OS=Homo	sapiens	GN=AGTRAP	PE=1	SV=1	
12	 Q8WXX5	 DNJC9_HUMAN	 DnaJ	homolog	subfamily	C	member	9	OS=Homo	sapiens	GN=DNAJC9	PE=1	SV=1	
13	 Q16625	 OCLN_HUMAN	 Occludin	OS=Homo	sapiens	GN=OCLN	PE=1	SV=1	
14	 Q6P2P2	 ANM9_HUMAN	 Putative	protein	arginine	N-methyltransferase	9	OS=Homo	sapiens	GN=PRMT9	PE=2	SV=1	
15	 P27361	 MK03_HUMAN	 Mitogen-activated	protein	kinase	3	OS=Homo	sapiens	GN=MAPK3	PE=1	SV=4	
16	 Q9UKG1	 DP13A_HUMAN	 DCC-interacting	protein	13-alpha	OS=Homo	sapiens	GN=APPL1	PE=1	SV=1	
17	 P17301	 ITA2_HUMAN	 Integrin	alpha-2	OS=Homo	sapiens	GN=ITGA2	PE=1	SV=1	
18	 Q49A26	 GLYR1_HUMAN	 Putative	oxidoreductase	GLYR1	OS=Homo	sapiens	GN=GLYR1	PE=1	SV=3	19	 Q9BXR6	 FHR5_HUMAN	 Complement	factor	H-related	protein	5	OS=Homo	sapiens	GN=CFHR5	PE=1	SV=1	
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Figure 3.15: Ubiquitination associated proteins are up regulated in TFG-RET expressing cells. (A) 
Mass spectrometric analysis showing up regulation of ubiquitination associated proteins in patient tumor 
samples. (B) Cell lysates of Nthy ctrl and Nthy TFG-RET cells were subjected to western blot analysis of 
the indicated proteins. (C) Total RNA extraction followed by cDNA synthesis from Nthy ctrl and Nthy 
TFG-RET cells was performed to determine the relative gene expression levels based on qRT-PCR 
studies (n = 3, paired t test, Two-tailed) (internal control – 18S, RPS13). Ubiquitination associated 
proteins were upregulated, not only at the protein level, but also at the mRNA level. 
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3.4.3 Inhibition of RET and ubiquitin-associated protein reduces colony formation of 
NThy TFG-RET cells 
 
Since our data suggested that HUWE1, USP9X and USP7 were up regulated in NThy 
TFG-RET cells, we next examined if inhibition of these proteins using chemical 
inhibitors would affect the transformation ability of NThy TFG-RET cells. We also 
checked the effect of inhibition of RET kinase using FDA approved tyrosine kinase 
inhibitors. Table 4 shows a list and short description about the inhibitors used in our 
experiments. Briefly, WP1130 is a cell-permeable chemical that has been demonstrated 
to directly inhibit the activity of DUBs including USP9X, USP5 and USP14 [171]. A 
study showed that WP1130 mediated DUB inhibition lead to tumor cell apoptosis as a 
result of formation of aggresomes due to induced accumulation of protein-ubiquitin 
conjugates [171]. XL184 (Cabozantinib), is a multiple receptor tyrosine kinase inhibitor 
that has the potential to produce synergistic antitumor effects [172]. Since it can bind to 
and inhibit many RTKs overexpressed in tumors including RET, VEGFR1/2/3, it can 
contribute to tumor regression by inhibiting tumor growth as well as angiogenesis 
[172]. Vandatenib is an orally available multiple kinase inhibitor that has the potential 
to inhibit VEGF signalling and oncogenic RET at nanomolar concentrations, and EGFR 
tyrosine kinase at submicromolar concentrations [173]. Hence, vandatenib also can act 
as both an anti-angiogenic as well as an anti-neoplastic drug. It has been demonstrated 
that Vandatenib can block phosphorylation and activity of RET oncoproteins (both RET 
activating mutants and RET fusions) in cells as well as inhibit the transforming effects 
of RET/PTC in cells and RET/PTC3-induced tumors in mice [174]. BI8622 and BI8626 
are small molecule inhibitors of HUWE1 that were identified using high-throughput 
screening in an attempt to repress MYC-activated genes by promoting stabilisation of 
MIZ1, a negative regulator of MYC, which in turn is degraded by E3 ligase HUWE1 
[175]. Since HUWE1 can autoubiquitinate its HECT-domain, the high throughput 
approach screened for the reduction in HUWE1 autoubiquitination activity [176]. We 
synthesised BI8622 and BI8626 (Syngene International Limited, India) and checked for 
the auto-ubiquitination of HUWE1 upon treatment with the inhibitors. NThy TFG-RET 
cells were treated with 20 µM BI-8622 or BI-8626 for 2 hours followed by treatment 
with proteasome inhibitor MG132 (10 µM) for 5 hours in order to capture the ubiquitin-
conjugated proteins. Ubiquitinated proteins were isolated using UBIQAPTURE-Q kit 
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followed by western blot analysis. Immunoblots showed that treatment of NThy TFG-
RET cells with BI-8622 and BI-8626 did indeed reduce ubiquitination of HUWE1 
(Figure 3.16). 
We investigated the effect of these inhibitors on the transformation of NThy-ori-3-1 
cells. Soft agar colony formation assay in the presence of inhibitors was conducted.  
The DUB inhibitor WP1130 and kinase inhibitor XL-184 significantly reduced the 
transforming ability of NThy-TFG-RET as seen by the reduction in the number of 
colonies formed (Figure 3.17). Both inhibitors of HUWE1 also reduced the 
transformation ability of NThy TFG-RET cells, although BI-8622 seem to inhibit 
transformation of NThy TFG-RET cells to a much greater extent (Figure 3.17).  
 
Table 4: List of inhibitors and targets/functions 
 
 
 
Figure 3.16: Immunoblot analysis showing reduced HUWE1 ubiquitination up on treatment with BI-
8622 (20 µM) and BI-8626 (20 µM).  
 
List	of	Inhibitors	and	targets/functions	Compound	 IC50	 Description	WP1130	 1.25	–	5	μM	(Usp9x)	 Deubiquitinase	inhibitor	XL184	(Cabozantinib)	 4	nM	(Ret)	 RTK	inhibitor,	Used	in	the	treatment	of	MTC,	RCC	Vandatenib	 40	nM	(VEGFR2)	110	nM	(VEGFR3)	500	nM		(EGFR	)	 TK	inhibitor,	used	in	the	treatment	of	MTC		BI8622	 3.1	μM					(HUWE1)	 HUWE1	inhibitor	
								BI8626			2.5	μM														2.5	μM	(HUWE1)	 HUWE1	inhibitor	RTK-Receptor	Tyrosine	Kinase,	TK-Tyrosine	Kinase	MTC-Medullary	Thyroid	Cancer,	RCC-Renal	Cell	Carcinoma		
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Figure 3.17: Tyrosine Kinase, DUB and HUWE1 inhibitors reduce oncogenic growth in TFG-RET 
expressing cells - soft agar colony formation assay. Nthy TFG-RET cells were cultured in soft agar 
colonies along with the indicated inhibitors for 2 weeks followed by staining with crystal violet. Inhibitor 
treatment resulted in the reduction in the relative number of colonies (Paired t test, two tailed, n=3, 
P<0.05). 
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4 Discussion 
 
BCR-ABL fusion (philadelphia chromosome), an inter-chromosomal translocation 
between ABL gene from chromosome 9 and BCR gene on chromosome 22, in patients 
with chronic myeloid leukaemia (CML) was the first ever described oncogenic gene 
fusion [177]. This discovery had lead to the development of targeted molecular 
therapies including imatinib, nilotinib and dasatinib for the treatment of CML patients 
harbouring BCR-ABL fusion [178, 179]. Since then, the list of oncogenic gene fusions 
identified has increased, although they seem to have a much higher frequency in 
haematological malignancies as compared to solid tumors. However, this discrepancy 
might be in part mostly due to the higher karyotypic complexity of heterogeneous solid 
tumors, which posed technical difficulties in employing cytogenetic tools to identify 
chromosomal rearrangements like chromosome banding and fluorescence in situ 
hybridisation [180]. Many shortcomings of these techniques including culturing tumor 
cells in vitro and poor banding resolutions were overcome to a good extent with the 
development of high throughput global genetic analysis tools which allowed genome 
wide gene expression and copy number profiling. This approach made it possible to 
identify genes that showed outlier expression values or copy number shifts, which were 
further investigated for involvement in fusion events. However, it was the development 
of next generation sequencing (NGS) technologies in the 2000s that contributed 
dramatically to the current list of identified gene fusions [181]. NGS enables an 
unbiased approach for massive and in depth sequencing of the genome, exome or 
transcriptome which thereby allows identification of molecular alterations. This, along 
with the tremendous advancements in bioinformatics and computational biology has 
drastically changed our understanding of the landscape of genomic fusions, particularly 
with respect to solid tumors. The discovery of the presence of recurrent fusions of 
TMPRSS2 with ETS transcription genes (ERG or ETV) in over 50% of prostate cancer 
patients on the basis of outlier gene expression studies and phosphoproteomic studies 
for the identification of known and novel tyrosine kinase fusions in non-small cell lung 
cancers revealed the so far unknown prevalence of oncogenic fusions in epithelial 
cancers [182, 183]. The Cancer Genome Atlas (TCGA), which was set up in an effort to 
unveil the spectra of oncogenic genetic alterations using high-end genomic analysis 
technologies, now serves as an immense resource of identified genetic alterations across 
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33 cancer types [184]. Tumor-Fusions, a data portal that catalogues tumor fusions 
detected from 9966 well-characterised cancer samples from TCGA now enlists 20,731 
fusion events [185]. The very high sensitivity offered by the recent high-end sequencing 
tools and the fact that gene fusions are also detected in non-malignant cells, emphasises 
the importance of characterising the functionality of the identified fusion products in 
order to distinguish nonspecific passenger fusions from recurrent oncogenic driver 
fusions. 
A recent study by Gao et al. estimates that 16.5% of cancers harbour oncogenic driver 
fusions and these fusions function as sole driver in more than 1% of these cancers [186]. 
The same study also identified druggable fusions in 6% of the total cancers investigated 
and suggested that fusions involving oncogenes exhibited a higher likelihood for 
overexpression, while those involving tumor suppressor genes showed underexpression 
tendencies. Certain types of cancers including sarcoma, stomach cancer and breast 
cancer show higher prevalence of fusion events and many fusions exhibit lineage 
specific occurrence as in the cases of TMPRSS2-ERG in prostate cancer, CCDC6-RET 
in thyroid cancer, and PML-RARA and CBFB-MYH1 in acute leukemia [185]. Fusions 
involving kinases, which result in the increased activity of the kinase involved are 
important oncogenic events that could be relevant in terms of targeted therapy. Kinase 
fusions involving tyrosine kinases (RET, NTRK1/3, ROS, ALK) and serine threonine 
kinases (A/B/CRAF, MAST1/2) have been reported in various types of cancers [107]. 
Kinase fusions can be either 5’ or 3’ kinase fusions with the kinase at the 5’ or 3’ end of 
the fusion gene, respectively. Gao et al.’s study suggests that while most of the 5’ 
kinase fusions showed lower expression with the partner gene in comparison with the 
kinase, most of the 3’ kinase fusions showed higher expression with the partner gene, 
probably as a consequence of higher promoter activity of the 5’ partner gene [186].  
Various studies have established the prevalence of NTRK fusions and RET fusions in 
PTCs and they form the underlying genetic alteration in about 5-13% and 13-43% of 
PTCs, respectively [187]. In this study, we identified a novel RET fusion in a PTC 
patient and functionally characterised its function and its role in oncogenesis. Further, 
we compared the genetic and proteomic expression profiles of normal and tumor tissues 
with the aim of identifying possible new therapeutic targets in PTCs. 
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4.1 Identification of a novel RET fusion in PTC 
 
Since BRAFV600E and NRAS mutations are the most common genetic alterations in 
PTC, we selected a patient who did not harbour these mutations with the aim of 
identifying novel molecular alterations in PTC. We conducted immunohistochemical 
staining that implied that the tumor was a PTC with follicular growth (Figure 1). RNA 
and protein samples were obtained from normal, tumor and metastatic tissues for 
subsequent genomics and proteomics analysis. RNA sequencing analysis identified a 
novel 3’ kinase fusion gene involving the N-terminal of TRK fused gene (TFG) and C-
terminal RET kinase, which would give rise to the 626 amino acid containing fusion 
product TFG-RET, and translating to an approximately 68 kDa size fusion protein. 
TFG-RET results from an inter-chromosomal translocation involving exons 1-4 of the 
TFG gene located on chromosome 3 and exons 11-20 of the RET proto-oncogene 
located on chromosome 10 (Figure 3.2.C). Chromosome fragile sites are regions in the 
chromosome that are known to be involved in the formation of DNA breaks and 
generation of cancer specific rearrangements in human cells [188]. Similar to all the 
oncogenic RET fusions reported in PTC to date, the breakpoint of RET in TFG-RET 
lies within the fragile site containing the 1.8 kb intron 11 of RET. The resulting fusion 
retains the entire kinase domain of RET intact, while it leads to the deletion of its the 
negative regulatory elements. RET itself is not expressed in the follicular cells of the 
thyroid, although it is expressed in the parafollicular C cells. TFG is a ubiquitously 
expressed protein containing 400 amino acids, which is conserved among many species 
including Caenorhabditis elegans. TFG has been identified to interact with and 
negatively regulate the tyrosine phosphatase protein SHP-1 that is involved in the down 
regulation of various signalling pathways [189]. Studies also suggest that TFG plays a 
role in the induction of NF-kB pathway through its interaction with NEMO and TANK, 
which are known regulators of NF-kB pathway [190]. TFG was initially reported as the 
fusion partner of NTRK1 gene, named TRK-T3, in human PTC [191]. Subsequently, 
TFG was also reported the fusion partner of NOR1 in extra skeletal myxoid 
chondrosarcoma as well as to form fusion with ALK gene in anaplastic large cell 
lymphoma as well as the fusion partner of NOR1 in extra skeletal myxoid 
chondrosarcoma [192-194]. Upon TFG-RET fusion, expression of the novel protein is 
regulated by the TFG promoter which eventually results in the unscheduled expression 
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of RET in the thyroid follicular cells. A study by Witte et al. showed that TFG localises 
at the endoplasmic reticulum (ER) and is involved in protein secretion [195]. The study 
also suggests that fusion of NTRK1 with TFG recruits NTRK1 to the ER exit sites 
which leads to an increased kinase activity of the TFG fused NTRK1 at the ER exit sites 
resulting in the premature stimulation of multiple effectors including ERK1/2 signalling 
as a possible mechanism by which TFG fusion results in oncogenicity. The N-terminus 
and other functional domains (discussed in detail later) contained within the TFG 
portion have been shown to play crucial roles in various steps involved in the activation 
of the oncogenic TRK-T3 [114, 196], [197].  
Apart from the TFG-RET fusion, our exome sequencing data also revealed the presence 
of other mutations that have not been yet well characterised (Figure 3.2 A,B and Table 
1). Among others, our data revealed a mutation in the protein kinase MAP2K2 (MEK2), 
which was detected only in metastatic lesions. MAP2K2 is an important member of the 
RAS-RAF-MEK-ERK pathway, which in turn regulates various cellular processes 
including cell proliferation, differentiation and migration [60]. No studies so far have 
reported any MAP2K2Q391H mutation in any pathologic conditions. MAP2K2Q391 
lies outside the kinase domain of MAP2K2, hence this mutation is less likely to directly 
affect the kinase activity of MAP2K2 [198]. Whether this mutation affects any other 
aspects of MAP2K2 like protein stability or protein-protein interactions remains to be 
investigated.  A mutation in Myc (MycS21N), which also has not been reported so far, 
was detected in the exome analysis. MYC is a transcription factor that undergoes 
oncogenic activation in about 30% of human cancers [199]. Oncogenic activation of 
Myc usually occurs through chromosomal translocation, gene amplification or retroviral 
insertional mutagenesis [200]. MycS21 lies within the transactivation domain of Myc 
that plays a role in the regulation of gene transcription [200].  It may be interesting to 
check if the MycS21N mutation affects gene transcription that may in turn have 
oncogenic consequences. 
 
4.2 TFG-RET is an oncogenic chromosomal rearrangement 
 
Not all fusion genes result in the formation of an oncogene, the fusions can also be mere 
‘passenger’ chromosomal translocations, which may not have any oncogenic or even 
functional consequence. So, we next aimed at investigating if the novel fusion gene we 
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identified was indeed oncogenic. For this we synthesised a plasmid construct in the 
pENTR221 gateway vector containing the TFG-RET sequence (from Invitrogen), which 
was subsequently cloned into various mammalian expression vector systems (pHAGE 
C-TAP (FLAG and HA tagged)) and Gateway™ pcDNA™-DEST40 Vector (His and 
V5 tagged). We established stable cell lines that constitutively expressed TFG-RET. 
NThy-ori-3-1 cells, which are immortalised normal human primary thyroid follicular 
epithelial cells, were stably transfected with pHAGE C-TAP TFG-RET constructs along 
with empty vector controls. Firstly, we checked if TFG-RET was phosphorylated at 
RET Y905, as Y905 has been identified as an auto-phosphorylation site of RET and it 
has been shown that impairing Y905 phosphorylation resulted in the impairment of 
kinase activity and transformation ability of RET [114, 169]. We observed that TFG-
RET was indeed phosphorylated at Y905 and further, we saw the activation of several 
pro-survival signalling proteins including phosphorylation of ERK1/2, AKT and 
STAT3, all of which are implied to play a role in RET mediated tumorogenicity (Figure 
3.3) [201-203]. We also observed the upregulation of oncogenic signalling pathways in 
293T cells that were transiently transfected with TFG-RET. Not surprisingly, we also 
observed that stable expression of TFG-RET increased cell proliferation in NThy-ori-3-
1 cells (Figure 3.3). While RET is located at the cell membrane, the novel fusion protein 
TFG-RET is mainly found in the cytosol (Figure 3.4). Within the fusion protein various 
domains including the transmembrane domain are deleted. This has also been observed 
for other RET fusions. We also detected TFG-RET at the plasma membrane. This could 
be explained by relocation due to interaction of RET fusion proteins with other docking 
and signal adaptor proteins like FRS2, SHC and Enigma and for subsequent 
propagation of signalling cascades [204, 205].  
We next investigated the ability of TFG-RET to induce malignant transformation in 
NThy-ori-3-1 cells. Soft agar colony formation assay is a technique used to evaluate the 
ability of cells to grow and divide in an anchorage-independent manner, which is a 
characteristic of transformed cells. We clearly observed that TFG-RET expression 
transformed NThy-ori-3-1 cells as it led to colony formation (Figure 3.5). To our 
knowledge this is the first study that demonstrates the transformation ability of a RET 
fusion in immortalised human thyroid cells. Phosphorylation of STAT3, ERK1/2 and 
Akt in TFG-RET expressing cells implied that TFG-RET exhibits kinase activity. We 
wanted to confirm that TFG-RET indeed possesses kinase activity and for this we 
performed in vitro kinase assay using MBP as the phosphorylation substrate. As the 
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mutation of lysine 758 which is present with in in the activation loop of full length RET 
abolishes the kinase activity of RET, we generated a kinase dead variant of TFG-RET 
by introducing a point mutation corresponding to K758M of RET (TFG-RETK270M). 
We used TFG-RETK270M as a negative control and wild type RET as a positive 
control in our kinase assay. Not surprisingly, TFG-RET phosphorylated MBP in vitro, 
which was also true for wild type RET, although the kinase activity was of TFG-RET 
was indeed abolished in the kinase dead mutant (Figure 3.6). 
 
 
4.3 TFG-RET forms dimers and heteromers 
 
Ligand-induced dimerisation and oligomerisation is a crucial step in receptor tyrosine 
kinases mediated cell signal transduction [206]. Structural studies suggest that 
autophosphorylation of receptor kinases occurs by a trans mechanism, i.e. between two 
kinase domains of distinct dimers rather than within the same dimer. Thus, 
oligomerisation is a crucial event in the autophosphorylation dependent activation of 
receptor kinases [207]. Previous studies showed that constitutive dimerisation and 
oligomerisation of RET fusion protein are mechanisms that are required for the 
transforming activity and activation of receptor tyrosine kinase oncogenes [208]. Greco 
et al. demonstrated that TFG containing NTRK fusion (termed as TRK-T3) required 
formation of oligomeric complexes for its transforming activity [196]. So, we next 
investigated if TFG-RET was capable of dimerisation. As RET is known to form 
dimers, we included wild type RET as well in our experiments along with TFG-RET. 
We checked the ability of TFG-RET to form homodimers as well as heterodimers with 
wild type RET. Our data (Figure 3.7) implied that TFG-RET exhibited both homomeric 
and heteromeric interactions with TFG-RET and WT-RET, respectively. We were then 
curious to check if TFG-RET also formed oligomeric complexes. For this, we 
conducted cross-linking assays using DTME. DTME is a cell membrane permeable 
cross-linker, which can conjugate sulfhydryl groups of proteins via maleimide group 
cross-linking. It contains a reducible disulphide bond, which enables the reversal of 
protein cross-linking using reducing agents like DTT. Our data (Figure 3.8) showed that 
upon crosslinking with DTME, TFG-RET formed high molecular weight protein 
complexes that were indicated by the shift in size of TFG-RET detection. RET WT also 
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formed high molecular weight complexes, which were not seen in gel analyses, most 
likely because of the very large size of the complex. Further, upon addition of the 
reducing agent DTT, the cross-linking was disrupted leading to the disassembly of the 
protein complex and subsequently, TFG-RET was detected as monomer. Together, 
these data suggest that TFG-RET can indeed form oligomers, which demonstrates to an 
extent, the mechanism behind TFG-RET oncogenicity as oligomerisation is a crucial 
requirement for kinase mediated signalling. 
 
4.4 TFG domains are crucial for oligomerisation and oncogenicity of TFG-RET 
 
Our next aim in the study was the characterisation of the role of TFG in the 
functionality of TFG-RET. The TFG segment in TFG-RET retained two of its distinct 
functional domains namely the Phox and Bem 1p (PB1) domain and the coiled-coil 
(CC) domain (Figure 3.9). The PB1 domains are protein modules comprising about 80 
amino acid residues, which are conserved across amoebas, fungi, plants and animals 
[209]. Interaction of PB1 containing proteins with other PB1 domain proteins mediates 
the formation of homomeric and heteromeric complexes, which in turn is crucial for 
various cellular signalling cascades. So far, PB1 domains are reported in 13 different 
human proteins including some scaffold and adaptor proteins like p62 and Nbr1, as well 
as kinases including the MAPK signalling proteins like MEK5, MEKK2 and MEKK3 
[210]. A study by Roccato et al. demonstrated that a K14A point mutation in the PB1 
domain of TFG in the TRK-T3 fusion completely abrogated the transforming ability of 
TRK-T3 oncogene [197]. However, it was also demonstrated that the self-association of 
TRK-T3 proteins was not dependent on the PB1 domain of TFG, but rather the CC 
domain [196]. This could imply that the role of the PB1 domain in inducing 
transformation of TRK-T3 is rather because of its role in interaction with other proteins 
leading to transformation associated cellular signalling. Further, they investigated the 
interaction between PB1 containing proteins and reported that TFG exhibited a weak 
self-interaction and was the only protein that did not interact with other PB1 domain 
containing proteins. Although not much is known about the possible domains with 
which the TFG PB1 domain might interact, these data suggest the probable PB1 
mediated interaction of TFG with other protein domains that might shed light about role 
of TFG in protein signalling [210]. 
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CC domains are super helical structures characterised by repetitive heptad peptide 
motifs that consist of 2 to 5 helices that are arranged either in parallel or anti-parallel to 
each other. They are important in the facilitation of oligomerisation of proteins and thus 
crucial for various signaling mechanisms. They are thought to act as molecular spacers 
separating functional domains and scaffold multimeric protein complexes [211]. 
Proteins known and predicted to contain CC domains comprise a wide spectrum 
including kinases, kinesins, kinetochore and centriole proteins as well the family of the 
structural maintenance of chromosome (SMC) proteins [211]. Various studies have 
implied the role of CC domain in cellular functions including accurate chromosome 
segregation [212], [213], vesicle tethering [214], DNA recognition and cleavage [211]. 
Gel filtration studies have demonstrated the ability of CC domain containing proteins to 
form molecular complexes [215]. The role of CC domains in regulating various 
signalling pathways has also been illustrated. The CC domain of Ras-GRF has been 
shown to be important for the calcium-mediated activation of Ras-GRF, which in turn is 
required for Ras activation [216]. A study by Zhang et al. demonstrated that the CC 
domain of the transcription factor STAT3 is important for its tyrosine phosphorylation 
and its subsequent translocation to the nucleus, recruitment to the cytokine receptor IL-
6 and subsequent tyrosine phosphorylation [217]. CC domain mediated dimerisation has 
been demonstrated to be crucial for the oncogenic activity of various tyrosine kinase 
fusions including TPR-MET and BCR-ABL [218, 219]. All NTRK and RET fusion 
proteins are predicted to contain one or multiple CC domains. These domains promote 
the dimerisation of the of the fusions proteins, that now lack the ligand binding domains 
due to their location upstream of the breakpoint [220, 221]. Monaco et al. demonstrated 
that the RET-PTC3 in which NcoA (also called RFG) is the fusion partner whose N-
terminal CC domain was important in the oligomerisation, activation and 
transformation ability of RET-PTC3 [222]. Similar observations emphasizing on the 
indispensible role of CC domains has been reported in the cases of RET-PTC1 as well 
[223]. A study aimed at the characterisation of TFG protein predicted the presence of a 
trimeric CC domain at the N-terminus of TFG [224]. The role of TFG CC domain in the 
oligomerisation and oncogenicity of TRK-T3 was demonstrated by Greco et al.[196]. 
The study clearly demonstrated that deletion of the CC domain abolished the ability of 
TRK-T3 to form complexes as well as affected focus formation in NIH3T3 cells. 
Our studies indicated that three point mutations (K14E.R22E.R23E) in the PB1 domain 
of TFG as well as the deletion of the CC domain reduced the autophosphorylation of 
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RET at Y905 (Figure 3.9 and 10). This effect was not seen in any of the single point 
mutants. This could be probably due to the fact that single point mutations are not 
sufficient to dampen the protein-protein interactions that are crucial for phosphorylation 
of RET Y905. It remains to be investigated whether each of these single point mutations 
affect other autophosphorylation sites of RET. Our gel filtration studies confirmed our 
previous observation that TFG-RET formed high molecular protein complexes and 
importantly, also suggested a role for both PB1 domain and CC domain in the 
oligomerisation of TFG-RET (Figure 3.11). This was in agreement with many other 
studies that were mentioned earlier which implied a role of both these domains in 
oligomerisation and activity of fusion proteins [196, 197]. Further, deletion of CC 
domain increased the stability of TFG-RET protein as seen in the cycloheximide chase 
assay, which might be probably because of the inability of CC domain deficient TFG-
RET to undergo proper protein folding and attain its normal conformation and/or 
interact with other proteins that would allow its proper regulation (Figure 3.12). We 
then checked the functional significance that these domains might have in terms of 
oncogenicity of TFG-RET. We used stable cells where we achieved comparable 
expression of TFG-RET and TFG-RETΔ97-124, while the TFG-RETK14E.R22E.R23E 
mutant expression was greatly reduced. This could be because of the reduced stability 
of the triple mutant, as was also implied in the cycloheximide chase assay. In agreement 
with previous studies, CC domain indeed seemed to play a role in the transforming 
ability of TFG-RET (Figure 3.13). As the expression of PB1 mutant was incomparable 
with TFG-RET, we were unable to comment on the role PB1 domain in the 
oncogenicity of TFG-RET. 
 
4.5 Ubiquitination-associated proteins are upregulated in TFG-RET expressing 
PTC 
 
Our proteomics studies implied differential expression of proteins among normal, tumor 
and metastasis patient tissue (Figure 3.14). Our data implied the up regulation of 
HUWE1 E3 ligase, USP9X and USP7 in the cancer samples and our data from studies 
in NThy-TFG-RET further strengthened our observations (Figure 3.15). HUWE1 (the 
HECT, UBA, and WWE domain-containing protein 1) is an E3 ligase whose role in 
cancer propagation is controversial, which can be probably attributed to the complexity 
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in HUWE1 mediated molecular regulation whose targets include MCL-1, c-MYC, p53,  
and histones that are involved in various tumorigenisis-associated cellular processes. 
Studies report the upregulation of HUWE1 at both transcriptomic and protein levels in 
lung, breast and colorectal carcinomas [225-227]. Adhikary et al. showed that HUWE1 
mediated lysine 63-linked polyubiquitination of MYC (which is not a degradation 
signal rather a regulatory modification) is required for the transactivation of multiple 
MYC targets, hence playing a crucial role in the tumor propagation [225]. Peter et al. 
showed that HUWE1 inhibition stabilised MIZ1, which in turn turned off the 
transcriptional activation of MYC activated target genes, hence inhibiting the oncogenic 
function of MYC in colorectal cancer [175]. The same work used high-throughput 
screening to develop HUWE1 inhibitors, which was also validated using functional 
assays. We used these inhibitors in our study too, and the results suggested that 
HUWE1 inhibition reduced TFG-RET-dependent transformation (Figure 3.16). Zhong 
et al. demonstrated that inhibition of HUWE1 stabilised MCL-1 which in turn 
attenuated the induction of apoptosis, as elimination of MCL-1 is an important step for 
DNA-damage-induced apoptosis [228]. Chen et al. showed that inhibition of HUWE1 
stabilises p53 and induces p53-dependent apoptosis, hence implying the tumor 
suppressive role of HUWE1 through p53 regulation [229]. These studies link HUWE1-
mediated degradation to divergent phenotypic effects – increased survival and increased 
apoptosis. Studies also suggest a role of HUWE1 as a tumor suppressor in colorectal 
cancer and thyroid cancer [230, 231]. Ma et al. reported the down regulation of HUWE1 
in thyroid cancer tissues compared to normal tissues and demonstrated that HUWE1 
knockdown lead to increased cell proliferation, cell migration and invasion in thyroid 
cancer cell lines (WRO, FTC133, BCPAP) [230]. The role that HUWE1 plays in 
oncogenicity might be determined by various factors like the type of tumor, the driver 
mutations involved and probably other factors, which clearly needs to be further 
investigated. It would be interesting to check if HUWE1 upregulation is seen in other 
RET fusion tumors as well as in PTCs in general. We also checked for any differential 
gene expression of the known HUWE1 targets in our PTC patient sample and could not 
detect any deregulation, which might be indicative of other substrates through which 
HUWE1 mediates cellular processes. 
Further, our studies also shows that inhibition of USP9X and USP7 using small 
molecule inhibitors also reduced the transformation ability of TFG-RET expressing 
immortalised thyroid cells. A study by Ritorto et al. demonstrated that WP1130 showed 
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lower activity and lesser selectivity towards DUBs when compared to other DUB 
inhibitors (like BAY 11-7082, NSC 697923, SJB3-019A, PR-619, HBX 41,108) 
included in the study [232]. So, these studies can be further confirmed by using other 
inhibitors like GNE-6640 and GNE-6776 that have been demonstrated to be more 
specific against USP7 [233]. USP7 has been shown to be associated with various 
cancers including prostate, lung, breast, leukaemia and colon cancers where it displays 
context-specific tumor suppressive and oncogenic roles [234]. A study by Cheng et al. 
showed that USP7 expression levels were increased from grade I to grade IV in the 
tumors of glioma patients and that expression of USP7 was associated with lower 
survival rates [235]. Another study that investigated the mechanism underlying cancer 
progression associated with nuclear exclusion of the PTEN tumour suppressor links 
deubiquitination of PTEN by USP7 to its nuclear localisation [236]. Further, they saw 
an overexpression of USP7 in prostate cancer. Apart from its role in stabilising p53, in a 
deubiquitination enzyme-activity independent manner, USP7 is also required for the 
regulation of sequence-specific DNA binding of p53 [237]. USP7 plays important roles 
in the regulation of genomic integrity, cell growth, apoptosis and various other 
important cellular processes, since it is activated by several substrates including HIF-1 
α, Ki-67, β-catenin, FOXO1, CCD6 and TRAF6 [234]. Increased USP9X expression in 
multiple myeloma patients has been associated with poor prognosis [238]. USP9X has 
been shown to stabilize the anti-apoptotic protein MCL1, which in turn promotes tumor 
survival. Further, USP9X overexpression correlated with MCL1 overexpression in 
human follicular lymphomas and diffuses large B-cell lymphomas [238]. Kushwaha et 
al.’s investigation to identify molecular targets that can promote radiation-induced 
apoptosis showed that USP9X inhibition using the small molecule inhibitor WP1130 
could synergise radiation-induced cytotoxicity in NSCLC cells with mid-to-high MCL1 
expression [239]. As in the case of E3 ligases, deciphering the roles of DUBs in cancer 
progression is a complex task mostly because of the large number of substrates and the 
consequential diversity in the mechanisms they regulate. However, as illustrated by 
some of the above-mentioned examples, we now understand these mechanisms better 
and can hopefully employ this knowledge to successful novel therapeutic interventions 
in the future. Since E3 ligases and DUBs are abundant in occurrence, they could serve 
as excellent diagnostic and prognostic markers as soon as we can establish reliable 
correlation between its expression and cancer – a rather easier and quicker exploitation 
than therapeutic intervention. It would be worth to investigate if these ubiquitination 
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associated proteins show similar expression patterns in other PTCs mediated by RET 
fusions or PTCs in general. The identification of unique expression patterns might serve 
as an excellent diagnostic tool that can aid the precise stratification of thyroid tumors – 
a long-standing problem in this area. 
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5 Outlook and perspective 
5.1 Precision medicine and personalised therapeutics 
 
Cancer is a disorder of the genome and the biggest challenge in the management of 
cancer is the inter- and intra-tumor diversity of the highly unstable genome that 
constantly undergoes changes. Every patient has a distinct set of molecular alterations 
that defines the tumor, and hence the ‘one-size-fits-all’ treatment approach for patients 
with similar clinical presentations might not be the most effective treatment strategy in 
many cases. Precision medicine, on the other hand is the approach where patient 
samples are investigated at the genomic and proteomic levels that can help better 
understand the disease, in order to conduct a distinct ‘personalised’ or ‘individualised’ 
treatment strategy that can be more effective than a general treatment approach [240]. 
The use of the tyrosine kinase inhibitor imatinib for the targeted interference of BCR-
ABL fusion in CML patients with this fusion and the use of vemurafenib for the 
treatment of melanoma patients with BRAFV600E mutation are excellent examples of 
how molecular information-driven clinical approaches can improve cancer treatment 
[241-243]. With the improvements made in the fields of genomic sequencing, 
proteomics and data analysis, we are now better equipped to implement personalised 
targeted therapeutics. 
Understanding the underlying genomic and proteomic alterations of PTC is important 
for the treatment and prognosis of PTC. A recent study by Musholt et al. revealed that 
RET/PTC1 arrangements were identified in 16% of PTC patients who did not harbour 
any BRAFV600E mutation [244]. Patients with the RET fusions were at a significantly 
higher risk of developing iodine refractory condition as well as lymph node metastasis. 
Another study using targeted NGS analysis of PTC patient samples with wild type 
BRAF identified two RET transformations (RUFY2-RET and KIAA1468-RET) which 
were previously not reported in PTC [245]. Conducting more studies like these can help 
reveal a more realistic spectrum of distribution of RET fusions in PTC and other 
tumors. Such studies will also help better correlate the association between RET fusions 
and disease prognosis, which can in turn contribute to better disease management 
through precision medicine. Subbiah et al.’s recent work reported that BLU-667 as a 
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highly potent and selective inhibitor of RET which could inhibit RET mutant and RET 
fusion harbouring NSCLC and thyroid xenografts [139]. These studies may pave the 
way for targeted therapeutics in tumors with RET fusion. Our studies establishes TFG-
RET as an oncogenic fusion and it would be interesting to conduct more targeted NGS 
analysis to investigate the presence of this alteration in other PTC and non-PTC tumors. 
The findings of these studies could then help tailor targeted therapeutics against RET 
fusion harbouring tumors. 
 
 
5.2 Proteomics and phospho-proteomics in cancer therapy 
 
The past few decades have seen tremendous development in the area of genomic 
analysis centred approach of understanding cancer, which has resulted in unprecedented 
improvement in the management of the disease. Nevertheless, in order to fully 
understand the molecular profile of tumors, it is also important to investigate what the 
genetic material finally translates to – i.e., the proteins, which are the ultimate effector 
molecules, their abundance, the post translational modifications they undergo, 
particularly phosphorylation and protein-protein interactions [246]. Large-scale 
proteome and transcriptome profiling experiments indicate only a partial correlation 
between mRNA abundances and protein abundances [246]. The human genome 
estimated to be comprised of only about 20,000 protein-coding genes gives rise to about 
an estimated 500,000 protein isoforms largely achieved by alternative splicing and post-
translational modifications [247], [248]. Advances in the field of mass spectrometry 
based proteomic studies along with bioinformatics not only improved our understanding 
of the protein expression profiles of cells and tissues, but have also helped develop 
complementary pathway analysis tools, which can give a better idea of the cellular 
regulation at a molecular level [248]. A very recent study by Tong et al. used a global 
phosphoproteomics data analysis workflow to analyse high-grade serous ovarian cancer 
to classify the cancer into distinct molecular subtypes based on phosphorylation-based 
markers, which could then predict clinically actionable kinases as drug targets [249]. 
Another study by Zhang et al. integrated mass spectrometry based proteomic 
characterisation of ovarian tumors with the TCGA genomic data identified protein 
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modulations including phosphorylation and acetylation, which could be associated with 
tumor stratification and patient outcomes [250]. 
Our studies have identified the upregulation of ubiquitination-associated proteins in 
PTC. It would be interesting to exploit proteomics analysis to investigate the expression 
of these proteins in a larger cohort of PTC patients and to check if the upregulation of 
these proteins has any correlation with RET fusions. These studies could also be 
extended to other solid tumors including lung and breast cancers where RET fusions are 
being reported. Such studies can help explore the potential of targeting the ubiquitome 
in addition to the kinases that might result in synergistic outcomes, or in cases where 
patients develop resistance to kinase inhibitors. 
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